pioglitazone has been researched along with Disease Models, Animal in 347 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pioglitazone treatment (n = 10) reduced hepatic fat as assessed by magnetic resonance spectroscopy, despite a significant increase in body weight (Δ = 3." | 9.15 | Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. ( Bajaj, M; Chan, L; Gonzalez, EV; Gutierrez, A; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P, 2011) |
| "The results showed significant improvement in the insulin sensitivity of pioglitazone-treated mice as manifested by significant reduction in the insulin resistance index." | 8.02 | Pioglitazone Enhances β-Arrestin2 Signaling and Ameliorates Insulin Resistance in Classical Insulin Target Tissues. ( El-Fayoumi, S; Fahmy, A; Ibrahim, I; Mahmoud, A; Mansour, R, 2021) |
| " In the present study, it was examined whether treatment with PPAR‑γ agonist pioglitazone (PIO) is beneficial in counteracting SEV‑induced neuroinflammation and cognitive decline in a rat model of CIH." | 7.91 | Pioglitazone prevents sevoflurane‑induced neuroinflammation and cognitive decline in a rat model of chronic intermittent hypoxia by upregulating hippocampal PPAR‑γ. ( Dong, P; Fei, J; Li, D; Li, L; Li, N; Lin, Q; Lu, L; Yang, B; Zhang, X, 2019) |
| "Neither KD treatment nor pioglitazone alone or in combination affected clonic seizures." | 7.85 | Synergistic protection against acute flurothyl-induced seizures by adjuvant treatment of the ketogenic diet with the type 2 diabetes drug pioglitazone. ( Matthews, SA; Simeone, KA; Simeone, TA, 2017) |
| " This study aimed to determine the effects of a PPAR-g agonist pioglitazone on atherogenesis in an ApoE knockout mouse (ApoE-/-) diabetic mouse model and in a cultured vascular smooth muscle cells (VSMCs) model." | 7.85 | Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling. ( Di, B; Gao, H; Li, H; Li, W; Shen, X, 2017) |
| "Male rats were randomly divided into three groups as follows: sham, sepsis, and sepsis + pioglitazone." | 7.81 | Protective effect of pioglitazone on sepsis-induced intestinal injury in a rodent model. ( Gao, M; Jiang, Y; Peng, Y; Xiao, X; Yang, M, 2015) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 7.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| "Pioglitazone treatment decreases portosystemic shunting via modulation of splanchnic inflammation and neoangiogenesis." | 7.80 | Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. ( Angermayr, B; Boucher, Y; Fuhrmann, V; Grahovac, J; Horvatits, T; Klein, S; Mitterhauser, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Stift, J; Trauner, M; Trebicka, J, 2014) |
| "Chronic treatment with pioglitazone exerts a more prominent gastroprotective effect on the stomach ulcers of cirrhotic rats compared to control group probably due to constitutive nitric oxide synthase induction or inducible nitric oxide synthase inhibition." | 7.79 | Enhanced anti-ulcer effect of pioglitazone on gastric ulcers in cirrhotic rats: the role of nitric oxide and IL-1β. ( Amirghofran, Z; Dehpour, AR; Heidari, R; Moezi, L; Monabati, A; Nekooeian, AA, 2013) |
| " In the present study, we investigated the anti-inflammatory effects of PPAR-γ agonist, pioglitazone, on murine model of endogenous uveitis." | 7.79 | Peroxisome proliferator-activated receptor-γ agonist pioglitazone suppresses experimental autoimmune uveitis. ( Goto, H; Hattori, T; Kezuka, T; Matsuda, R; Nakagawa, H; Okunuki, Y; Tajima, K; Ueda, S; Usui, Y, 2013) |
| "Taken together, sub-chronic pioglitazone treatment exerts anti-convulsant effects in intravenous and intraperitoneal pentylenetetrazole-induced seizures of mice probably through induction of constitutive nitric oxide synthase." | 7.78 | Sub-chronic treatment with pioglitazone exerts anti-convulsant effects in pentylenetetrazole-induced seizures of mice: The role of nitric oxide. ( Dehpour, AR; Ghorbani, H; Hassanipour, M; Hassanpour, S; Moezi, L; Shafaroodi, H; Zaeri, M, 2012) |
| "Nutritional approaches are sought to overcome the limits of pioglitazone in metabolic syndrome and non-alcoholic fatty liver disease." | 7.78 | Spirulina improves non-alcoholic steatohepatitis, visceral fat macrophage aggregation, and serum leptin in a mouse model of metabolic syndrome. ( Fujimoto, M; Fujimoto, T; Gershwin, ME; Selmi, C; Shimada, Y; Tsuneyama, K, 2012) |
| " In the present study, we investigated the effect of pioglitazone on the development of azoxymethane-induced colon aberrant crypt foci (ACF) in KK-Ay obesity and diabetes model mice, and tried to clarify mechanisms by which the PPARγ ligand inhibits ACF development." | 7.78 | Suppressive effect of pioglitazone, a PPAR gamma ligand, on azoxymethane-induced colon aberrant crypt foci in KK-Ay mice. ( Fujii, G; Komiya, M; Mutoh, M; Nakano, K; Takahashi, M; Takasu, S; Teraoka, N; Ueno, T; Wakabayashi, K; Yamamoto, M; Yanaka, A, 2012) |
| "The purpose of this study was to test the hypothesis that atrial fibrosis and enhanced vulnerability to AF evoked by pressure overload can be attenuated by pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, via suppression of inflammatory profibrotic signals." | 7.77 | Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. ( Hara, M; Kume, O; Nagano-Torigoe, Y; Nakagawa, M; Saikawa, T; Takahashi, N; Teshima, Y; Wakisaka, O; Yoshimatsu, H; Yufu, K, 2011) |
| "We showed that activation of PPARγ receptors by pioglitazone (0, 10, and 30 mg/kg) and rosiglitazone (0, 10 and 30 mg/kg) given orally selectively reduced alcohol drinking." | 7.77 | Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. ( Braconi, S; Cannella, N; Ciccocioppo, R; Cippitelli, A; Demopulos, G; Gaitanaris, G; Heilig, M; Kallupi, M; Massi, M; Ruggeri, B; Somaini, L; Stopponi, S, 2011) |
| " Pioglitazone treatment (3 mg/kg body weight/d for 6 weeks), a peroxisome proliferator-activated receptor γ agonist, reversibly improved atherogenic dyslipidemia and insulin resistance and fully restored flow-mediated dilation with persistent benefits." | 7.77 | Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone. ( Cheng, H; Ding, Y; Han, C; Hou, N; Huang, PL; Li, C; Li, K; Liu, N; Liu, Y; Mao, J; Raab, S; Sebokova, E; Shang, S; Song, Z; Wang, H; Wang, J; Xue, L; Zhang, H; Zhang, R; Zhang, X; Zhang, Y; Zheng, W; Zhu, T, 2011) |
| " To test this hypothesis, we analyzed long-term metabolic effects of pioglitazone and the activation of nPKC-epsilon and -theta isoforms in an animal model of the metabolic syndrome, the spontaneously hypertensive rat (a congenic SHR strain with wild type Cd36 gene) fed a diet with 60 % sucrose from the age of 4 to 8 months." | 7.76 | Long-term pioglitazone treatment augments insulin sensitivity and PKC-epsilon and PKC-theta activation in skeletal muscles in sucrose fed rats. ( Kazdová, L; Marková, I; Mlejnek, P; Musilová, A; Pravenec, M; Šimáková, M; Zídek, V, 2010) |
| "To examine the additive protective effects of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone (Pio) and the angiotensin II receptor blocker candesartan (Cand) in a murine model of renal fibrosis: mice with unilateral ureteral obstruction (UUO)." | 7.76 | Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice. ( Higashi, K; Hyodo, T; Kumagai, H; Kushiyama, T; Miura, S; Oda, T; Sakurai, Y; Suzuki, S; Yamada, M, 2010) |
| "Present study was carried out to investigate the possible neuroprotective effect of pioglitazone, an antidiabetic agent, peroxisome proliferator-activated receptor gamma (PPARgamma) agonist on acute phase changes in mice model of cerebral ischemia induced by Bilateral Common Carotid artery Occlusion (BCCAO)." | 7.76 | Neuroprotective effect of pioglitazone on acute phase changes induced by partial global cerebral ischemia in mice. ( Aggarwal, R; Chakrabarti, A; Medhi, B, 2010) |
| "The insulin-sensitizing drug pioglitazone has been reported to be protective against myocardial infarction." | 7.75 | Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction. ( Fujiwara, H; Fujiwara, T; Iwasa, M; Kawamura, I; Kobayashi, H; Minatoguchi, S; Nagashima, K; Narentuoya, B; Nishigaki, K; Sumi, S; Takemura, G; Ushikoshi, H; Yamaki, T; Yasuda, S, 2009) |
| "The present study was undertaken to investigate possible mechanism of pioglitazone-induced beneficial effect in memory deficits associated with experimental dementia." | 7.75 | Exploring mechanism of pioglitazone-induced memory restorative effect in experimental dementia. ( Jaggi, AS; Kaur, B; Singh, N, 2009) |
| "To clarify the role of peroxisome proliferator activated receptor gamma (PPARgamma) in neuropathic pain, we examined the effect of pioglitazone, a PPARgamma agonist, on tactile allodynia and thermal hyperalgesia in a neuropathic pain model." | 7.74 | Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury. ( Kiguchi, N; Kishioka, S; Kobayashi, Y; Maeda, T; Ozaki, M, 2008) |
| " Using a murine model of steatohepatitis (mice fed a diet deficient in methionine and choline-MCD diet), we tested the effects of the insulin-sensitising, PPARgamma agonist drug pioglitazone (PGZ) on systemic and intrahepatic insulin sensitivity and on liver pathology." | 7.74 | Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone. ( Horsmans, YJ; Lebrun, VA; Leclercq, IA; Stärkel, P, 2007) |
| "Pioglitazone (1 mg x kg(-1) x d(-1)) was orally administered to stroke-prone spontaneously hypertensive rats (SHRSP) to examine the effect on incidental stroke, cerebrovascular injury, brain inflammation, oxidative stress, and vascular endothelial dysfunction induced by hypertension." | 7.74 | Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2007) |
| "We compared the effectiveness of the PPAR-gamma agonist pioglitazone (PIO) to the established effectiveness of a glucocorticoid receptor agonist, dexamethasone (DEX), in a murine model of asthma induced by cockroach allergen (CRA)." | 7.74 | Pioglitazone is as effective as dexamethasone in a cockroach allergen-induced murine model of asthma. ( Berlin, AA; Lukacs, NW; Narala, VR; Ranga, R; Reddy, RC; Smith, MR; Standiford, TJ, 2007) |
| "Rabbits subjected to ventricular tachypacing at 380 to 400 bpm for 4 weeks in the absence and presence of treatment with pioglitazone, candesartan, and combined pioglitazone and candesartan were assessed by electrophysiologic study, atrial fibrosis measurements, and cytokine expression analyses." | 7.74 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. ( Harata, S; Inden, Y; Kitamura, K; Murohara, T; Nattel, S; Shimano, M; Tsuji, Y; Uchikawa, T, 2008) |
| "To investigate the effects of pioglitazone on cardiac hypertrophy in vitro and in vivo." | 7.73 | [Pioglitazone inhibits cardiac hypertrophy of rats in vitro and in vivo]. ( Liu, YX; Wu, SM; Ye, P; Zhang, C, 2005) |
| "To evaluate the in vivo therapeutic effect of pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, on the development of lesions in a guinea pig model of osteoarthritis (OA), and to determine the influence of pioglitazone on the synthesis of matrix metalloproteinase 13 (MMP-13) and interleukin-1beta (IL-1beta) in articular cartilage." | 7.73 | Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs. ( Kobayashi, T; Martel-Pelletier, J; Naito, T; Nakamura, A; Notoya, K; Pelletier, JP; Unno, S, 2005) |
| "Insulin-resistant, obesity-prone mice (KK strain) were treated with pioglitazone, placebo, or the sulfonylurea compound, glipizide, for 2." | 7.73 | Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. ( Bodary, PF; Eitzman, DT; Jongeward, KL; King, SA; Vargas, FB; Wickenheiser, KJ, 2005) |
| " The aim of this study was to investigate the capacity of chiglitazar to improve insulin resistance and dyslipidemia in monosodium L-glutamate (MSG) obese rats and to determine whether its lipid-lowering effect is mediated through its activation of PPARalpha." | 7.73 | The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. ( Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ, 2006) |
| " Because proinflammatory cytokines play a critical role in left ventricular (LV) remodeling after myocardial infarction (MI), we examined the effects of pioglitazone treatment in an experimental model of chronic heart failure." | 7.71 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. ( Egashira, K; Hayashidani, S; Ikeuchi, M; Ishibashi, M; Kubota, T; Shiomi, T; Suematsu, N; Takeshita, A; Tsutsui, H; Wen, J, 2002) |
| "In rats subjected to cerebral ischemia, post-ischemic treatment with either dose of pioglitazone alleviated particular motor deficits and sensory impairments on day 2 after MCAO." | 6.77 | Treatment of rats with pioglitazone in the reperfusion phase of focal cerebral ischemia: a preclinical stroke trial. ( Culman, J; Glatz, T; Gohlke, P; Herdegen, T; Nguyen-Ngoc, M; Zhao, Y, 2012) |
| "Pioglitazone treatment increased oxygen saturation and pTyr14cav-1 vs." | 5.72 | Pioglitazone restores phosphorylation of downregulated caveolin-1 in right ventricle of monocrotaline-induced pulmonary hypertension. ( Balis, P; Doka, G; Klimas, J; Kmecova, Z; Krenek, P; Malikova, E; Pivackova, LB; Trubacova, S; Velasova, E, 2022) |
| "Osteosarcoma has been reported with treatment failure in up to 40% of cases." | 5.62 | Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft. ( Gopisetty, G; Jayavelu, S; Natarajan, A; Rajkumar, T; Ramachandran, B; Sundersingh, S, 2021) |
| "Pioglitazone treatment started at the first signs of fibrosis in both models." | 5.51 | Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. ( Arora, G; Baumert, TF; Erstad, DJ; Fuchs, BC; Ghoshal, S; Hoshida, Y; Lanuti, M; Li, S; Masia, R; Sojoodi, M; Tanabe, KK, 2019) |
| "There are only a few studies on the treatment of dermal fibrosis with sustained-release drugs." | 5.51 | Nanoparticle-mediated local delivery of pioglitazone attenuates bleomycin-induced skin fibrosis. ( Arita, T; Asai, J; Jo, JI; Kanemaru, M; Katoh, N; Kawai-Ohnishi, M; Tabata, Y; Tsutsumi, M; Wada, M, 2019) |
| "Pioglitazone is a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist and is widely used to treat type 2 diabetes." | 5.51 | Low-dose pioglitazone can ameliorate learning and memory impairment in a mouse model of dementia by increasing LRP1 expression in the hippocampus. ( Cha, BS; Kang, ES; Kim, E; Lee, BW; Lee, HC; Lee, M; Lee, PH; Lee, YH; Moon, JH; Seok, H; Shin, E; Yun, MR, 2019) |
| "Pioglitazone (PIO) is a peroxisome proliferator-activated receptor-γ agonist widely repositioned as an adjuvant of various drugs that have toxic effects due to its antioxidant and anti-inflammatory effects." | 5.51 | Pioglitazone as an adjuvant of amphotericin B for the treatment of cryptococcosis. ( Carmo, PHF; Costa, MC; de Brito, CB; de Souza, DG; Emídio, ECP; Freitas, GJC; Paixão, TA; Ribeiro, NQ; Santos, APN; Santos, DA; Silva, MF, 2019) |
| "Treatment with pioglitazone, significantly attenuated the postnatal propionic acid-induced social impairment, repetitive behavior, hyperactivity, anxiety and low exploratory activity." | 5.51 | A selective peroxisome proliferator-activated receptor-γ agonist benefited propionic acid induced autism-like behavioral phenotypes in rats by attenuation of neuroinflammation and oxidative stress. ( Mirza, R; Sharma, B, 2019) |
| "Pioglitazone treatment did not influence body weight or ovarian weight in either group." | 5.48 | Pioglitazone is effective for multiple phenotyepes of the Zucker fa/fa rat with polycystc ovary morphology and insulin resistance. ( Baba, T; Endo, T; Honnma, H; Ikeda, K; Kiya, T; Kuno, Y; Morishita, M; Saito, T, 2018) |
| "Insulin resistance has been identified as the key mechanism linking depression and diabetes." | 5.46 | Curcumin reverses the depressive-like behavior and insulin resistance induced by chronic mild stress. ( Li, YC; Li, YJ; Qiao, JY; Shen, JD; Wei, Y, 2017) |
| "PIO attenuates injury-induced neointima formation, in part, through the activation of AMPK." | 5.46 | Pioglitazone Attenuates Injury-Induced Neointima Formation in Mouse Femoral Artery Partially through the Activation of AMP-Activated Protein Kinase. ( Fairaq, A; Osman, I; Segar, L, 2017) |
| "Rats treated with boswellic acids (125 or 250 mg/kg) or pioglitazone showed improved insulin sensitivity and a reduction in liver index, activities of liver enzymes, serum TNF-α and IL-6 as well as hepatic iNOS expression and HNE formation compared to HFD group." | 5.42 | Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure. ( Abdelaziz, EZ; Barakat, BM; Bilasy, SE; Farag, NE; Fawzy, MS; Zaitone, SA, 2015) |
| "Pioglitazone is a peroxisome proliferator-activated receptor (PPAR) γ agonist and, although it is mostly used as an antidiabetic agent, it has been reported to have analgesic effects." | 5.40 | Antinociceptive and antidiarrheal effects of pioglitazone in a rat model of diarrhoea-predominant irritable bowel syndrome: role of nitric oxide. ( Azary, S; Dehpour, AR; Gharedaghi, MH; Javidan, AN; Kazemi, MH; Khalifeh-Soltani, A; Moradi, K; Paragomi, P; Rahimian, R; Sakuma, S, 2014) |
| "Pioglitazone pretreatment also suppressed NF-κB activation and altered GFAP overexpression." | 5.39 | Protective effect of pioglitazone on retinal ischemia/reperfusion injury in rats. ( Xiao, YQ; Ye, W; Zhang, XY; Zhang, Y, 2013) |
| "X-linked adrenoleukodystrophy is a neurometabolic disorder caused by inactivation of the peroxisomal ABCD1 transporter of very long-chain fatty acids." | 5.39 | Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy. ( Aubourg, P; Beal, MF; Calingasan, NY; Dumont, M; Ferrer, I; Fourcade, S; Galea, E; Galino, J; Martínez, JJ; Morató, L; Naudí, A; Pamplona, R; Portero-Otín, M; Pujol, A; Ruiz, M; Starkov, AA, 2013) |
| "Pioglitazone treatment significantly increased phosphorylated (p-) Akt but significantly reduced p-ERK1/2 and p-JNK." | 5.38 | PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. ( Aonuma, K; Hirayama, A; Igarashi, M; Ito, Y; Murakoshi, N; Seo, Y; Tada, H; Xu, D, 2012) |
| "Pioglitazone treatment (2." | 5.38 | Reduction of renal lipid content and proteinuria by a PPAR-γ agonist in a rat model of angiotensin II-induced hypertension. ( Hongo, M; Ishizaka, N; Nagai, R; Saito, K; Sakamoto, A, 2012) |
| "Pioglitazone is a novel class of oral antidiabetic agents currently used to treat type 2 diabetes mellitus." | 5.38 | Protective effects of pioglitazone on renal ischemia-reperfusion injury in mice. ( Hu, H; Huang, X; Shi, Z; Wang, G; Xi, X; Zou, C, 2012) |
| "Pioglitazone was administered prophylactically and pancreatic inflammation was assessed." | 5.38 | Pioglitazone, a PPAR-γ activator, attenuates the severity of cerulein-induced acute pancreatitis by modulating early growth response-1 transcription factor. ( Chen, G; Liu, J; Wan, H; Yuan, Y, 2012) |
| "Pioglitazone was given at the dose of 10mg/kgd by gavage for the last 12 weeks of the 16-week period." | 5.37 | Effect of pioglitazone on altered expression of Aβ metabolism-associated molecules in the brain of fructose-drinking rats, a rodent model of insulin resistance. ( Dong, C; Hou, L; Hou, X; Liu, X; Luo, D; Wang, M; Xu, S, 2011) |
| "Treatment with pioglitazone significantly inhibited the increases in the serum interleukin-6 and monocyte chemoattractant protein-1 (MCP-1) levels after CLP and lowered the mRNA expressions of proinflammatory cytokines, interleukin-6, and MCP-1 in omental tissue after CLP." | 5.37 | Effects of pioglitazone on survival and omental adipocyte function in mice with sepsis induced by cecal ligation and puncture. ( Kutsukake, M; Matsuda, A; Matsutani, T; Sasajima, K; Tamura, K; Tsujimura, Y; Uchida, E, 2011) |
| "Inflammation is an essential component of vulnerable or high-risk atheromas." | 5.37 | Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. ( Calcagno, C; Dickson, SD; Fayad, ZA; Fisher, EA; Fuster, V; Hayashi, K; Lin, J; Moon, MJ; Moshier, E; Mounessa, JS; Nicolay, K; Roytman, M; Rudd, JH; Tsimikas, S; Vucic, E, 2011) |
| "Sustained left ventricular hypertrophy (LVH) accelerates cardiac dysfunction and heart failure." | 5.36 | Activation of PPARgamma by pioglitazone does not attenuate left ventricular hypertrophy following aortic banding in rats. ( Bekeredjian, R; Buss, SJ; Hagenmüller, M; Hardt, SE; Katus, HA; Münz, S; Ochs, M; Pichler, M; Weiss, CS, 2010) |
| "Pioglitazone pretreatment also attenuated the oxidative stress and DNA fragmentation after cerebral IR injury." | 5.35 | Protective effects of pioglitazone against global cerebral ischemic-reperfusion injury in gerbils. ( Iyer, S; Kaundal, RK; Kumar, A; Sharma, SS, 2009) |
| " In patients with polycystic ovary syndrome and insulin resistance, pioglitazone-induced improvement of insulin action is associated with an increase in muscle ApoJ and LRP2 expression." | 5.34 | Apolipoprotein J is a hepatokine regulating muscle glucose metabolism and insulin sensitivity. ( Aroda, V; Ciaraldi, TP; Dagon, Y; Henry, RR; Heo, JI; Hong, SH; Huang, H; Hwang, WM; Kang, MC; Kim, MS; Kim, SS; Kim, YB; Lee, SH; Lima, IS; Park, KS; Pereira de Moura, L; Seo, JA; Uner, A; Vijyakumar, A; Willnow, TE; Yang, WM, 2020) |
| "Fenofibrate did not inhibit mechanical allodynia or paw edema induced by phorbol-12,13-didecanoate (PDD), a protein kinase C activator, in rats." | 5.34 | Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. ( Bertollo, CM; Coelho, MM; Costa, KA; Nascimento, EB; Oliveira, AC; Rocha, LT, 2007) |
| "Treatment with pioglitazone and rosiglitazone significantly decreased the AT(1)R specific binding in HFD fed rats." | 5.34 | PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance. ( Gaikwad, AB; Ramarao, P; Viswanad, B, 2007) |
| "Pioglitazone reduced the development of cartilage lesions in a dose-dependent manner, with the highest dosage producing a statistically significant change (P < 0." | 5.34 | The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: in vivo protective effects mediated through the inhibition of key signaling and cataboli ( Boileau, C; Boily, M; Fahmi, H; Martel-Pelletier, J; Mineau, F; Pelletier, JP, 2007) |
| "When pioglitazone was administered to the rats at a dose of 10 mg/kg/day for 4 weeks from 12 weeks of age, plasma triglyceride and insulin levels and systolic blood pressure decreased, and blood glucose reduction in response to insulin was normalized." | 5.30 | Effect of an insulin sensitizer, pioglitazone, on hypertension in fructose-drinking rats. ( Ikeda, H; Nomura, C; Odaka, H; Suzuki, M, 1997) |
| "Fenofibrate is a peroxisome proliferator-activated receptor-α that has been clinically used to treat dyslipidemia and insulin resistance." | 5.19 | Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue. ( Chen, M; Deng, D; Fang, Z; Hu, H; Luo, L; Wang, Y; Xu, M, 2014) |
| " Pioglitazone treatment (n = 10) reduced hepatic fat as assessed by magnetic resonance spectroscopy, despite a significant increase in body weight (Δ = 3." | 5.15 | Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. ( Bajaj, M; Chan, L; Gonzalez, EV; Gutierrez, A; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P, 2011) |
| ", pioglitazone and metformin) used for the treatment of insulin resistance in PCOS, on androgen production." | 4.93 | Cellular and Animal Studies: Insights into Pathophysiology and Therapy of PCOS. ( Indran, IR; Lee, BH; Yong, EL, 2016) |
| "The results showed significant improvement in the insulin sensitivity of pioglitazone-treated mice as manifested by significant reduction in the insulin resistance index." | 4.02 | Pioglitazone Enhances β-Arrestin2 Signaling and Ameliorates Insulin Resistance in Classical Insulin Target Tissues. ( El-Fayoumi, S; Fahmy, A; Ibrahim, I; Mahmoud, A; Mansour, R, 2021) |
| "Pioglitazone belongs to the class of drugs thiazolidinediones (TZDs) and is an oral hypoglycemic drug, used in the treatment of type 2 diabetes, which improves insulin sensitivity in target tissues." | 3.96 | MicroRNA miR-222 mediates pioglitazone beneficial effects on skeletal muscle of diet-induced obese mice. ( Araújo Dos Santos, B; Araújo, HN; da Paixão, AO; de Mendonça, M; de Sousa, É; Imamura de Lima, T; Murata, GM; Passos Simões Fróes Guimarães, DS; Rodrigues, AC; Roveratti Spagnol, A; Silveira, LR, 2020) |
| "Female prepubertal rats were treated with equine chorionic gonadotropin (eCG) to induce folliculogenesis, together with dehydroepiandrosterone (DHEA) to induce hyperandrogenism and/or PGZ to evaluate PPARG activation." | 3.91 | Treatment with the synthetic PPARG ligand pioglitazone ameliorates early ovarian alterations induced by dehydroepiandrosterone in prepubertal rats. ( Abruzzese, GA; Ferreira, SR; Heber, MF; Motta, AB; Velez, LM, 2019) |
| " However, liraglutide induced weight loss, improved glycaemic control, reduced ALT and AST and showed some beneficial effects upon steatosis and lobular inflammation." | 3.91 | Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue. ( Brockbank, S; Bruun, MF; Cruwys, S; Daniels, SJ; Detlefsen, S; Hein, P; Henriksen, K; Hjuler, ST; Karsdal, MA; Leeming, DJ, 2019) |
| " In the present study, it was examined whether treatment with PPAR‑γ agonist pioglitazone (PIO) is beneficial in counteracting SEV‑induced neuroinflammation and cognitive decline in a rat model of CIH." | 3.91 | Pioglitazone prevents sevoflurane‑induced neuroinflammation and cognitive decline in a rat model of chronic intermittent hypoxia by upregulating hippocampal PPAR‑γ. ( Dong, P; Fei, J; Li, D; Li, L; Li, N; Lin, Q; Lu, L; Yang, B; Zhang, X, 2019) |
| " Here, we used a model of HA pregnancy in mice to determine whether hypoxia-induced fetal growth restriction reduces placental PPAR-γ protein expression and placental vascularization and, if so, to evaluate the effectiveness of the selective PPAR-γ agonist pioglitazone (PIO) for preventing hypoxia-induced IUGR." | 3.91 | Pharmacological activation of peroxisome proliferator-activated receptor γ (PPAR-γ) protects against hypoxia-associated fetal growth restriction. ( Dodson, RB; Doyle, AS; Julian, CG; Lane, SL; Lorca, RA; Matarrazo, CJ; Moore, LG; Park, H; Rathi, H; Wolfson, GH, 2019) |
| " 2) Systemic administration of a PPARγ agonist, pioglitazone (PIO), attenuates whisker pad mechanical allodynia at doses of 300 mg/kg i." | 3.85 | PPARγ Agonists Attenuate Trigeminal Neuropathic Pain. ( Danaher, RJ; Lyons, DN; Miller, CS; Westlund, KN; Zhang, L, 2017) |
| "Neither KD treatment nor pioglitazone alone or in combination affected clonic seizures." | 3.85 | Synergistic protection against acute flurothyl-induced seizures by adjuvant treatment of the ketogenic diet with the type 2 diabetes drug pioglitazone. ( Matthews, SA; Simeone, KA; Simeone, TA, 2017) |
| " This study aimed to determine the effects of a PPAR-g agonist pioglitazone on atherogenesis in an ApoE knockout mouse (ApoE-/-) diabetic mouse model and in a cultured vascular smooth muscle cells (VSMCs) model." | 3.85 | Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling. ( Di, B; Gao, H; Li, H; Li, W; Shen, X, 2017) |
| "Pioglitazone treatment significantly decreased serum RBP4 levels in obese rats, which was correlated with reduced body weight and increased insulin sensitivity." | 3.81 | Pioglitazone lowers serum retinol binding protein 4 by suppressing its expression in adipose tissue of obese rats. ( Han, J; Jia, W; Liu, X; Wei, L; Xiao, Y; Zhang, J; Zhu, C, 2015) |
| "Male rats were randomly divided into three groups as follows: sham, sepsis, and sepsis + pioglitazone." | 3.81 | Protective effect of pioglitazone on sepsis-induced intestinal injury in a rodent model. ( Gao, M; Jiang, Y; Peng, Y; Xiao, X; Yang, M, 2015) |
| " The present study investigated the effect of the PPAR-γ agonist, pioglitazone, on the mammalian target of rapamycin (mTOR) signaling pathway in a rat model of pentylenetetrazol (PTZ)-induced status epilepticus (SE)." | 3.81 | Peroxisome proliferator-activated receptor-γ agonist inhibits the mammalian target of rapamycin signaling pathway and has a protective effect in a rat model of status epilepticus. ( Liu, Y; San, YZ; Shi, PP; Zhang, Y; Zhu, YL, 2015) |
| " Pioglitazone treatment normalized mitoflash frequency and morphology while restored mitochondrial respiratory function and insulin sensitivity in 12 weeks mt-cpYFP db/db mice." | 3.81 | Mitoflash altered by metabolic stress in insulin-resistant skeletal muscle. ( Cheng, H; Ding, Y; Fang, H; Hou, N; Ma, Q; Pan, L; Shang, W; Sun, T; Sun, X; Wang, X; Xiao, Y; Zhang, X; Zhou, J, 2015) |
| "To define the components of the metabolic syndrome that contribute to diabetic polyneuropathy (DPN) in type 2 diabetes mellitus (T2DM), we treated the BKS db/db mouse, an established murine model of T2DM and the metabolic syndrome, with the thiazolidinedione class drug pioglitazone." | 3.81 | The Metabolic Syndrome and Microvascular Complications in a Murine Model of Type 2 Diabetes. ( Backus, C; Brosius, FC; Dauch, JR; Feldman, EL; Hayes, JM; Hinder, LM; Hur, J; Kretzler, M; Pennathur, S, 2015) |
| "Peroxisome proliferator-activated receptor x03B3; agonists have been shown to inhibit angiotensin II (AngII)-induced experimental abdominal aortic aneurysms." | 3.81 | Pioglitazone Identifies a New Target for Aneurysm Treatment: Role of Egr1 in an Experimental Murine Model of Aortic Aneurysm. ( Charolidi, N; Cockerill, GW; Laing, K; Nohturfft, A; Pearce, S; Pirianov, G; Torsney, E, 2015) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 3.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| "PPARγ agonist pioglitazone pretreatment significantly reduces infarct volume and attenuates neurological deficits following spinal cord ischemia." | 3.80 | A peroxisome proliferator-activated receptor gamma agonist attenuates neurological deficits following spinal cord ischemia in rats. ( Han, S; Hwang, J; Kim, H; Lim, C; Min, S; Nahm, SF; Park, K; Park, S, 2014) |
| "Pioglitazone treatment decreases portosystemic shunting via modulation of splanchnic inflammation and neoangiogenesis." | 3.80 | Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. ( Angermayr, B; Boucher, Y; Fuhrmann, V; Grahovac, J; Horvatits, T; Klein, S; Mitterhauser, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Stift, J; Trauner, M; Trebicka, J, 2014) |
| "Pioglitazone effectively prevents lung injury caused by CLP-induced sepsis by maintaining the anti-inflammatory status of visceral adipose tissue." | 3.80 | Pioglitazone attenuates lung injury by modulating adipose inflammation. ( Kobayashi, M; Kutsukake, M; Matsuda, A; Matsutani, T; Tachikawa, E; Tamura, K; Uchida, E, 2014) |
| "To examine the effect of pioglitazone on erectile function in a rat model of postprostatectomy erectile dysfunction." | 3.80 | Efficacy of pioglitazone on erectile function recovery in a rat model of cavernous nerve injury. ( Aliperti, LA; Gokce, A; Hagan, SS; Hellstrom, JA; Hellstrom, WJ; Kadowitz, PJ; Lasker, GF; Sikka, SC; Trost, LW, 2014) |
| "Chronic treatment with pioglitazone exerts a more prominent gastroprotective effect on the stomach ulcers of cirrhotic rats compared to control group probably due to constitutive nitric oxide synthase induction or inducible nitric oxide synthase inhibition." | 3.79 | Enhanced anti-ulcer effect of pioglitazone on gastric ulcers in cirrhotic rats: the role of nitric oxide and IL-1β. ( Amirghofran, Z; Dehpour, AR; Heidari, R; Moezi, L; Monabati, A; Nekooeian, AA, 2013) |
| " Administration of DAGA (200 mg/kg) reduced SBP and significantly improved the FPG and HOMA-IR (homeostatis model assessment-insulin resistance) with modest improvement in lipid profile without decrease in body weight similar to pioglitazone." | 3.79 | Effect of a deacyl gymnemic acid on glucose homeostasis & metabolic parameters in a rat model of metabolic syndrome. ( Bhansali, S; Malhotra, S; Pandhi, P; Shafiq, N; Sharma, S; Singh, AP; Singh, I; Singh, PK, 2013) |
| " In the present study, we investigated the anti-inflammatory effects of PPAR-γ agonist, pioglitazone, on murine model of endogenous uveitis." | 3.79 | Peroxisome proliferator-activated receptor-γ agonist pioglitazone suppresses experimental autoimmune uveitis. ( Goto, H; Hattori, T; Kezuka, T; Matsuda, R; Nakagawa, H; Okunuki, Y; Tajima, K; Ueda, S; Usui, Y, 2013) |
| "The peroxisome proliferator activated receptor-γ (PPARγ) agonist, pioglitazone (PIO), exerts anti-diabetic properties associated with increased fat mass, whereas the retinoid X receptor (RXR) antagonist HX531 demonstrates anti-obesity and anti-diabetic effects with reduced body weight and fat pad mass." | 3.78 | RXR antagonism induces G0 /G1 cell cycle arrest and ameliorates obesity by up-regulating the p53-p21(Cip1) pathway in adipocytes. ( Eguchi, J; Hida, A; Hida, K; Inoue, K; Kagechika, H; Kanzaki, M; Katayama, A; Makino, H; Murakami, K; Nakatsuka, A; Ogawa, D; Terami, T; Teshigawara, S; Wada, J, 2012) |
| "Taken together, sub-chronic pioglitazone treatment exerts anti-convulsant effects in intravenous and intraperitoneal pentylenetetrazole-induced seizures of mice probably through induction of constitutive nitric oxide synthase." | 3.78 | Sub-chronic treatment with pioglitazone exerts anti-convulsant effects in pentylenetetrazole-induced seizures of mice: The role of nitric oxide. ( Dehpour, AR; Ghorbani, H; Hassanipour, M; Hassanpour, S; Moezi, L; Shafaroodi, H; Zaeri, M, 2012) |
| "Nutritional approaches are sought to overcome the limits of pioglitazone in metabolic syndrome and non-alcoholic fatty liver disease." | 3.78 | Spirulina improves non-alcoholic steatohepatitis, visceral fat macrophage aggregation, and serum leptin in a mouse model of metabolic syndrome. ( Fujimoto, M; Fujimoto, T; Gershwin, ME; Selmi, C; Shimada, Y; Tsuneyama, K, 2012) |
| " Diabetic nephropathic rats were orally given vehicle, pioglitazone, aliskiren, or combined pioglitazone and aliskiren for four weeks to compare their effects on cardiovascular injury, particularly myocardial fibrosis." | 3.78 | Beneficial effects of pioglitazone against cardiovascular injury are enhanced by combination with aliskiren in a rat model of diabetic nephropathy. ( Asker, ME; Elrashidy, RA; Mohamed, HE, 2012) |
| " In the present study, we investigated the effect of pioglitazone on the development of azoxymethane-induced colon aberrant crypt foci (ACF) in KK-Ay obesity and diabetes model mice, and tried to clarify mechanisms by which the PPARγ ligand inhibits ACF development." | 3.78 | Suppressive effect of pioglitazone, a PPAR gamma ligand, on azoxymethane-induced colon aberrant crypt foci in KK-Ay mice. ( Fujii, G; Komiya, M; Mutoh, M; Nakano, K; Takahashi, M; Takasu, S; Teraoka, N; Ueno, T; Wakabayashi, K; Yamamoto, M; Yanaka, A, 2012) |
| "To examine the impact of a recent surgery on development of endometriosis-related adhesions in a chimeric model and to determine the therapeutic efficacy of pioglitazone (PIO)." | 3.77 | Development and prevention of postsurgical adhesions in a chimeric mouse model of experimental endometriosis. ( Bruner-Tran, KL; Camargos, AF; Carvalho-Macedo, AC; Crispens, MA; Herington, JL; Lebovic, DI; Osteen, KG, 2011) |
| "The purpose of this study was to test the hypothesis that atrial fibrosis and enhanced vulnerability to AF evoked by pressure overload can be attenuated by pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, via suppression of inflammatory profibrotic signals." | 3.77 | Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. ( Hara, M; Kume, O; Nagano-Torigoe, Y; Nakagawa, M; Saikawa, T; Takahashi, N; Teshima, Y; Wakisaka, O; Yoshimatsu, H; Yufu, K, 2011) |
| " Moreover, macrophage PPAR-γ was required for accelerating pioglitazone-mediated recovery from dextran sodium sulfate (DSS) colitis, providing a cellular target for the anti-inflammatory effects of PPAR-γ agonists in IBD." | 3.77 | Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease. ( Bassaganya-Riera, J; Climent, M; Evans, C; Guri, AJ; Hontecillas, R; Horne, WT; Sobral, BW; Zhang, Y, 2011) |
| " Here, we tested the effect of a potent and selective peroxisome proliferator-activated receptor-γ agonist, rivoglitazone (Rivo), a newly synthesized thiazolidinedione derivative, on adiponectin, insulin resistance, and atherosclerosis." | 3.77 | Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone. ( Funahashi, T; Hirata, A; Hiuge-Shimizu, A; Kihara, S; Maeda, N; Nakamura, K; Nakatsuji, H; Okuno, A; Shimomura, I, 2011) |
| "We showed that activation of PPARγ receptors by pioglitazone (0, 10, and 30 mg/kg) and rosiglitazone (0, 10 and 30 mg/kg) given orally selectively reduced alcohol drinking." | 3.77 | Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. ( Braconi, S; Cannella, N; Ciccocioppo, R; Cippitelli, A; Demopulos, G; Gaitanaris, G; Heilig, M; Kallupi, M; Massi, M; Ruggeri, B; Somaini, L; Stopponi, S, 2011) |
| " Pioglitazone treatment (3 mg/kg body weight/d for 6 weeks), a peroxisome proliferator-activated receptor γ agonist, reversibly improved atherogenic dyslipidemia and insulin resistance and fully restored flow-mediated dilation with persistent benefits." | 3.77 | Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone. ( Cheng, H; Ding, Y; Han, C; Hou, N; Huang, PL; Li, C; Li, K; Liu, N; Liu, Y; Mao, J; Raab, S; Sebokova, E; Shang, S; Song, Z; Wang, H; Wang, J; Xue, L; Zhang, H; Zhang, R; Zhang, X; Zhang, Y; Zheng, W; Zhu, T, 2011) |
| "The present study has been designed to investigate the potential of peroxisome proliferator-activated receptor-gamma ([PPAR]-γ) agonists, pioglitazone, and rosiglitazone in hyperhomocysteinemia-induced vascular dementia of rats." | 3.77 | Pharmacological investigations on potential of peroxisome proliferator-activated receptor-gamma agonists in hyperhomocysteinemia-induced vascular dementia in rats. ( Jaggi, AS; Sain, H; Sharma, B; Singh, N, 2011) |
| " To test this hypothesis, we analyzed long-term metabolic effects of pioglitazone and the activation of nPKC-epsilon and -theta isoforms in an animal model of the metabolic syndrome, the spontaneously hypertensive rat (a congenic SHR strain with wild type Cd36 gene) fed a diet with 60 % sucrose from the age of 4 to 8 months." | 3.76 | Long-term pioglitazone treatment augments insulin sensitivity and PKC-epsilon and PKC-theta activation in skeletal muscles in sucrose fed rats. ( Kazdová, L; Marková, I; Mlejnek, P; Musilová, A; Pravenec, M; Šimáková, M; Zídek, V, 2010) |
| "A prospective, randomized, placebo-controlled study was conducted in a baboon model to determine if a thiazolidinedione agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone, can impede the development of endometriosis." | 3.76 | Peroxisome proliferator-activated receptor-(gamma) receptor ligand partially prevents the development of endometrial explants in baboons: a prospective, randomized, placebo-controlled study. ( Chai, DC; D'Hooghe, T; Lebovic, DI; Mwenda, JM; Santi, A; Xu, X, 2010) |
| "To examine the additive protective effects of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone (Pio) and the angiotensin II receptor blocker candesartan (Cand) in a murine model of renal fibrosis: mice with unilateral ureteral obstruction (UUO)." | 3.76 | Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice. ( Higashi, K; Hyodo, T; Kumagai, H; Kushiyama, T; Miura, S; Oda, T; Sakurai, Y; Suzuki, S; Yamada, M, 2010) |
| " Pioglitazone treatment altered fat distribution, improved insulin sensitivity and normalized lipid and insulin level in rats on the high-fat diet." | 3.76 | Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia. ( Jena, G; Ramarao, P; Vikram, A, 2010) |
| "Present study was carried out to investigate the possible neuroprotective effect of pioglitazone, an antidiabetic agent, peroxisome proliferator-activated receptor gamma (PPARgamma) agonist on acute phase changes in mice model of cerebral ischemia induced by Bilateral Common Carotid artery Occlusion (BCCAO)." | 3.76 | Neuroprotective effect of pioglitazone on acute phase changes induced by partial global cerebral ischemia in mice. ( Aggarwal, R; Chakrabarti, A; Medhi, B, 2010) |
| " Here, in an animal model of obesity and insulin resistance, the metabolic response to cevoglitazar, a dual PPARalpha/gamma, was characterized using a combination of in vivo and ex vivo magnetic resonance methodologies and compared to treatment effects of fenofibrate, a PPARalpha agonist, and pioglitazone, a PPARgamma agonist." | 3.75 | Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats. ( Boettcher, BR; Gao, J; Gounarides, JS; Laurent, D, 2009) |
| "The insulin-sensitizing drug pioglitazone has been reported to be protective against myocardial infarction." | 3.75 | Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction. ( Fujiwara, H; Fujiwara, T; Iwasa, M; Kawamura, I; Kobayashi, H; Minatoguchi, S; Nagashima, K; Narentuoya, B; Nishigaki, K; Sumi, S; Takemura, G; Ushikoshi, H; Yamaki, T; Yasuda, S, 2009) |
| " In this study, we used a mouse model of asthma to evaluate the effect of two PPARgamma agonists, rosiglitazone or pioglitazone, on IL-17 expression in allergic airway disease." | 3.75 | Peroxisome proliferator-activated receptor gamma agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation. ( Chae, HJ; Choe, YH; Kim, SR; Lee, KS; Lee, YC; Min, KH; Moon, H; Park, SJ; Yoo, WH, 2009) |
| "The present study was undertaken to investigate possible mechanism of pioglitazone-induced beneficial effect in memory deficits associated with experimental dementia." | 3.75 | Exploring mechanism of pioglitazone-induced memory restorative effect in experimental dementia. ( Jaggi, AS; Kaur, B; Singh, N, 2009) |
| "To clarify the role of peroxisome proliferator activated receptor gamma (PPARgamma) in neuropathic pain, we examined the effect of pioglitazone, a PPARgamma agonist, on tactile allodynia and thermal hyperalgesia in a neuropathic pain model." | 3.74 | Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury. ( Kiguchi, N; Kishioka, S; Kobayashi, Y; Maeda, T; Ozaki, M, 2008) |
| " Using a murine model of steatohepatitis (mice fed a diet deficient in methionine and choline-MCD diet), we tested the effects of the insulin-sensitising, PPARgamma agonist drug pioglitazone (PGZ) on systemic and intrahepatic insulin sensitivity and on liver pathology." | 3.74 | Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone. ( Horsmans, YJ; Lebrun, VA; Leclercq, IA; Stärkel, P, 2007) |
| "To clarify the causal relationship between insulin resistance and the development of NASH, steatohepatitis was induced in obese diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) and nondiabetic control Long-Evans Tokushima Otsuka (LETO) rats by feeding them a methionine and choline-deficient (MCD) diet." | 3.74 | Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. ( Akahori, H; Kaneko, S; Kita, Y; Kurita, S; Matsuzawa, N; Misu, H; Nakanuma, Y; Ota, T; Sakurai, M; Takamura, T; Uno, M; Zen, Y, 2007) |
| "Prominent weight gain (mostly subcutaneous fat area) was observed in the pioglitazone-treated OLETF (O-P) rats versus significant weight loss was observed in the metformin-treated OLETF (O-M) rats." | 3.74 | The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats. ( Ahn, CW; Cha, BS; Choi, SH; Kim, DJ; Kim, SK; Lee, HC; Lee, YJ; Lim, SK; Zhao, ZS, 2007) |
| "Pioglitazone (1 mg x kg(-1) x d(-1)) was orally administered to stroke-prone spontaneously hypertensive rats (SHRSP) to examine the effect on incidental stroke, cerebrovascular injury, brain inflammation, oxidative stress, and vascular endothelial dysfunction induced by hypertension." | 3.74 | Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2007) |
| "We examined oxidative stress and metabolic characteristics of the spontaneously hypertensive hyperlipidemic rat (SHHR) when it was fed a high-fat diet and sucrose solution (HFDS) after N(G)-nitro-L-arginine methyl ester ingestion to develop a rat model of metabolic syndrome." | 3.74 | Effects of pioglitazone on increases in visceral fat accumulation and oxidative stress in spontaneously hypertensive hyperlipidemic rats fed a high-fat diet and sucrose solution. ( Iwai, S; Kobayashi, S; Kumai, T; Oguchi, K; Okazaki, M; Saiki, R, 2007) |
| " Pioglitazone has antiatherogenic property through the inhibition of inflammation." | 3.74 | Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting. ( Daida, H; Ikeda, E; Kajimoto, K; Kasai, T; Kubota, N; Miyauchi, K; Sumiyoshi, K; Yokoyama, T, 2008) |
| "We investigated the effects of ischemic preconditioning (IP) on reperfusion arrhythmias in type 2 diabetic rats as well as the effects of the insulin sensitizer pioglitazone." | 3.74 | The insulin sensitizer pioglitazone improves the deterioration of ischemic preconditioning in type 2 diabetes mellitus rats. ( Kawai, M; Mochizuki, S; Mori, C; Ogawa, K; Okazaki, F; Sasaki, H; Shimizu, M; Takatsuka, H; Taniguchi, I, 2007) |
| "We compared the effectiveness of the PPAR-gamma agonist pioglitazone (PIO) to the established effectiveness of a glucocorticoid receptor agonist, dexamethasone (DEX), in a murine model of asthma induced by cockroach allergen (CRA)." | 3.74 | Pioglitazone is as effective as dexamethasone in a cockroach allergen-induced murine model of asthma. ( Berlin, AA; Lukacs, NW; Narala, VR; Ranga, R; Reddy, RC; Smith, MR; Standiford, TJ, 2007) |
| "The present results suggest that pioglitazone improves not only insulin resistance, but also the dysfunctions in vascular control regulated by adrenergic and CGRPergic nerves in the hyperinsulinaemic state." | 3.74 | Pioglitazone opposes neurogenic vascular dysfunction associated with chronic hyperinsulinaemia. ( Egawa, T; Hanafusa, N; Kawasaki, H; Mio, M; Takatori, S; Yabumae, N; Zamami, Y, 2008) |
| "Peroxisome proliferator-activated receptor (PPAR)-gamma ligand, pioglitazone (PIO), is reported to induce edema especially in postmenopausal women." | 3.74 | Renal cytochrome P450 as a determinant of impaired natriuresis by PPAR-gamma ligands in ovariectomized obese rats. ( Hasegawa, K; Hayashi, K; Homma, K; Ito, O; Kanda, T; Omata, K; Saruta, T; Sugano, N; Tatematsu, S; Wakino, S; Yoshioka, K, 2008) |
| "Rabbits subjected to ventricular tachypacing at 380 to 400 bpm for 4 weeks in the absence and presence of treatment with pioglitazone, candesartan, and combined pioglitazone and candesartan were assessed by electrophysiologic study, atrial fibrosis measurements, and cytokine expression analyses." | 3.74 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. ( Harata, S; Inden, Y; Kitamura, K; Murohara, T; Nattel, S; Shimano, M; Tsuji, Y; Uchikawa, T, 2008) |
| "To investigate the effects of pioglitazone on cardiac hypertrophy in vitro and in vivo." | 3.73 | [Pioglitazone inhibits cardiac hypertrophy of rats in vitro and in vivo]. ( Liu, YX; Wu, SM; Ye, P; Zhang, C, 2005) |
| "To evaluate the in vivo therapeutic effect of pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, on the development of lesions in a guinea pig model of osteoarthritis (OA), and to determine the influence of pioglitazone on the synthesis of matrix metalloproteinase 13 (MMP-13) and interleukin-1beta (IL-1beta) in articular cartilage." | 3.73 | Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs. ( Kobayashi, T; Martel-Pelletier, J; Naito, T; Nakamura, A; Notoya, K; Pelletier, JP; Unno, S, 2005) |
| " We have used a mouse model for asthma to determine the effect of PPARgamma agonists, rosiglitazone or pioglitazone, and PPARgamma on allergen-induced bronchial inflammation and airway hyperresponsiveness." | 3.73 | PPAR-gamma modulates allergic inflammation through up-regulation of PTEN. ( Chai, OH; Hwang, PH; Kim, JS; Lee, KS; Lee, MK; Lee, YC; Park, SJ; Song, CH; Yi, HK, 2005) |
| "Insulin-resistant, obesity-prone mice (KK strain) were treated with pioglitazone, placebo, or the sulfonylurea compound, glipizide, for 2." | 3.73 | Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. ( Bodary, PF; Eitzman, DT; Jongeward, KL; King, SA; Vargas, FB; Wickenheiser, KJ, 2005) |
| " The aim of this study was to investigate the capacity of chiglitazar to improve insulin resistance and dyslipidemia in monosodium L-glutamate (MSG) obese rats and to determine whether its lipid-lowering effect is mediated through its activation of PPARalpha." | 3.73 | The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. ( Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ, 2006) |
| " Therefore, we examined the effect of pioglitazone, a PPARgamma agonist, on chronic left ventricular remodeling after experimental myocardial infarction (MI) in mice." | 3.72 | Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. ( Bauersachs, J; Bayer, B; Ertl, G; Frantz, S; Galuppo, P; Hu, K; Schmidt, I; Strotmann, J; Widder, J; Witzel, CC, 2004) |
| " Because proinflammatory cytokines play a critical role in left ventricular (LV) remodeling after myocardial infarction (MI), we examined the effects of pioglitazone treatment in an experimental model of chronic heart failure." | 3.71 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. ( Egashira, K; Hayashidani, S; Ikeuchi, M; Ishibashi, M; Kubota, T; Shiomi, T; Suematsu, N; Takeshita, A; Tsutsui, H; Wen, J, 2002) |
| " In the present study, we examined the role of PPARgamma in angiotensin II (Ang II)-induced hypertrophy of neonatal rat cardiac myocytes and in pressure overload-induced cardiac hypertrophy of mice." | 3.71 | Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. ( Asakawa, M; Hasegawa, H; Kadowaki, T; Komuro, I; Kubota, N; Masuda, Y; Nagai, T; Saito, T; Takano, H; Uozumi, H, 2002) |
| "In rats subjected to cerebral ischemia, post-ischemic treatment with either dose of pioglitazone alleviated particular motor deficits and sensory impairments on day 2 after MCAO." | 2.77 | Treatment of rats with pioglitazone in the reperfusion phase of focal cerebral ischemia: a preclinical stroke trial. ( Culman, J; Glatz, T; Gohlke, P; Herdegen, T; Nguyen-Ngoc, M; Zhao, Y, 2012) |
| "Similar insulin resistance is found in type 2 diabetes and is currently treated with insulin sensitizers (IS)." | 2.61 | A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer's Disease in transgenic mice. ( Craig, A; Issberner, J; Parvez, F, 2019) |
| "As rosiglitazone has recently been linked to a higher risk of heart failure, stroke, and all-cause mortality in old patients, it has been interrupted from the European market." | 2.50 | Modulatory effects of peroxisome proliferator-activated receptor-γ on CXCR3 chemokines. ( Antonelli, A; Di Domenicantonio, A; Fallahi, P; Ferrari, SM; Ferri, C; Manfredi, A, 2014) |
| "Autosomal dominant polycystic kidney disease (ADPKD) is the most common of the monogenic disorders and is characterized by bilateral renal cysts; cysts in other organs including liver, pancreas, spleen, testis and ovary; vascular abnormalities including intracranial aneurysms and subarachnoid hemorrhage; and cardiac disorders such as left ventricular hypertrophy (LVH), mitral valve regurgitation, mitral valve prolapse and aortic regurgitation." | 2.48 | PPAR-γ agonists in polycystic kidney disease with frequent development of cardiovascular disorders. ( Nagao, S; Yamaguchi, T, 2012) |
| "Treatment with pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, resulted in attenuation of pressure overload-induced LA fibrosis." | 2.48 | Novel strategy to prevent atrial fibrosis and fibrillation. ( Fukunaga, N; Hara, M; Kume, O; Saikawa, T; Takahashi, N; Teshima, Y; Wakisaka, O, 2012) |
| "The prevalence of NAFLD is likely to increase over time due to the epidemics of obesity and diabetes." | 2.48 | Vitamin E and nonalcoholic fatty liver disease. ( Pacana, T; Sanyal, AJ, 2012) |
| "Pioglitazone treatment increased oxygen saturation and pTyr14cav-1 vs." | 1.72 | Pioglitazone restores phosphorylation of downregulated caveolin-1 in right ventricle of monocrotaline-induced pulmonary hypertension. ( Balis, P; Doka, G; Klimas, J; Kmecova, Z; Krenek, P; Malikova, E; Pivackova, LB; Trubacova, S; Velasova, E, 2022) |
| "Pioglitazone was administered in BDL rats two weeks after the surgery for the next continuous four weeks." | 1.72 | Peroxisome proliferator-activated receptor-γ doesn't modify altered electrophysiological properties of the CA1 pyramidal neurons in a rat model of hepatic cirrhosis. ( Aghaei, I; Nazari, A; Pooladvand, V; Razavinasab, M; Shabani, M; Tahamtan, M, 2022) |
| "The HFHFr diet induced severe NAFLD in terms of steatosis, hepatitis, and fibrosis." | 1.72 | The effects of the voglibose on non-alcoholic fatty liver disease in mice model. ( Bae, J; Cha, BS; Kang, ES; Lee, BW; Lee, JY; Lee, M; Lee, YH; Shin, E, 2022) |
| "Osteosarcoma has been reported with treatment failure in up to 40% of cases." | 1.62 | Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft. ( Gopisetty, G; Jayavelu, S; Natarajan, A; Rajkumar, T; Ramachandran, B; Sundersingh, S, 2021) |
| "Pioglitazone treatment attenuated obesity-induced elastin fiber fragmentation and elastolytic activity and ameliorated the obesity-induced upregulation of cathepsin S and metalloproteinase 12, predominantly in the PVAT." | 1.62 | PPARγ activation improves the microenvironment of perivascular adipose tissue and attenuates aortic stiffening in obesity. ( Chen, JY; Chiou, YW; Jheng, HF; Kao, LZ; Leu, SY; Li, CY; Lien, IC; Tai, HC; Tang, MJ; Tsai, PJ; Tsai, YS; Weng, WT; Wu, YP; Yang, CC, 2021) |
| "Carvacrol treatment improved inhaled PQ-induced lug injury similar to the effects of dexamethasone." | 1.62 | Carvacrol and PPARγ agonist, pioglitazone, affects inhaled paraquat-induced lung injury in rats. ( Amin, F; Boskabady, MH; Kazerani, HR; Memarzia, A; Rad, HK, 2021) |
| "Pre-treatment with fenofibrate and pioglitazone in addition to their combination improved neurobehavioral dysfunction, reduced cerebral infarct volume, attenuated inflammatory and apoptotic markers and ameliorated histopathological changes in I/R injured rats." | 1.56 | The impact of single and combined PPAR-α and PPAR-γ activation on the neurological outcomes following cerebral ischemia reperfusion. ( Abdelrehim, AB; Ahmed, AF; Heeba, GH; Shehata, AHF, 2020) |
| "Ischemia reperfusion injury (IRI) during liver-metastasis resection for treatment of colon cancer may increase the risk of further metastasis." | 1.56 | Ischemia reperfusion-induced metastasis is resistant to PPARγ agonist pioglitazone in a murine model of colon cancer. ( Aoki, T; Bouvet, M; Fukuda, Y; Higuchi, T; Hoffman, RM; Inubushi, S; Murakami, M; Nishino, H; Singh, SR; Sugisawa, N; Tashiro, Y; Yamamoto, J, 2020) |
| "Traumatic brain injury is a leading cause of death and disability around the world." | 1.51 | Pioglitazone treatment prior to transplantation improves the efficacy of human mesenchymal stem cells after traumatic brain injury in rats. ( Das, M; Foran, E; Han, JY; Mayilsamy, K; Mohapatra, S; Mohapatra, SS; Tang, X; Willing, AE, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD) has become a major cause of chronic liver disease." | 1.51 | Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. ( Chen, L; Gao, YS; Li, YH; Sun, Y; Wang, M; Wang, Y; Wu, MY; Yang, JM; Zhang, SJ; Zhang, XL; Zheng, FJ; Zhou, L; Zhou, YM, 2019) |
| "Pioglitazone treatment started at the first signs of fibrosis in both models." | 1.51 | Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. ( Arora, G; Baumert, TF; Erstad, DJ; Fuchs, BC; Ghoshal, S; Hoshida, Y; Lanuti, M; Li, S; Masia, R; Sojoodi, M; Tanabe, KK, 2019) |
| "Cisplatin produced mechanical and cold hyperalgesia and decreased electrical thresholds of Aδ and C fibers, which were attenuated by coadministration of pioglitazone (10 mg/kg, intraperitoneally [i." | 1.51 | Pioglitazone, a PPARγ agonist, reduces cisplatin-evoked neuropathic pain by protecting against oxidative stress. ( Albino-Ramírez, AM; Khasabov, SG; Khasabova, IA; Kim, AH; Olson, JK; Seybold, VS; Simone, DA; Uhelski, ML; Wagner, CL, 2019) |
| "Pioglitazone can suppress the luminal occlusions of the tracheal graft in an allograft through enhanced Treg infiltration, and may provide new therapies to prevent BO." | 1.51 | The prevention of tracheal graft occlusion using pioglitazone: A mouse tracheal transplant model study. ( Ohtsuka, T; Shigenobu, T; Shimoda, M, 2019) |
| "There are only a few studies on the treatment of dermal fibrosis with sustained-release drugs." | 1.51 | Nanoparticle-mediated local delivery of pioglitazone attenuates bleomycin-induced skin fibrosis. ( Arita, T; Asai, J; Jo, JI; Kanemaru, M; Katoh, N; Kawai-Ohnishi, M; Tabata, Y; Tsutsumi, M; Wada, M, 2019) |
| "Pioglitazone is a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist and is widely used to treat type 2 diabetes." | 1.51 | Low-dose pioglitazone can ameliorate learning and memory impairment in a mouse model of dementia by increasing LRP1 expression in the hippocampus. ( Cha, BS; Kang, ES; Kim, E; Lee, BW; Lee, HC; Lee, M; Lee, PH; Lee, YH; Moon, JH; Seok, H; Shin, E; Yun, MR, 2019) |
| "Pioglitazone has been used for the treatment of nonalcoholic fatty liver disease (NAFLD) related to diabetes." | 1.51 | Adiponectin is required for pioglitazone-induced improvements in hepatic steatosis in mice fed a high-fat diet. ( de Mendonça, M; de Sousa, É; Dos Santos, BAC; Rodrigues, AC, 2019) |
| "Pioglitazone (PIO) is a peroxisome proliferator-activated receptor-γ agonist widely repositioned as an adjuvant of various drugs that have toxic effects due to its antioxidant and anti-inflammatory effects." | 1.51 | Pioglitazone as an adjuvant of amphotericin B for the treatment of cryptococcosis. ( Carmo, PHF; Costa, MC; de Brito, CB; de Souza, DG; Emídio, ECP; Freitas, GJC; Paixão, TA; Ribeiro, NQ; Santos, APN; Santos, DA; Silva, MF, 2019) |
| "Treatment with pioglitazone, significantly attenuated the postnatal propionic acid-induced social impairment, repetitive behavior, hyperactivity, anxiety and low exploratory activity." | 1.51 | A selective peroxisome proliferator-activated receptor-γ agonist benefited propionic acid induced autism-like behavioral phenotypes in rats by attenuation of neuroinflammation and oxidative stress. ( Mirza, R; Sharma, B, 2019) |
| "Pioglitazone treatment did not influence body weight or ovarian weight in either group." | 1.48 | Pioglitazone is effective for multiple phenotyepes of the Zucker fa/fa rat with polycystc ovary morphology and insulin resistance. ( Baba, T; Endo, T; Honnma, H; Ikeda, K; Kiya, T; Kuno, Y; Morishita, M; Saito, T, 2018) |
| "Pioglitazone treatment significantly altered levels of hepatic metabolites, including free fatty acids, lysophosphatidylcholines and phosphatidylcholines, in the liver." | 1.48 | Metabolomic and lipidomic analysis of the effect of pioglitazone on hepatic steatosis in a rat model of obese Type 2 diabetes. ( Jung, ES; Kim, DH; Lee, CH; Liu, KH; Park, CY; Suh, DH; Yang, H, 2018) |
| "Pioglitazone is an FDA-approved PPAR-γ agonist drug used to treat diabetes, and it has demonstrated neuroprotective effects in multiple models of central nervous system (CNS) injury." | 1.46 | Pioglitazone treatment following spinal cord injury maintains acute mitochondrial integrity and increases chronic tissue sparing and functional recovery. ( Bailey, WM; Cox, DH; Geldenhuys, WJ; Gensel, JC; Gollihue, JL; Patel, SP; Rabchevsky, AG; Sullivan, PG, 2017) |
| "Insulin resistance has been identified as the key mechanism linking depression and diabetes." | 1.46 | Curcumin reverses the depressive-like behavior and insulin resistance induced by chronic mild stress. ( Li, YC; Li, YJ; Qiao, JY; Shen, JD; Wei, Y, 2017) |
| "PIO attenuates injury-induced neointima formation, in part, through the activation of AMPK." | 1.46 | Pioglitazone Attenuates Injury-Induced Neointima Formation in Mouse Femoral Artery Partially through the Activation of AMP-Activated Protein Kinase. ( Fairaq, A; Osman, I; Segar, L, 2017) |
| "Asiatic acid (AA) has been demonstrated to exhibit anti-diabetic activity." | 1.46 | Protective effects of asiatic acid in a spontaneous type 2 diabetic mouse model. ( Fan, Y; Guo, X; Han, L; Hou, Y; Liu, T; Luo, G; Ma, X; Matsabisa, M; Qin, L; Sun, W; Wu, L; Xu, G; Xu, T; Zhou, J, 2017) |
| "Pioglitazone treatment significantly increased urinary calcium, serum TRAP, mRNA expression of RANKL, PPAR-γ as well as significantly decreased Runx2, OPG, osteocalcin and AMPK levels in diabetic rats." | 1.46 | Pioglitazone-induced bone loss in diabetic rats and its amelioration by berberine: A portrait of molecular crosstalk. ( Adil, M; Kandhare, AD; Mansoori, MN; Sharma, M; Singh, D, 2017) |
| "Pioglitazone treatment rescued a third of these proteins, mainly those associated with oxidative stress, promotion of cerebrovascular vasocontractile tone, and vascular compliance." | 1.46 | Proteomic differences in brain vessels of Alzheimer's disease mice: Normalization by PPARγ agonist pioglitazone. ( Badhwar, A; Brown, R; Hamel, E; Haqqani, AS; Stanimirovic, DB, 2017) |
| "Using a mouse model of lung squamous cell carcinoma (SCC), we performed transcriptome sequencing (RNA-Seq) to profile bronchial airway gene expression and found activation of the PI3K and Myc signaling networks in cytologically normal bronchial airway epithelial cells of mice with preneopastic lung SCC lesions, which was reversed by treatment with the PI3K Inhibitor XL-147 and pioglitazone, respectively." | 1.46 | Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents. ( Lubet, RA; Miller, MS; Pan, J; Szabo, E; Wang, Y; Xiong, D; You, M; Zhang, Q, 2017) |
| " Chronic administration of pioglitazone could contract this effect of BDL on event frequency and interevent interval, though the difference with the sham group was still significant in the duration of action potential." | 1.43 | Alterations in the intrinsic electrophysiological properties of Purkinje neurons in a rat model of hepatic encephalopathy: Relative preventing effect of PPARγ agonist. ( Aghaei, I; Dehpour, A; Haghani, M; Hajali, V; Shabani, M; Sheibani, V, 2016) |
| "Treatment with pioglitazone and ceftriaxone significantly prevented these behavioral, biochemical, mitochondrial and cellular alterations in rats." | 1.43 | Ameliorative potential of pioglitazone and ceftriaxone alone and in combination in rat model of neuropathic pain: Targeting PPARγ and GLT-1 pathways. ( Bhatnagar, A; Ekavali, E; Garg, S; Kumar, A; Pottabathini, R, 2016) |
| "To successfully treat Alzheimer's disease (AD), pathophysiological events in preclinical stages need to be identified." | 1.43 | Neuroinflammation impairs adaptive structural plasticity of dendritic spines in a preclinical model of Alzheimer's disease. ( Dorostkar, MM; Herms, J; Ohli, J; Schüller, U; Shi, Y; Zou, C, 2016) |
| "Pioglitazone treatment improved survival, reduced PASP, muscularization of small pulmonary arteries, and medial wall thickness." | 1.43 | Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension. ( Baldus, S; Behringer, A; Berghausen, EM; Blaschke, F; Caglayan, E; Er, F; Gassanov, N; Kappert, K; Odenthal, M; Rosenkranz, S; Ten Freyhaus, H; Trappiel, M; Wellnhofer, E, 2016) |
| "Pioglitazone is a type of peroxisome proliferator-activated receptor x03B3; agonist and is capable of alleviating renal ischemia-reperfusion injury." | 1.43 | Pioglitazone, a Peroxisome Proliferator-Activated Receptor x03B3; Agonist, Ameliorates Chronic Kidney Disease by Enhancing Antioxidative Capacity and Attenuating Angiogenesis in the Kidney of a 5/6 Nephrectomized Rat Model. ( Feng, J; Lu, C; Ma, J; Sun, L; Wang, D; Wang, L; Xu, T; Yao, L; Yuan, Q, 2016) |
| "Pioglitazone was administered intragastrically once per day for 3 weeks at different doses." | 1.43 | The antidepressant-like effects of pioglitazone in a chronic mild stress mouse model are associated with PPARγ-mediated alteration of microglial activation phenotypes. ( Fan, Y; Peng, C; Wu, X; Xie, X; Yan, S; You, Z; Zhang, J; Zhao, Q, 2016) |
| "Pioglitazone-pretreated ASCs had a more potent therapeutic effect than non-pretreated ASCs in the repair of both elastase-induced and smoke-induced emphysema models (mean linear intercept, 78." | 1.43 | Therapeutic effects of adipose-derived stem cells pretreated with pioglitazone in an emphysema mouse model. ( Hong, SH; Hong, Y; Kim, YS; Oh, YM, 2016) |
| "Sporadic Alzheimer's disease (AD) is a multifactorial metabolic brain disorder characterized by progressive neurodegeneration." | 1.42 | Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice. ( Blanchard, J; Gong, CX; Iqbal, K; Li, X; Li, Y; Liu, F; Yu, Y, 2015) |
| "Treatment with pioglitazone (PG), an activator of PPARγ, improved the viability of the cellular model of SBMA." | 1.42 | Pioglitazone suppresses neuronal and muscular degeneration caused by polyglutamine-expanded androgen receptors. ( Adachi, H; Iida, M; Ikenaka, K; Katsuno, M; Kishida, K; Kondo, N; Miyazaki, Y; Nakatsuji, H; Sobue, G; Tohnai, G; Watanabe, H; Yamamoto, M, 2015) |
| "Pretreatment with pioglitazone, as a PPARγ agonist, potentiated the anticonvulsant effects of WIN, while PPARγ antagonist inhibited these anticonvulsant effects partially." | 1.42 | Involvement of PPAR receptors in the anticonvulsant effects of a cannabinoid agonist, WIN 55,212-2. ( Aghaei, HN; Dehpour, AR; Ebrahimi, A; Gholizadeh, R; Gooshe, M; Mousavizadeh, K; Payandemehr, B; Rahimian, R; Varastehmoradi, B, 2015) |
| "Pioglitazone was administered in a dose of 1mg/kg at 10min after the brain trauma." | 1.42 | A single dose of PPARγ agonist pioglitazone reduces cortical oxidative damage and microglial reaction following lateral fluid percussion brain injury in rats. ( Dolenec, P; Mršić-Pelčić, J; Pilipović, K; Župan, G; Župan, Ž, 2015) |
| "Pioglitazone is a peroxisome proliferator-activated receptor (PPAR)-γ agonist that exhibits anti-inflammatory activity and is neuroprotective." | 1.42 | Pioglitazone blocks ethanol induction of microglial activation and immune responses in the hippocampus, cerebellum, and cerebral cortex in a mouse model of fetal alcohol spectrum disorders. ( Douglas, JC; Drew, PD; Johnson, JW; Kane, CJ; Phelan, KD, 2015) |
| "Rats treated with boswellic acids (125 or 250 mg/kg) or pioglitazone showed improved insulin sensitivity and a reduction in liver index, activities of liver enzymes, serum TNF-α and IL-6 as well as hepatic iNOS expression and HNE formation compared to HFD group." | 1.42 | Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure. ( Abdelaziz, EZ; Barakat, BM; Bilasy, SE; Farag, NE; Fawzy, MS; Zaitone, SA, 2015) |
| "Pioglitazone is a peroxisome proliferator-activated receptor-γ antidiabetic agent with antiproliferative effects on smooth muscle cells (SMCs), and antioxidant and anti-inflammatory actions." | 1.42 | The possible protective effect of simvastatin and pioglitazone separately and in combination on bleomycin-induced changes in mice thin skin. ( Balaha, M; Kandeel, S, 2015) |
| " When mice were dosed with racemic pioglitazone, the concentration of (+)-pioglitazone was 46." | 1.42 | Influence of drug transporters and stereoselectivity on the brain penetration of pioglitazone as a potential medicine against Alzheimer's disease. ( Chang, KL; Ho, PC; Pee, HN; Yang, S, 2015) |
| "Non-alcoholic fatty liver disease (NAFLD) defines a wide spectrum of liver diseases that extends from simple steatosis to non-alcoholic steatohepatitis." | 1.42 | LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD). ( Costa Oliveira, A; de Lima, Mdo C; de Oliveira Cipriano Torres, D; dos Santos Gomes, FO; dos Santos Silva, B; dos Santos, LA; Lima Ribeiro, E; Peixoto, CA; Pitta, Ida R; Soares e Silva, AK, 2015) |
| "Pioglitazone (3 mg/kg/day) was given to the combined therapy and pioglitazone groups by oral gavage at the same time for another 2 weeks." | 1.42 | Peroxisome Proliferator-Activated Receptor Gamma Promotes Mesenchymal Stem Cells to Express Connexin43 via the Inhibition of TGF-β1/Smads Signaling in a Rat Model of Myocardial Infarction. ( Guo, T; Hou, J; Huang, H; Long, H; Wang, J; Wang, L; Wang, T; Wu, Q; Xing, Y; Zheng, S; Zhong, T; Zhou, C, 2015) |
| "Hyperglycemia was induced by streptozotocin treatment." | 1.42 | Hyperglycemia and PPARγ Antagonistically Influence Macrophage Polarization and Infarct Healing After Ischemic Stroke. ( Gliem, M; Hartung, HP; Jander, S; Klotz, L; van Rooijen, N, 2015) |
| " The current study was carried out to investigate the effects of chronic administration of pioglitazone, a PPAR-γ agonist, on cognitive impairment in an animal model of Alzheimer's disease induced by β-amyloid." | 1.40 | Role of nuclear receptor on regulation of BDNF and neuroinflammation in hippocampus of β-amyloid animal model of Alzheimer's disease. ( Kumar, A; Prakash, A, 2014) |
| "Pretreatment with pioglitazone dose-dependently attenuated gastric lesions induced by ethanol in both sham and cholestatic rats, but this effect was more prominent in cholestatic ones." | 1.40 | The increased gastroprotective effect of pioglitazone in cholestatic rats: role of nitric oxide and tumour necrosis factor alpha. ( Amirghofran, Z; Dehpour, AR; Janahmadi, Z; Moezi, L; Nekooeian, AA, 2014) |
| "Pioglitazone is a peroxisome proliferator-activated receptor (PPAR) γ agonist and, although it is mostly used as an antidiabetic agent, it has been reported to have analgesic effects." | 1.40 | Antinociceptive and antidiarrheal effects of pioglitazone in a rat model of diarrhoea-predominant irritable bowel syndrome: role of nitric oxide. ( Azary, S; Dehpour, AR; Gharedaghi, MH; Javidan, AN; Kazemi, MH; Khalifeh-Soltani, A; Moradi, K; Paragomi, P; Rahimian, R; Sakuma, S, 2014) |
| "Dry eye was induced in 6-week-old female C57 mice." | 1.40 | Decreased PPAR-γ expression in the conjunctiva and increased expression of TNF-α and IL-1β in the conjunctiva and tear fluid of dry eye mice. ( Chen, Y; Li, B; Li, M; Sheng, M; Wang, W; Yang, L; Zhang, X, 2014) |
| "Pioglitazone treatment also resulted in increased expression of markers of mitochondrial biogenesis in brown adipose tissue and white adipose tissue, with mild elevations observed in animals treated with alogliptin alone." | 1.40 | Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats. ( Bettaieb, A; Cummings, BP; Graham, JL; Haj, FG; Havel, PJ; Stanhope, K, 2014) |
| "Pioglitazone pretreatment also suppressed NF-κB activation and altered GFAP overexpression." | 1.39 | Protective effect of pioglitazone on retinal ischemia/reperfusion injury in rats. ( Xiao, YQ; Ye, W; Zhang, XY; Zhang, Y, 2013) |
| "X-linked adrenoleukodystrophy is a neurometabolic disorder caused by inactivation of the peroxisomal ABCD1 transporter of very long-chain fatty acids." | 1.39 | Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy. ( Aubourg, P; Beal, MF; Calingasan, NY; Dumont, M; Ferrer, I; Fourcade, S; Galea, E; Galino, J; Martínez, JJ; Morató, L; Naudí, A; Pamplona, R; Portero-Otín, M; Pujol, A; Ruiz, M; Starkov, AA, 2013) |
| "Pioglitazone (PIO) is a member of the thiazolidinediones - a group of insulin-sensitizing drugs that are selective agonists of peroxisome proliferator-activated receptor gamma (PPARγ)." | 1.39 | Pioglitazone does not improve insulin signaling in mice with GH over-expression. ( Bartke, A; Gesing, A; Masternak, MM, 2013) |
| " Oral dyskinesia was induced by chronic administration of haloperidol (1 mg/kg i." | 1.39 | Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)--α and γ agonist against a rat model of oral dyskinesia. ( Budhiraja, RD; Grover, S; Kumar, P; Singh, K; Vikram, V, 2013) |
| "The objective of the current study was to assess the possible pharmacokinetic interactions of spirulina with glitazones in an insulin resistance rat model." | 1.39 | Assessment of pharmacokinetic interaction of spirulina with glitazone in a type 2 diabetes rat model. ( Al-Dhubiab, BE; Chattopadhyaya, I; Gupta, A; Gupta, S; Kumria, R; Nair, A, 2013) |
| "Pioglitazone treatment significantly increased phosphorylated (p-) Akt but significantly reduced p-ERK1/2 and p-JNK." | 1.38 | PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. ( Aonuma, K; Hirayama, A; Igarashi, M; Ito, Y; Murakoshi, N; Seo, Y; Tada, H; Xu, D, 2012) |
| "Pioglitazone treatment (2." | 1.38 | Reduction of renal lipid content and proteinuria by a PPAR-γ agonist in a rat model of angiotensin II-induced hypertension. ( Hongo, M; Ishizaka, N; Nagai, R; Saito, K; Sakamoto, A, 2012) |
| "Pioglitazone was also investigated for its effects on parameters of oxidative stress by measuring malondialdehyde (MDA) and reduced glutathione (GSH) levels in the brain." | 1.38 | Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease. ( Gupta, LK; Gupta, R, 2012) |
| "Pioglitazone is a novel class of oral antidiabetic agents currently used to treat type 2 diabetes mellitus." | 1.38 | Protective effects of pioglitazone on renal ischemia-reperfusion injury in mice. ( Hu, H; Huang, X; Shi, Z; Wang, G; Xi, X; Zou, C, 2012) |
| "Telmisartan is an angiotensin II receptor blocker, which acts as a partial agonist of peroxisome proliferator activator receptor-γ (PPAR-γ)." | 1.38 | Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia. ( Hirata, Y; Hishikari, K; Isobe, M; Masumura, M; Nagai, R; Nagashima, A; Ogawa, M; Shimizu, T; Suzuki, J; Takayama, K; Watanabe, R, 2012) |
| "Pioglitazone was administered prophylactically and pancreatic inflammation was assessed." | 1.38 | Pioglitazone, a PPAR-γ activator, attenuates the severity of cerulein-induced acute pancreatitis by modulating early growth response-1 transcription factor. ( Chen, G; Liu, J; Wan, H; Yuan, Y, 2012) |
| "Pioglitazone treatment resulted in the phenotypic polarization of microglial cells from a proinflammatory M1 state, into an anti-inflammatory M2 state that was associated with enhanced phagocytosis of deposited forms of amyloid." | 1.38 | Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. ( Karlo, JC; Landreth, GE; Mandrekar-Colucci, S, 2012) |
| "Treatment of pioglitazone lowered blood glucose level and prevented delay of MNCV in SDT fatty rats." | 1.38 | Diabetic peripheral neuropathy in Spontaneously Diabetic Torii-Lepr(fa) (SDT fatty) rats. ( Kemmochi, Y; Matsushita, M; Mera, Y; Ohta, T; Sasase, T; Sato, E; Tadaki, H; Tomimoto, D; Yamaguchi, T, 2012) |
| "Treatment with Pioglitazone prevented the increase in the number of activated microglia and no difference was observed between sham and Pioglitazone-treated animals." | 1.37 | Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. ( Bing, G; Gao, J; Liu, M; Pauly, JR; Readnower, R; Sauerbeck, A; Sullivan, PG, 2011) |
| "Permanent middle cerebral artery occlusion (pMCAO) model was induced by using an intraluminal filament technique in rats." | 1.37 | Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor-κB signaling pathway. ( Hong, LZ; Liu, CF; Liu, J; Qin, AP; Qin, ZH; Wei, C; Xu, M; Zhang, HL; Zhao, XY, 2011) |
| "Rodent models of FASD have previously demonstrated that both Purkinje cells and granule cells, which are the two major types of neurons in the cerebellum, are highly susceptible to the toxic effects of ethanol." | 1.37 | Protection of neurons and microglia against ethanol in a mouse model of fetal alcohol spectrum disorders by peroxisome proliferator-activated receptor-γ agonists. ( Douglas, JC; Drew, PD; Han, L; Kane, CJ; Phelan, KD; Smith, RR; Xie, J, 2011) |
| "Pioglitazone was given at the dose of 10mg/kgd by gavage for the last 12 weeks of the 16-week period." | 1.37 | Effect of pioglitazone on altered expression of Aβ metabolism-associated molecules in the brain of fructose-drinking rats, a rodent model of insulin resistance. ( Dong, C; Hou, L; Hou, X; Liu, X; Luo, D; Wang, M; Xu, S, 2011) |
| "Pioglitazone (PGZ) is an agonist of peroxisome proliferator-activated receptor gamma (PPARg), itself a member of the nuclear receptor superfamily, responsible for the modulation of a number of metabolic pathways, including cell differentiation, metabolism of lipids and inflammation." | 1.37 | Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models. ( Borbath, I; Stärkel, P, 2011) |
| "Treatment with pioglitazone significantly inhibited the increases in the serum interleukin-6 and monocyte chemoattractant protein-1 (MCP-1) levels after CLP and lowered the mRNA expressions of proinflammatory cytokines, interleukin-6, and MCP-1 in omental tissue after CLP." | 1.37 | Effects of pioglitazone on survival and omental adipocyte function in mice with sepsis induced by cecal ligation and puncture. ( Kutsukake, M; Matsuda, A; Matsutani, T; Sasajima, K; Tamura, K; Tsujimura, Y; Uchida, E, 2011) |
| "Inflammation is an essential component of vulnerable or high-risk atheromas." | 1.37 | Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. ( Calcagno, C; Dickson, SD; Fayad, ZA; Fisher, EA; Fuster, V; Hayashi, K; Lin, J; Moon, MJ; Moshier, E; Mounessa, JS; Nicolay, K; Roytman, M; Rudd, JH; Tsimikas, S; Vucic, E, 2011) |
| "Pioglitazone treatment (2 wk) ameliorated dysmetabolism, increased islet insulin content, restored glucose-stimulated insulin secretion, and preserved beta-cell mass in db/db mice but had no significant effects in m/m mice." | 1.36 | Molecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARgamma agonist. ( Hamamoto, S; Hashiramoto, M; Kaku, K; Kanda, Y; Kawasaki, F; Matsuki, M; Nakashima, K; Shimoda, M; Tawaramoto, K, 2010) |
| "Sustained left ventricular hypertrophy (LVH) accelerates cardiac dysfunction and heart failure." | 1.36 | Activation of PPARgamma by pioglitazone does not attenuate left ventricular hypertrophy following aortic banding in rats. ( Bekeredjian, R; Buss, SJ; Hagenmüller, M; Hardt, SE; Katus, HA; Münz, S; Ochs, M; Pichler, M; Weiss, CS, 2010) |
| " Translation of these findings into clinical therapy will require careful assessment of dosing paradigms and effective time windows for treatment." | 1.36 | Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion. ( Blankenship, DA; Gamboa, J; Hilow, E; Karl, M; Landreth, GE; Niemi, JP; Sundararajan, S, 2010) |
| "Mechanical hyperalgesia was measured using Von-Frey filament tests before and after the surgery." | 1.36 | Repeated administration of pioglitazone attenuates development of hyperalgesia in a rat model of neuropathic pain. ( Duan, M; Hui, K; Ji, Q; Jia, H; Li, W; Xu, J; Zhu, S, 2010) |
| "Pioglitazone treatment of virally-infected smoke-exposed mice proved more efficacious than the steroid intervention." | 1.36 | Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection. ( Bauer, CM; Botelho, FM; Brown, EG; Lambert, KN; Mossman, KL; Stämpfli, MR; Taylor, JD; Zavitz, CC, 2010) |
| "Pioglitazone treatment reduced the infarct size and improved neurological functions." | 1.35 | Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia. ( Culman, J; Gohlke, P; Herdegen, T; Patzer, A; Stöck, I; Zhao, Y, 2008) |
| " Chronic administration of pioglitazone (10 and 30 mg/kg, p." | 1.35 | Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease. ( Kaundal, RK; Kumar, P; More, S; Sharma, SS, 2009) |
| "Pioglitazone pretreatment also attenuated the oxidative stress and DNA fragmentation after cerebral IR injury." | 1.35 | Protective effects of pioglitazone against global cerebral ischemic-reperfusion injury in gerbils. ( Iyer, S; Kaundal, RK; Kumar, A; Sharma, SS, 2009) |
| "Glioblastoma represent the most common primary brain tumor in adults and are currently considered incurable." | 1.35 | PPARgamma and RXRgamma ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models. ( Heneka, MT; Hermes, M; Kummer, MP; Orlandi, M; Papi, A; Tatenhorst, L; Terwel, D, 2009) |
| "Pioglitazone-treated mice showed improvement in insulin resistance, adipokine, and lipid profile." | 1.35 | The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus. ( Brosius, FC; Hodgin, JB; Kaplan, MJ; Kretzler, M; Park, JL; Pennathur, S; Randolph, A; Somers, EC; Thacker, SG; Wang, JH; Zhang, H; Zhao, W, 2009) |
| "Cystic epithelia in polycystic kidney disease display features similar to malignant cells." | 1.35 | Effect of pioglitazone on survival and renal function in a mouse model of polycystic kidney disease. ( Baird, BC; Germino, GG; Kohan, DE; Piontek, K; Raphael, KL; Strait, KA; Stricklett, PK, 2009) |
| "Treatment with candesartan, pioglitazone, and their combination resulted in significantly reduced mRNA expression of the inflammatory markers CXCL1 and TNFalpha in vivo (P<0." | 1.35 | Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain. ( Kintscher, U; Krikov, M; Müller, S; Schefe, JH; Schmerbach, K; Thoene-Reineke, C; Unger, T; Villringer, A, 2008) |
| "Pioglitazone did inhibit the increase in expressions vs I/R (P < 0." | 1.35 | Antiapoptosis and mitochondrial effect of pioglitazone preconditioning in the ischemic/reperfused heart of rat. ( Feng, YB; Lang, MJ; Li, J; Mao, XB; Tian, L, 2008) |
| "Pioglitazone treatment ameliorated the level of decrease in adiponectin expression and improved colonic inflammation induced by the omega-3 fat-rich diet." | 1.35 | Omega-3 fatty acids exacerbate DSS-induced colitis through decreased adiponectin in colonic subepithelial myofibroblasts. ( Hokari, R; Itoh, K; Kawaguchi, A; Komoto, S; Kurihara, C; Matsunaga, H; Miura, S; Nagao, S; Nakamura, M; Okada, Y; Okudaira, K; Takebayashi, K; Tsuzuki, Y; Watanabe, C, 2008) |
| "Fenofibrate did not inhibit mechanical allodynia or paw edema induced by phorbol-12,13-didecanoate (PDD), a protein kinase C activator, in rats." | 1.34 | Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. ( Bertollo, CM; Coelho, MM; Costa, KA; Nascimento, EB; Oliveira, AC; Rocha, LT, 2007) |
| "Treatment with pioglitazone and rosiglitazone significantly decreased the AT(1)R specific binding in HFD fed rats." | 1.34 | PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance. ( Gaikwad, AB; Ramarao, P; Viswanad, B, 2007) |
| "Rosiglitazone treatment curtailed the post-ischemic expression of the pro-inflammatory genes interleukin-1beta, interleukin-6, macrophage inflammatory protein-1alpha, monocyte chemoattractant protein-1, cyclooxygenase-2, inducible nitric oxide synthase, early growth response-1, CCAAT/enhancer binding protein-beta and nuclear factor-kappa B, and increased the expression of the anti-oxidant enzymes catalase and copper/zinc-superoxide dismutase." | 1.34 | Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. ( Bowen, KK; Feinstein, DL; Kapadia, R; Liang, J; Satriotomo, I; Tureyen, K; Vemuganti, R, 2007) |
| "The term nonalcoholic steatohepatitis (NASH) has recently been proposed to identify a fatty liver disease accompanied by diffuse fatty infiltration and inflammation." | 1.34 | Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. ( Fujita, K; Inamori, M; Iwasaki, T; Kirikoshi, H; Maeyama, S; Mawatari, H; Nakajima, A; Nozaki, Y; Saito, S; Takahashi, H; Terauchi, Y; Wada, K; Yoneda, M, 2007) |
| "Diabetic nephropathy is the most serious of complications in diabetes mellitus." | 1.34 | Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats. ( Cho, BP; Chung, CH; Koh, JH; Lee, BJ; Lee, EY; Lee, MY; Shin, JY; Shin, YG; Won, CS, 2007) |
| "Pioglitazone reduced the development of cartilage lesions in a dose-dependent manner, with the highest dosage producing a statistically significant change (P < 0." | 1.34 | The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: in vivo protective effects mediated through the inhibition of key signaling and cataboli ( Boileau, C; Boily, M; Fahmi, H; Martel-Pelletier, J; Mineau, F; Pelletier, JP, 2007) |
| "Our results identify hyperinsulinemia and the attendant increase of TGF-beta expression as potential therapeutic targets in diabetes independent of glycemic control." | 1.34 | Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model. ( Izuhara, Y; Kakuta, T; Miyata, T; Ohtomo, S; Takizawa, S; van Ypersele de Strihou, C; Yamada, N, 2007) |
| "Pioglitazone treatment extended survival by 13%, and it reduced gliosis as assessed by immunohistochemical staining for CD-40 and GFAP." | 1.33 | Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. ( Beal, MF; Calingasan, NY; Chen, J; Kiaei, M; Kipiani, K, 2005) |
| "Neuritic plaques in the brain of Alzheimer's disease patients are characterized by beta-amyloid deposits associated with a glia-mediated inflammatory response." | 1.33 | Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. ( Dewachter, I; Dumitrescu-Ozimek, L; Hanke, A; Heneka, MT; Klockgether, T; Kuiperi, C; Landreth, GE; O'Banion, K; Sastre, M; Van Leuven, F, 2005) |
| "Fenofibrate treatment significantly improved lipoprotein metabolism toward a less atherogenic phenotype but did not affect insulin sensitivity." | 1.33 | PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. ( Fiévet, C; Fruchart, JC; Hennuyer, N; Mezdour, H; Staels, B; Tailleux, A; Torpier, G, 2005) |
| "Pioglitazone or vehicle were i." | 1.33 | The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. ( Culman, J; Gohlke, P; Herdegen, T; Patzer, A; Zhao, Y, 2005) |
| "Using cells and prostate cancer xenograft mouse models, we demonstrate in this study that a combination treatment using the PPARgamma agonist pioglitazone and the histone deacetylase inhibitor valproic acid is more efficient at inhibiting prostate tumor growth than each individual therapy." | 1.33 | Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. ( Abella, A; Annicotte, JS; Berthe, ML; Culine, S; Dubus, P; Fajas, L; Fritz, V; Iankova, I; Iborra, F; Maudelonde, T; Miard, S; Noël, D; Pillon, A; Sarruf, D, 2006) |
| "The use of PPAR-gamma agonists in the treatment of heart failure is, however, controversial." | 1.32 | Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure. ( Thiemermann, C, 2004) |
| "Because coronary artery disease is a major complication for such patients, it is important to determine the effects of PPARgamma activation on arteriosclerosis." | 1.31 | Antiinflammatory and antiarteriosclerotic effects of pioglitazone. ( Egashira, K; Hiasa, K; Ichiki, T; Inoue, S; Ishibashi, M; Kitamoto, S; Ni, W; Takeshita, A; Usui, M; Zhao, Q, 2002) |
| "When pioglitazone was administered to the rats at a dose of 10 mg/kg/day for 4 weeks from 12 weeks of age, plasma triglyceride and insulin levels and systolic blood pressure decreased, and blood glucose reduction in response to insulin was normalized." | 1.30 | Effect of an insulin sensitizer, pioglitazone, on hypertension in fructose-drinking rats. ( Ikeda, H; Nomura, C; Odaka, H; Suzuki, M, 1997) |
| "The effects of dietary fructose alone or in combination with a new oral agent, pioglitazone, on VLDL-triglyceride (TG) turnover were studied in genetically obese Wistar fatty rats characterized by hyperinsulinemia (7,488 +/- 954 pmol/l), hyperglycemia, (22." | 1.29 | VLDL triglyceride kinetics in Wistar fatty rats, an animal model of NIDDM: effects of dietary fructose alone or in combination with pioglitazone. ( Amano, N; Ebara, T; Hirano, T; Hozumi, T; Ishida, Y; Kazumi, T; Odaka, H; Yoshino, G, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (1.44) | 18.2507 |
| 2000's | 90 (25.94) | 29.6817 |
| 2010's | 222 (63.98) | 24.3611 |
| 2020's | 30 (8.65) | 2.80 |
| Authors | Studies |
|---|---|
| Cantello, BC | 1 |
| Cawthorne, MA | 1 |
| Cottam, GP | 1 |
| Duff, PT | 1 |
| Haigh, D | 1 |
| Hindley, RM | 1 |
| Lister, CA | 1 |
| Smith, SA | 1 |
| Thurlby, PL | 1 |
| Nazreen, S | 1 |
| Alam, MS | 1 |
| Hamid, H | 1 |
| Yar, MS | 1 |
| Dhulap, A | 1 |
| Alam, P | 1 |
| Pasha, MA | 1 |
| Bano, S | 1 |
| Alam, MM | 1 |
| Haider, S | 1 |
| Kharbanda, C | 1 |
| Ali, Y | 1 |
| Pillai, KK | 1 |
| Choung, W | 1 |
| Jung, HJ | 1 |
| Nam, EH | 1 |
| Yang, D | 1 |
| Yoo, B | 1 |
| Choi, H | 1 |
| Lee, BR | 1 |
| Park, M | 1 |
| Jang, SM | 1 |
| Lim, JS | 1 |
| Kim, KH | 1 |
| Chin, J | 1 |
| Jung, K | 1 |
| Lee, G | 1 |
| Kim, SH | 2 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 3 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Biechele, G | 2 |
| Blume, T | 1 |
| Deussing, M | 1 |
| Zott, B | 1 |
| Shi, Y | 2 |
| Xiang, X | 1 |
| Franzmeier, N | 1 |
| Kleinberger, G | 1 |
| Peters, F | 1 |
| Ochs, K | 1 |
| Focke, C | 1 |
| Sacher, C | 1 |
| Wind, K | 1 |
| Schmidt, C | 1 |
| Lindner, S | 1 |
| Gildehaus, FJ | 1 |
| Eckenweber, F | 2 |
| Beyer, L | 1 |
| von Ungern-Sternberg, B | 1 |
| Bartenstein, P | 2 |
| Baumann, K | 1 |
| Dorostkar, MM | 2 |
| Rominger, A | 1 |
| Cumming, P | 1 |
| Willem, M | 1 |
| Adelsberger, H | 1 |
| Herms, J | 3 |
| Brendel, M | 2 |
| Assmann, AK | 1 |
| Goschmer, D | 1 |
| Sugimura, Y | 1 |
| Chekhoeva, A | 1 |
| Barth, M | 1 |
| Assmann, A | 1 |
| Lichtenberg, A | 1 |
| Akhyari, P | 1 |
| Zheng, J | 1 |
| Chen, X | 1 |
| Wu, L | 2 |
| Zhou, Y | 1 |
| Wang, Z | 1 |
| Li, J | 4 |
| Liu, Y | 7 |
| Peng, G | 1 |
| Berggren, PO | 1 |
| Zheng, X | 1 |
| Tong, N | 1 |
| Malikova, E | 1 |
| Kmecova, Z | 1 |
| Doka, G | 1 |
| Pivackova, LB | 1 |
| Balis, P | 1 |
| Trubacova, S | 1 |
| Velasova, E | 1 |
| Krenek, P | 1 |
| Klimas, J | 1 |
| Santos, DFS | 1 |
| Donahue, RR | 1 |
| Laird, DE | 1 |
| Oliveira, MCG | 1 |
| Taylor, BK | 1 |
| Piątkowska-Chmiel, I | 1 |
| Herbet, M | 1 |
| Gawrońska-Grzywacz, M | 1 |
| Dudka, J | 1 |
| Zamanian, MY | 1 |
| Taheri, N | 1 |
| Opulencia, MJC | 1 |
| Bokov, DO | 1 |
| Abdullaev, SY | 1 |
| Gholamrezapour, M | 1 |
| Heidari, M | 1 |
| Bazmandegan, G | 1 |
| Tahamtan, M | 1 |
| Aghaei, I | 2 |
| Shabani, M | 2 |
| Nazari, A | 1 |
| Pooladvand, V | 1 |
| Razavinasab, M | 1 |
| Bae, J | 1 |
| Lee, JY | 1 |
| Shin, E | 2 |
| Lee, M | 2 |
| Lee, YH | 2 |
| Lee, BW | 2 |
| Kang, ES | 2 |
| Cha, BS | 3 |
| Camacho, RC | 1 |
| Polidori, D | 1 |
| Chen, T | 1 |
| Chen, B | 1 |
| Hsu, HH | 1 |
| Gao, B | 1 |
| Marella, M | 1 |
| Lubomirski, M | 1 |
| Beavers, T | 1 |
| Cabrera, J | 1 |
| Wong, P | 1 |
| Nawrocki, AR | 1 |
| Kunze, LH | 1 |
| Ruch, F | 1 |
| Wind-Mark, K | 1 |
| Dinkel, L | 1 |
| Feyen, P | 1 |
| Ziegler, S | 1 |
| Paeger, L | 1 |
| Tahirovic, S | 1 |
| Elkhatib, MAW | 1 |
| Mroueh, A | 1 |
| Rafeh, RW | 1 |
| Sleiman, F | 1 |
| Fouad, H | 1 |
| Saad, EI | 1 |
| Fouda, MA | 1 |
| Elgaddar, O | 1 |
| Issa, K | 1 |
| Eid, AH | 1 |
| Eid, AA | 1 |
| Abd-Elrahman, KS | 1 |
| El-Yazbi, AF | 1 |
| Das, M | 1 |
| Mayilsamy, K | 1 |
| Tang, X | 1 |
| Han, JY | 2 |
| Foran, E | 1 |
| Willing, AE | 1 |
| Mohapatra, SS | 1 |
| Mohapatra, S | 1 |
| Yang, JM | 1 |
| Sun, Y | 1 |
| Wang, M | 2 |
| Zhang, XL | 1 |
| Zhang, SJ | 1 |
| Gao, YS | 1 |
| Chen, L | 1 |
| Wu, MY | 1 |
| Zhou, L | 1 |
| Zhou, YM | 1 |
| Wang, Y | 4 |
| Zheng, FJ | 1 |
| Li, YH | 1 |
| de Mendonça, M | 2 |
| de Sousa, É | 2 |
| da Paixão, AO | 1 |
| Araújo Dos Santos, B | 1 |
| Roveratti Spagnol, A | 1 |
| Murata, GM | 1 |
| Araújo, HN | 1 |
| Imamura de Lima, T | 1 |
| Passos Simões Fróes Guimarães, DS | 1 |
| Silveira, LR | 1 |
| Rodrigues, AC | 2 |
| Zhang, R | 2 |
| Shen, H | 1 |
| Kong, J | 1 |
| Lv, X | 1 |
| Yonutas, HM | 1 |
| Hubbard, WB | 1 |
| Pandya, JD | 2 |
| Vekaria, HJ | 1 |
| Geldenhuys, WJ | 2 |
| Sullivan, PG | 4 |
| Nasreen, W | 1 |
| Sarker, S | 1 |
| Sufian, MA | 1 |
| Md Opo, FAD | 1 |
| Shahriar, M | 1 |
| Akhter, R | 1 |
| Halim, MA | 1 |
| Wachal, Z | 1 |
| Bombicz, M | 1 |
| Priksz, D | 1 |
| Hegedűs, C | 1 |
| Kovács, D | 1 |
| Szabó, AM | 1 |
| Kiss, R | 1 |
| Németh, J | 1 |
| Juhász, B | 1 |
| Szilvássy, Z | 1 |
| Varga, B | 1 |
| Shehata, AHF | 1 |
| Ahmed, AF | 1 |
| Abdelrehim, AB | 1 |
| Heeba, GH | 1 |
| Seo, JA | 1 |
| Kang, MC | 1 |
| Yang, WM | 1 |
| Hwang, WM | 1 |
| Kim, SS | 1 |
| Hong, SH | 2 |
| Heo, JI | 1 |
| Vijyakumar, A | 1 |
| Pereira de Moura, L | 1 |
| Uner, A | 1 |
| Huang, H | 3 |
| Lee, SH | 1 |
| Lima, IS | 1 |
| Park, KS | 1 |
| Kim, MS | 1 |
| Dagon, Y | 1 |
| Willnow, TE | 1 |
| Aroda, V | 1 |
| Ciaraldi, TP | 1 |
| Henry, RR | 1 |
| Kim, YB | 1 |
| Qin, X | 1 |
| Wang, W | 2 |
| Wu, H | 1 |
| Liu, D | 1 |
| Wang, R | 1 |
| Xu, J | 2 |
| Jiang, H | 1 |
| Pan, F | 1 |
| Nakano, Y | 2 |
| Arima, T | 1 |
| Tobita, Y | 1 |
| Uchiyama, M | 2 |
| Shimizu, A | 2 |
| Takahashi, H | 3 |
| Natarajan, A | 1 |
| Ramachandran, B | 1 |
| Gopisetty, G | 1 |
| Jayavelu, S | 1 |
| Sundersingh, S | 1 |
| Rajkumar, T | 1 |
| Tashiro, Y | 1 |
| Nishino, H | 1 |
| Higuchi, T | 1 |
| Sugisawa, N | 1 |
| Fukuda, Y | 2 |
| Yamamoto, J | 1 |
| Inubushi, S | 1 |
| Aoki, T | 1 |
| Murakami, M | 1 |
| Singh, SR | 1 |
| Bouvet, M | 1 |
| Hoffman, RM | 1 |
| Hanson, KA | 1 |
| McCormack, G | 1 |
| Atkinson, RAK | 1 |
| Dittmann, J | 1 |
| Vickers, JC | 1 |
| Fernandez-Martos, CM | 1 |
| King, AE | 1 |
| Luo, Q | 1 |
| Su, Z | 1 |
| Xing, J | 2 |
| Wu, J | 1 |
| Xiang, L | 1 |
| Huang, Y | 3 |
| Pan, H | 1 |
| Wu, X | 2 |
| Zhang, X | 5 |
| Yan, F | 1 |
| Zhang, H | 4 |
| Chen, JY | 1 |
| Wu, YP | 1 |
| Li, CY | 1 |
| Jheng, HF | 1 |
| Kao, LZ | 1 |
| Yang, CC | 1 |
| Leu, SY | 1 |
| Lien, IC | 1 |
| Weng, WT | 1 |
| Tai, HC | 1 |
| Chiou, YW | 1 |
| Tang, MJ | 1 |
| Tsai, PJ | 1 |
| Tsai, YS | 1 |
| Amin, F | 1 |
| Memarzia, A | 1 |
| Rad, HK | 1 |
| Kazerani, HR | 1 |
| Boskabady, MH | 1 |
| Zhao, Y | 4 |
| Lützen, U | 1 |
| Gohlke, P | 4 |
| Jiang, P | 1 |
| Herdegen, T | 4 |
| Culman, J | 4 |
| Ito, Y | 2 |
| Yamamoto, M | 3 |
| Furukawa, S | 1 |
| Fukui, M | 1 |
| Morishita, K | 1 |
| Kitao, T | 1 |
| Shirahase, H | 1 |
| El-Fayoumi, S | 1 |
| Mansour, R | 1 |
| Mahmoud, A | 1 |
| Fahmy, A | 1 |
| Ibrahim, I | 1 |
| Abdelhafez, AT | 1 |
| Gomaa, AMS | 1 |
| Ahmed, AM | 1 |
| Sayed, MM | 1 |
| Ahmed, MA | 1 |
| Hidalgo-Figueroa, S | 1 |
| Navarrete-Vázquez, G | 1 |
| Estrada-Soto, S | 1 |
| Giles-Rivas, D | 1 |
| Alarcón-Aguilar, FJ | 2 |
| León-Rivera, I | 1 |
| Giacoman-Martínez, A | 1 |
| Miranda Pérez, E | 1 |
| Almanza-Pérez, JC | 1 |
| Patel, SP | 1 |
| Cox, DH | 1 |
| Gollihue, JL | 1 |
| Bailey, WM | 1 |
| Gensel, JC | 1 |
| Rabchevsky, AG | 1 |
| Shen, JD | 2 |
| Wei, Y | 1 |
| Li, YJ | 2 |
| Qiao, JY | 1 |
| Li, YC | 2 |
| Wassef, MAE | 1 |
| Tork, OM | 1 |
| Rashed, LA | 1 |
| Ibrahim, W | 1 |
| Morsi, H | 1 |
| Rabie, DMM | 1 |
| Gao, F | 1 |
| Zang, L | 1 |
| Wu, DY | 1 |
| Zhang, Q | 3 |
| Wang, HB | 1 |
| Tian, GL | 1 |
| Mu, YM | 1 |
| Osman, I | 1 |
| Fairaq, A | 1 |
| Segar, L | 1 |
| Lyons, DN | 2 |
| Zhang, L | 2 |
| Danaher, RJ | 2 |
| Miller, CS | 2 |
| Westlund, KN | 2 |
| Ma, F | 1 |
| Sirbu, C | 1 |
| Simeone, TA | 2 |
| Matthews, SA | 2 |
| Simeone, KA | 2 |
| Sun, W | 2 |
| Xu, G | 2 |
| Guo, X | 2 |
| Luo, G | 1 |
| Hou, Y | 1 |
| Zhou, J | 2 |
| Xu, T | 2 |
| Qin, L | 1 |
| Fan, Y | 2 |
| Han, L | 2 |
| Matsabisa, M | 1 |
| Ma, X | 1 |
| Liu, T | 2 |
| Adil, M | 1 |
| Mansoori, MN | 1 |
| Singh, D | 1 |
| Kandhare, AD | 1 |
| Sharma, M | 1 |
| Hsiao, PJ | 1 |
| Chiou, HC | 1 |
| Jiang, HJ | 1 |
| Lee, MY | 2 |
| Hsieh, TJ | 1 |
| Kuo, KK | 1 |
| Sallese, A | 1 |
| Suzuki, T | 1 |
| McCarthy, C | 1 |
| Bridges, J | 1 |
| Filuta, A | 1 |
| Arumugam, P | 1 |
| Shima, K | 1 |
| Ma, Y | 1 |
| Wessendarp, M | 1 |
| Black, D | 1 |
| Chalk, C | 1 |
| Carey, B | 1 |
| Trapnell, BC | 1 |
| Mak, A | 1 |
| Kato, R | 1 |
| Weston, K | 1 |
| Hayes, A | 1 |
| Uetrecht, J | 1 |
| Bonato, JM | 1 |
| Bassani, TB | 2 |
| Milani, H | 1 |
| Vital, MABF | 2 |
| de Oliveira, RMW | 1 |
| Pane, B | 1 |
| Gazzola, V | 1 |
| Spinella, G | 1 |
| Bagnato, P | 1 |
| Grillo, F | 1 |
| Vellone, VG | 1 |
| Palombo, D | 1 |
| Shen, D | 1 |
| Li, H | 2 |
| Zhou, R | 1 |
| Liu, MJ | 1 |
| Yu, H | 1 |
| Wu, DF | 1 |
| Al Sharif, M | 1 |
| Alov, P | 1 |
| Diukendjieva, A | 1 |
| Vitcheva, V | 1 |
| Simeonova, R | 1 |
| Krasteva, I | 1 |
| Shkondrov, A | 1 |
| Tsakovska, I | 1 |
| Pajeva, I | 1 |
| Gao, H | 1 |
| Shen, X | 1 |
| Di, B | 1 |
| Motohashi, Y | 1 |
| Kemmochi, Y | 2 |
| Maekawa, T | 2 |
| Tadaki, H | 2 |
| Sasase, T | 2 |
| Tanaka, Y | 1 |
| Kakehashi, A | 1 |
| Yamada, T | 2 |
| Ohta, T | 3 |
| Morishita, M | 1 |
| Endo, T | 1 |
| Baba, T | 1 |
| Kuno, Y | 1 |
| Ikeda, K | 1 |
| Kiya, T | 1 |
| Honnma, H | 1 |
| Saito, T | 3 |
| Toriniwa, Y | 1 |
| Miyajima, K | 1 |
| Ishii, Y | 1 |
| Uno, K | 1 |
| Matsui, T | 1 |
| Kume, S | 1 |
| Ekladious, ST | 1 |
| El Sayed, NS | 1 |
| Ali, RM | 1 |
| Al-Shorbagy, MY | 1 |
| Helmy, MW | 1 |
| El-Abhar, HS | 1 |
| Refaie, MMM | 1 |
| El-Hussieny, M | 1 |
| Yang, H | 2 |
| Suh, DH | 1 |
| Kim, DH | 1 |
| Jung, ES | 1 |
| Liu, KH | 1 |
| Lee, CH | 1 |
| Park, CY | 1 |
| Chang, L | 1 |
| Zhao, X | 1 |
| Garcia-Barrio, M | 1 |
| Zhang, J | 3 |
| Eugene Chen, Y | 1 |
| Tokutome, M | 2 |
| Matoba, T | 2 |
| Okahara, A | 1 |
| Fujiwara, M | 1 |
| Koga, JI | 1 |
| Nakano, K | 3 |
| Tsutsui, H | 2 |
| Egashira, K | 4 |
| Silva-Abreu, M | 1 |
| Calpena, AC | 1 |
| Andrés-Benito, P | 1 |
| Aso, E | 1 |
| Romero, IA | 1 |
| Roig-Carles, D | 1 |
| Gromnicova, R | 1 |
| Espina, M | 1 |
| Ferrer, I | 2 |
| García, ML | 1 |
| Male, D | 1 |
| Li, S | 2 |
| Ghoshal, S | 1 |
| Sojoodi, M | 1 |
| Arora, G | 1 |
| Masia, R | 1 |
| Erstad, DJ | 1 |
| Lanuti, M | 1 |
| Hoshida, Y | 1 |
| Baumert, TF | 1 |
| Tanabe, KK | 1 |
| Fuchs, BC | 1 |
| Jönsson, TJ | 1 |
| Schäfer, HL | 1 |
| Herling, AW | 2 |
| Brönstrup, M | 1 |
| Khasabova, IA | 1 |
| Khasabov, SG | 1 |
| Olson, JK | 1 |
| Uhelski, ML | 1 |
| Kim, AH | 1 |
| Albino-Ramírez, AM | 1 |
| Wagner, CL | 1 |
| Seybold, VS | 1 |
| Simone, DA | 1 |
| Velez, LM | 1 |
| Abruzzese, GA | 1 |
| Heber, MF | 1 |
| Ferreira, SR | 1 |
| Motta, AB | 1 |
| Nozu, T | 1 |
| Miyagishi, S | 1 |
| Nozu, R | 1 |
| Takakusaki, K | 1 |
| Okumura, T | 1 |
| Shigenobu, T | 1 |
| Ohtsuka, T | 1 |
| Shimoda, M | 3 |
| Kanemaru, M | 1 |
| Asai, J | 1 |
| Jo, JI | 1 |
| Arita, T | 1 |
| Kawai-Ohnishi, M | 1 |
| Tsutsumi, M | 1 |
| Wada, M | 1 |
| Tabata, Y | 1 |
| Katoh, N | 1 |
| Zhang, C | 4 |
| Zhang, Y | 7 |
| Daniels, SJ | 1 |
| Leeming, DJ | 1 |
| Detlefsen, S | 1 |
| Bruun, MF | 1 |
| Hjuler, ST | 1 |
| Henriksen, K | 1 |
| Hein, P | 1 |
| Karsdal, MA | 1 |
| Brockbank, S | 1 |
| Cruwys, S | 1 |
| Seok, H | 1 |
| Yun, MR | 1 |
| Moon, JH | 1 |
| Kim, E | 1 |
| Lee, PH | 1 |
| Lee, HC | 2 |
| Li, N | 1 |
| Lu, L | 2 |
| Lin, Q | 1 |
| Li, L | 1 |
| Dong, P | 1 |
| Yang, B | 1 |
| Li, D | 1 |
| Fei, J | 1 |
| Mori, D | 1 |
| Miyagawa, S | 1 |
| Matsuura, R | 1 |
| Sougawa, N | 1 |
| Fukushima, S | 1 |
| Ueno, T | 2 |
| Toda, K | 1 |
| Kuratani, T | 1 |
| Tomita, K | 1 |
| Maeda, N | 2 |
| Shimomura, I | 2 |
| Sawa, Y | 1 |
| Chang, KL | 2 |
| Wong, LR | 1 |
| Pee, HN | 2 |
| Yang, S | 2 |
| Ho, PC | 2 |
| Lane, SL | 1 |
| Dodson, RB | 1 |
| Doyle, AS | 1 |
| Park, H | 1 |
| Rathi, H | 1 |
| Matarrazo, CJ | 1 |
| Moore, LG | 1 |
| Lorca, RA | 1 |
| Wolfson, GH | 1 |
| Julian, CG | 1 |
| Chen, Z | 1 |
| Yuan, P | 1 |
| Sun, X | 2 |
| Tang, K | 1 |
| Liu, H | 1 |
| Han, S | 2 |
| Ye, T | 1 |
| Liu, X | 3 |
| Yang, X | 2 |
| Zeng, J | 1 |
| Yan, L | 1 |
| Xiao, K | 1 |
| Ye, Z | 1 |
| Xu, H | 1 |
| Machado, MMF | 1 |
| Cóppola-Segovia, V | 1 |
| Moura, ELR | 1 |
| Zanata, SM | 1 |
| Andreatini, R | 1 |
| Dos Santos, BAC | 1 |
| Craig, A | 1 |
| Parvez, F | 1 |
| Issberner, J | 1 |
| Omeragic, A | 1 |
| Kara-Yacoubian, N | 1 |
| Kelschenbach, J | 1 |
| Sahin, C | 1 |
| Cummins, CL | 1 |
| Volsky, DJ | 1 |
| Bendayan, R | 1 |
| Ribeiro, NQ | 1 |
| Santos, APN | 1 |
| Emídio, ECP | 1 |
| Costa, MC | 1 |
| Freitas, GJC | 1 |
| Carmo, PHF | 1 |
| Silva, MF | 1 |
| de Brito, CB | 1 |
| de Souza, DG | 1 |
| Paixão, TA | 1 |
| Santos, DA | 1 |
| Mirza, R | 1 |
| Sharma, B | 4 |
| Merkulova, A | 1 |
| Mitchell, SC | 1 |
| Stavrou, EX | 1 |
| Forbes, GL | 1 |
| Schmaier, AH | 1 |
| Zhang, XY | 1 |
| Xiao, YQ | 1 |
| Ye, W | 1 |
| Moezi, L | 3 |
| Heidari, R | 1 |
| Amirghofran, Z | 2 |
| Nekooeian, AA | 2 |
| Monabati, A | 1 |
| Dehpour, AR | 7 |
| Lee, JO | 1 |
| Auger, C | 1 |
| Park, DH | 1 |
| Kang, M | 1 |
| Oak, MH | 1 |
| Kim, KR | 1 |
| Schini-Kerth, VB | 1 |
| Morató, L | 1 |
| Galino, J | 1 |
| Ruiz, M | 1 |
| Calingasan, NY | 2 |
| Starkov, AA | 1 |
| Dumont, M | 1 |
| Naudí, A | 1 |
| Martínez, JJ | 1 |
| Aubourg, P | 1 |
| Portero-Otín, M | 1 |
| Pamplona, R | 1 |
| Galea, E | 2 |
| Beal, MF | 2 |
| Fourcade, S | 1 |
| Pujol, A | 1 |
| Prakash, A | 2 |
| Kumar, A | 5 |
| Kim, H | 1 |
| Hwang, J | 1 |
| Park, S | 1 |
| Nahm, SF | 1 |
| Min, S | 1 |
| Lim, C | 1 |
| Park, K | 1 |
| Bhansali, S | 1 |
| Shafiq, N | 1 |
| Pandhi, P | 1 |
| Singh, AP | 1 |
| Singh, I | 1 |
| Singh, PK | 1 |
| Sharma, S | 1 |
| Malhotra, S | 1 |
| Chen, M | 1 |
| Deng, D | 1 |
| Fang, Z | 1 |
| Xu, M | 2 |
| Hu, H | 2 |
| Luo, L | 1 |
| Gesing, A | 1 |
| Bartke, A | 1 |
| Masternak, MM | 1 |
| Grover, S | 1 |
| Kumar, P | 3 |
| Singh, K | 1 |
| Vikram, V | 1 |
| Budhiraja, RD | 1 |
| Okunuki, Y | 1 |
| Usui, Y | 1 |
| Nakagawa, H | 1 |
| Tajima, K | 1 |
| Matsuda, R | 1 |
| Ueda, S | 1 |
| Hattori, T | 1 |
| Kezuka, T | 1 |
| Goto, H | 1 |
| Duelsner, A | 1 |
| Gatzke, N | 1 |
| Hillmeister, P | 1 |
| Glaser, J | 1 |
| Zietzer, A | 1 |
| Nagorka, S | 1 |
| Janke, D | 1 |
| Pfitzner, J | 1 |
| Stawowy, P | 1 |
| Meyborg, H | 1 |
| Urban, D | 1 |
| Bondke Persson, A | 1 |
| Buschmann, IR | 1 |
| Masuda, Y | 2 |
| Nagasaka, S | 1 |
| Gupta, A | 1 |
| Nair, A | 1 |
| Kumria, R | 1 |
| Al-Dhubiab, BE | 1 |
| Chattopadhyaya, I | 1 |
| Gupta, S | 1 |
| Janahmadi, Z | 1 |
| Paragomi, P | 1 |
| Rahimian, R | 2 |
| Kazemi, MH | 1 |
| Gharedaghi, MH | 1 |
| Khalifeh-Soltani, A | 1 |
| Azary, S | 1 |
| Javidan, AN | 1 |
| Moradi, K | 1 |
| Sakuma, S | 1 |
| Utreras, E | 1 |
| Hamada, R | 1 |
| Prochazkova, M | 1 |
| Terse, A | 1 |
| Takahashi, S | 1 |
| Ohshima, T | 1 |
| Kulkarni, AB | 1 |
| Schwabl, P | 1 |
| Payer, BA | 1 |
| Grahovac, J | 1 |
| Klein, S | 1 |
| Horvatits, T | 1 |
| Mitterhauser, M | 1 |
| Stift, J | 1 |
| Boucher, Y | 1 |
| Trebicka, J | 1 |
| Trauner, M | 1 |
| Angermayr, B | 1 |
| Fuhrmann, V | 1 |
| Reiberger, T | 1 |
| Peck-Radosavljevic, M | 1 |
| Nenicu, A | 1 |
| Körbel, C | 1 |
| Gu, Y | 1 |
| Menger, MD | 1 |
| Laschke, MW | 1 |
| Chen, Y | 1 |
| Yang, L | 1 |
| Li, M | 1 |
| Li, B | 1 |
| Sheng, M | 1 |
| Cummings, BP | 1 |
| Bettaieb, A | 1 |
| Graham, JL | 1 |
| Stanhope, K | 1 |
| Haj, FG | 1 |
| Havel, PJ | 1 |
| Kutsukake, M | 2 |
| Matsutani, T | 2 |
| Tamura, K | 2 |
| Matsuda, A | 2 |
| Kobayashi, M | 3 |
| Tachikawa, E | 1 |
| Uchida, E | 2 |
| Kabiri, N | 1 |
| Tabandeh, MR | 1 |
| Tabatabaie, SR | 1 |
| Ferrari, SM | 1 |
| Antonelli, A | 1 |
| Di Domenicantonio, A | 1 |
| Manfredi, A | 1 |
| Ferri, C | 1 |
| Fallahi, P | 1 |
| Yu, Y | 2 |
| Li, X | 1 |
| Blanchard, J | 1 |
| Li, Y | 2 |
| Iqbal, K | 1 |
| Liu, F | 1 |
| Gong, CX | 1 |
| Barbiero, JK | 1 |
| Santiago, RM | 1 |
| Persike, DS | 1 |
| da Silva Fernandes, MJ | 1 |
| Tonin, FS | 1 |
| da Cunha, C | 1 |
| Lucio Boschen, S | 1 |
| Lima, MM | 1 |
| Vital, MA | 1 |
| Iida, M | 1 |
| Katsuno, M | 1 |
| Nakatsuji, H | 2 |
| Adachi, H | 1 |
| Kondo, N | 1 |
| Miyazaki, Y | 1 |
| Tohnai, G | 1 |
| Ikenaka, K | 1 |
| Watanabe, H | 1 |
| Kishida, K | 1 |
| Sobue, G | 1 |
| Abdel-Rahman, EM | 1 |
| Okusa, MD | 1 |
| Joardar, A | 1 |
| Menzl, J | 1 |
| Podolsky, TC | 1 |
| Manzo, E | 1 |
| Estes, PS | 1 |
| Ashford, S | 1 |
| Zarnescu, DC | 1 |
| Aliperti, LA | 1 |
| Lasker, GF | 1 |
| Hagan, SS | 1 |
| Hellstrom, JA | 1 |
| Gokce, A | 1 |
| Trost, LW | 1 |
| Kadowitz, PJ | 1 |
| Sikka, SC | 1 |
| Hellstrom, WJ | 1 |
| Payandemehr, B | 1 |
| Ebrahimi, A | 1 |
| Gholizadeh, R | 1 |
| Varastehmoradi, B | 1 |
| Gooshe, M | 1 |
| Aghaei, HN | 1 |
| Mousavizadeh, K | 1 |
| Kimura, T | 1 |
| Kaneto, H | 1 |
| Hirukawa, H | 1 |
| Okauchi, S | 1 |
| Kohara, K | 1 |
| Hamamoto, S | 3 |
| Tawaramoto, K | 2 |
| Hashiramoto, M | 2 |
| Kaku, K | 3 |
| Ryder, RE | 1 |
| Fernandez-Boyanapalli, RF | 2 |
| Frasch, SC | 2 |
| Thomas, SM | 1 |
| Malcolm, KC | 1 |
| Nicks, M | 1 |
| Harbeck, RJ | 1 |
| Jakubzick, CV | 1 |
| Nemenoff, R | 1 |
| Henson, PM | 2 |
| Holland, SM | 2 |
| Bratton, DL | 2 |
| Pilipović, K | 1 |
| Župan, Ž | 1 |
| Dolenec, P | 1 |
| Mršić-Pelčić, J | 1 |
| Župan, G | 1 |
| Lan, LF | 1 |
| Zheng, L | 1 |
| Ji, XT | 1 |
| Fan, YH | 1 |
| Zeng, JS | 1 |
| Zhu, C | 1 |
| Xiao, Y | 2 |
| Han, J | 1 |
| Wei, L | 1 |
| Jia, W | 1 |
| Drew, PD | 2 |
| Johnson, JW | 1 |
| Douglas, JC | 2 |
| Phelan, KD | 2 |
| Kane, CJ | 2 |
| Zaitone, SA | 1 |
| Barakat, BM | 1 |
| Bilasy, SE | 1 |
| Fawzy, MS | 1 |
| Abdelaziz, EZ | 1 |
| Farag, NE | 1 |
| Kandeel, S | 1 |
| Balaha, M | 1 |
| Gao, M | 1 |
| Jiang, Y | 1 |
| Xiao, X | 2 |
| Peng, Y | 1 |
| Yang, M | 1 |
| Chen, J | 2 |
| Soares e Silva, AK | 1 |
| de Oliveira Cipriano Torres, D | 1 |
| dos Santos Gomes, FO | 1 |
| dos Santos Silva, B | 1 |
| Lima Ribeiro, E | 1 |
| Costa Oliveira, A | 1 |
| dos Santos, LA | 1 |
| de Lima, Mdo C | 1 |
| Pitta, Ida R | 1 |
| Peixoto, CA | 1 |
| San, YZ | 1 |
| Shi, PP | 1 |
| Zhu, YL | 1 |
| Savage, JC | 1 |
| Jay, T | 1 |
| Goduni, E | 1 |
| Quigley, C | 1 |
| Mariani, MM | 1 |
| Malm, T | 1 |
| Ransohoff, RM | 1 |
| Lamb, BT | 1 |
| Landreth, GE | 5 |
| Ding, Y | 2 |
| Fang, H | 1 |
| Shang, W | 1 |
| Sun, T | 1 |
| Hou, N | 2 |
| Pan, L | 1 |
| Ma, Q | 1 |
| Wang, X | 1 |
| Cheng, H | 2 |
| Hur, J | 1 |
| Dauch, JR | 1 |
| Hinder, LM | 1 |
| Hayes, JM | 1 |
| Backus, C | 1 |
| Pennathur, S | 2 |
| Kretzler, M | 2 |
| Brosius, FC | 2 |
| Feldman, EL | 1 |
| Xue, BJ | 1 |
| Wei, SG | 1 |
| Zhang, ZH | 1 |
| Beltz, TG | 1 |
| Guo, F | 1 |
| Johnson, AK | 1 |
| Felder, RB | 1 |
| Charolidi, N | 1 |
| Pirianov, G | 1 |
| Torsney, E | 1 |
| Pearce, S | 1 |
| Laing, K | 1 |
| Nohturfft, A | 1 |
| Cockerill, GW | 1 |
| Skerrett, R | 1 |
| Pellegrino, MP | 1 |
| Casali, BT | 1 |
| Taraboanta, L | 1 |
| Yamamoto, S | 1 |
| Zhong, J | 1 |
| Yancey, PG | 1 |
| Zuo, Y | 1 |
| Linton, MF | 1 |
| Fazio, S | 1 |
| Narita, I | 1 |
| Kon, V | 1 |
| Hou, J | 2 |
| Wang, L | 2 |
| Guo, T | 1 |
| Xing, Y | 1 |
| Zheng, S | 1 |
| Zhou, C | 1 |
| Long, H | 1 |
| Zhong, T | 1 |
| Wu, Q | 1 |
| Wang, J | 2 |
| Wang, T | 1 |
| Surapaneni, KM | 1 |
| Vishnu Priya, V | 1 |
| Mallika, J | 1 |
| Chen, C | 1 |
| Ma, C | 1 |
| Xia, Y | 1 |
| Gliem, M | 1 |
| Klotz, L | 2 |
| van Rooijen, N | 1 |
| Hartung, HP | 1 |
| Jander, S | 1 |
| Bojková, B | 1 |
| Orendáš, P | 1 |
| Kajo, K | 1 |
| Kubatka, P | 1 |
| Výbohová, D | 1 |
| Bálentová, S | 1 |
| Kružliak, P | 1 |
| Zulli, A | 1 |
| Demečková, V | 1 |
| Péč, M | 1 |
| Adamkov, M | 1 |
| Falcone, EL | 1 |
| Zerbe, CS | 1 |
| Marciano, BE | 1 |
| Shafaroodi, H | 2 |
| Hassanipour, M | 2 |
| Mousavi, Z | 1 |
| Rahimi, N | 1 |
| Sasagawa, S | 1 |
| Nishimura, Y | 1 |
| Koiwa, J | 1 |
| Nomoto, T | 1 |
| Shintou, T | 1 |
| Murakami, S | 1 |
| Yuge, M | 1 |
| Kawaguchi, K | 1 |
| Kawase, R | 1 |
| Miyazaki, T | 1 |
| Tanaka, T | 1 |
| Jain, S | 2 |
| Sharma, BM | 1 |
| Hajali, V | 1 |
| Dehpour, A | 1 |
| Haghani, M | 1 |
| Sheibani, V | 1 |
| Pottabathini, R | 1 |
| Bhatnagar, A | 1 |
| Garg, S | 1 |
| Ekavali, E | 1 |
| Zou, C | 2 |
| Ohli, J | 1 |
| Schüller, U | 1 |
| Behringer, A | 1 |
| Trappiel, M | 1 |
| Berghausen, EM | 1 |
| Ten Freyhaus, H | 1 |
| Wellnhofer, E | 1 |
| Odenthal, M | 1 |
| Blaschke, F | 1 |
| Er, F | 1 |
| Gassanov, N | 1 |
| Rosenkranz, S | 1 |
| Baldus, S | 1 |
| Kappert, K | 1 |
| Caglayan, E | 1 |
| Nakashiro, S | 1 |
| Umezu, R | 1 |
| Koga, J | 1 |
| Katsuki, S | 1 |
| Sunagawa, K | 1 |
| Pinto, M | 1 |
| Nissanka, N | 1 |
| Peralta, S | 1 |
| Brambilla, R | 1 |
| Diaz, F | 1 |
| Moraes, CT | 1 |
| Kamimura, D | 1 |
| Uchino, K | 1 |
| Ishigami, T | 1 |
| Hall, ME | 1 |
| Umemura, S | 1 |
| DiBattista, AM | 1 |
| Dumanis, SB | 1 |
| Newman, J | 1 |
| Rebeck, GW | 1 |
| Indran, IR | 1 |
| Lee, BH | 1 |
| Yong, EL | 1 |
| Butterick, TA | 1 |
| Hocum Stone, L | 1 |
| Duffy, C | 1 |
| Holley, C | 1 |
| Cabrera, JA | 1 |
| Crampton, M | 1 |
| Ward, HB | 1 |
| Kelly, RF | 1 |
| McFalls, EO | 1 |
| Sun, L | 1 |
| Yuan, Q | 1 |
| Yao, L | 1 |
| Feng, J | 1 |
| Ma, J | 1 |
| Lu, C | 1 |
| Wang, D | 1 |
| Badhwar, A | 1 |
| Brown, R | 1 |
| Stanimirovic, DB | 1 |
| Haqqani, AS | 1 |
| Hamel, E | 2 |
| Samson, KK | 1 |
| Yasui, T | 1 |
| Okada, A | 1 |
| Ando, R | 1 |
| Taguchi, K | 1 |
| Tozawa, K | 1 |
| Kohri, K | 1 |
| Welling, LC | 1 |
| Welling, MS | 1 |
| Teixeira, MJ | 1 |
| Figueiredo, EG | 1 |
| Kubota, T | 2 |
| Kubota, N | 3 |
| Sato, H | 1 |
| Inoue, M | 1 |
| Kumagai, H | 2 |
| Iwamura, T | 1 |
| Takamoto, I | 1 |
| Kobayashi, T | 2 |
| Moroi, M | 1 |
| Terauchi, Y | 3 |
| Tobe, K | 1 |
| Ueki, K | 1 |
| Kadowaki, T | 4 |
| Zhao, Q | 2 |
| Yan, S | 1 |
| Xie, X | 1 |
| Peng, C | 1 |
| You, Z | 1 |
| Liu, YM | 1 |
| Chen, JJ | 1 |
| Pei, YY | 1 |
| Fang, XY | 1 |
| Hong, Y | 1 |
| Kim, YS | 1 |
| Oh, YM | 1 |
| Tapia-Pérez, JH | 1 |
| Preininger, R | 1 |
| Kirches, E | 1 |
| Reinhold, A | 1 |
| Butzmann, J | 1 |
| Prilloff, S | 1 |
| Mawrin, C | 1 |
| Schneider, T | 1 |
| Xiong, D | 1 |
| Pan, J | 1 |
| Szabo, E | 1 |
| Miller, MS | 1 |
| Lubet, RA | 1 |
| You, M | 1 |
| Zhang, Z | 1 |
| Yuan, H | 1 |
| Zhao, H | 1 |
| Qi, B | 1 |
| Li, F | 1 |
| An, L | 1 |
| Corsini, I | 1 |
| Polvani, S | 1 |
| Tarocchi, M | 1 |
| Tempesti, S | 1 |
| Marroncini, G | 1 |
| Generoso, M | 1 |
| Bresci, C | 1 |
| Gozzini, E | 1 |
| Bianconi, T | 1 |
| Galli, A | 1 |
| Dani, C | 1 |
| Yu, J | 1 |
| Grachtchouk, V | 1 |
| Qin, T | 1 |
| Lumeng, CN | 1 |
| Sartor, MA | 1 |
| Koenig, RJ | 1 |
| Joubert, M | 1 |
| Jagu, B | 1 |
| Montaigne, D | 1 |
| Marechal, X | 1 |
| Tesse, A | 1 |
| Ayer, A | 1 |
| Dollet, L | 1 |
| Le May, C | 1 |
| Toumaniantz, G | 1 |
| Manrique, A | 1 |
| Charpentier, F | 1 |
| Staels, B | 2 |
| Magré, J | 1 |
| Cariou, B | 1 |
| Prieur, X | 1 |
| Okoduwa, SI | 1 |
| Umar, IA | 1 |
| James, DB | 1 |
| Inuwa, HM | 1 |
| Wuertz, BR | 1 |
| Darrah, L | 1 |
| Wudel, J | 1 |
| Ondrey, FG | 1 |
| Akai, S | 1 |
| Oda, S | 1 |
| Yokoi, T | 1 |
| Nicolakakis, N | 1 |
| Aboulkassim, T | 1 |
| Ongali, B | 1 |
| Lecrux, C | 1 |
| Fernandes, P | 1 |
| Rosa-Neto, P | 1 |
| Tong, XK | 1 |
| Ye, Y | 3 |
| Lin, Y | 3 |
| Perez-Polo, JR | 3 |
| Birnbaum, Y | 2 |
| Manickavasagam, S | 1 |
| Tieu, BC | 1 |
| Patzer, A | 2 |
| Stöck, I | 1 |
| Kaundal, RK | 2 |
| More, S | 1 |
| Sharma, SS | 2 |
| Maeda, T | 3 |
| Kiguchi, N | 2 |
| Kobayashi, Y | 1 |
| Ozaki, M | 2 |
| Kishioka, S | 2 |
| Zhang, F | 1 |
| Dey, D | 1 |
| Bränström, R | 1 |
| Forsberg, L | 1 |
| Lu, M | 1 |
| Sjöholm, A | 1 |
| Sugimoto, M | 1 |
| Arai, H | 1 |
| Tamura, Y | 1 |
| Murayama, T | 1 |
| Khaengkhan, P | 1 |
| Nishio, T | 1 |
| Ono, K | 1 |
| Ariyasu, H | 1 |
| Akamizu, T | 1 |
| Ueda, Y | 1 |
| Kita, T | 1 |
| Harada, S | 1 |
| Kamei, K | 1 |
| Yokode, M | 1 |
| Ji, S | 1 |
| Kronenberg, G | 1 |
| Balkaya, M | 1 |
| Färber, K | 1 |
| Gertz, K | 1 |
| Kettenmann, H | 1 |
| Endres, M | 1 |
| Laurent, D | 1 |
| Gounarides, JS | 1 |
| Gao, J | 2 |
| Boettcher, BR | 1 |
| Miyata, T | 2 |
| van Ypersele de Strihou, C | 2 |
| Yasuda, S | 1 |
| Kobayashi, H | 1 |
| Iwasa, M | 1 |
| Kawamura, I | 1 |
| Sumi, S | 1 |
| Narentuoya, B | 1 |
| Yamaki, T | 1 |
| Ushikoshi, H | 1 |
| Nishigaki, K | 1 |
| Nagashima, K | 1 |
| Takemura, G | 1 |
| Fujiwara, T | 1 |
| Fujiwara, H | 1 |
| Minatoguchi, S | 1 |
| Iyer, S | 1 |
| Debiais, F | 1 |
| Bajwa, PJ | 1 |
| Lee, JW | 1 |
| Straus, DS | 1 |
| Lytle, C | 1 |
| Papi, A | 1 |
| Tatenhorst, L | 1 |
| Terwel, D | 1 |
| Hermes, M | 1 |
| Kummer, MP | 2 |
| Orlandi, M | 1 |
| Heneka, MT | 5 |
| Iizuka, K | 1 |
| Hamaue, N | 1 |
| Machida, T | 1 |
| Hirafuji, M | 1 |
| Tsuji, M | 1 |
| Zhao, W | 1 |
| Thacker, SG | 1 |
| Hodgin, JB | 1 |
| Wang, JH | 1 |
| Park, JL | 1 |
| Randolph, A | 1 |
| Somers, EC | 1 |
| Kaplan, MJ | 1 |
| Park, SJ | 3 |
| Lee, KS | 3 |
| Kim, SR | 2 |
| Min, KH | 2 |
| Choe, YH | 1 |
| Moon, H | 1 |
| Chae, HJ | 1 |
| Yoo, WH | 1 |
| Lee, YC | 3 |
| Kaur, B | 1 |
| Singh, N | 2 |
| Jaggi, AS | 2 |
| Raphael, KL | 1 |
| Strait, KA | 1 |
| Stricklett, PK | 1 |
| Baird, BC | 1 |
| Piontek, K | 1 |
| Germino, GG | 1 |
| Kohan, DE | 1 |
| Makino, N | 1 |
| Oyama, J | 1 |
| Higuchi, Y | 1 |
| Mimori, K | 1 |
| Kanda, Y | 2 |
| Kawasaki, F | 2 |
| Nakashima, K | 1 |
| Matsuki, M | 1 |
| Shibata, N | 2 |
| Yamamoto, T | 2 |
| Hiroi, A | 1 |
| Omi, Y | 1 |
| Kato, Y | 1 |
| Marková, I | 1 |
| Zídek, V | 1 |
| Musilová, A | 1 |
| Šimáková, M | 1 |
| Mlejnek, P | 1 |
| Kazdová, L | 1 |
| Pravenec, M | 1 |
| Kim, YJ | 1 |
| Kim, L | 1 |
| Choi, SJ | 1 |
| Park, IS | 1 |
| Kim, JM | 1 |
| Chu, YC | 1 |
| Cha, DR | 1 |
| Weiss, CS | 1 |
| Hagenmüller, M | 1 |
| Pichler, M | 1 |
| Münz, S | 1 |
| Ochs, M | 1 |
| Buss, SJ | 1 |
| Bekeredjian, R | 1 |
| Katus, HA | 1 |
| Hardt, SE | 1 |
| Lebovic, DI | 2 |
| Mwenda, JM | 1 |
| Chai, DC | 1 |
| Santi, A | 1 |
| Xu, X | 1 |
| D'Hooghe, T | 1 |
| Hu, Z | 1 |
| Collino, M | 1 |
| Aragno, M | 1 |
| Castiglia, S | 1 |
| Miglio, G | 1 |
| Tomasinelli, C | 1 |
| Boccuzzi, G | 1 |
| Thiemermann, C | 3 |
| Fantozzi, R | 1 |
| Al-Azzam, SI | 1 |
| Abdul-Razzak, KK | 1 |
| Jaradat, MW | 1 |
| Kalonia, H | 1 |
| Higashi, K | 1 |
| Oda, T | 2 |
| Kushiyama, T | 1 |
| Hyodo, T | 1 |
| Yamada, M | 2 |
| Suzuki, S | 1 |
| Sakurai, Y | 2 |
| Miura, S | 3 |
| Baraka, A | 1 |
| ElGhotny, S | 1 |
| Gamboa, J | 1 |
| Blankenship, DA | 1 |
| Niemi, JP | 1 |
| Karl, M | 2 |
| Hilow, E | 2 |
| Sundararajan, S | 2 |
| Jia, H | 1 |
| Zhu, S | 1 |
| Ji, Q | 1 |
| Hui, K | 1 |
| Duan, M | 1 |
| Vikram, A | 1 |
| Jena, G | 1 |
| Ramarao, P | 2 |
| Herington, JL | 1 |
| Crispens, MA | 1 |
| Carvalho-Macedo, AC | 1 |
| Camargos, AF | 1 |
| Bruner-Tran, KL | 1 |
| Osteen, KG | 1 |
| Sauerbeck, A | 1 |
| Readnower, R | 1 |
| Liu, M | 1 |
| Pauly, JR | 1 |
| Bing, G | 1 |
| Bauer, CM | 1 |
| Zavitz, CC | 1 |
| Botelho, FM | 1 |
| Lambert, KN | 1 |
| Brown, EG | 1 |
| Mossman, KL | 1 |
| Taylor, JD | 1 |
| Stämpfli, MR | 1 |
| Kume, O | 2 |
| Takahashi, N | 2 |
| Wakisaka, O | 2 |
| Nagano-Torigoe, Y | 1 |
| Teshima, Y | 2 |
| Nakagawa, M | 1 |
| Yufu, K | 1 |
| Hara, M | 2 |
| Saikawa, T | 2 |
| Yoshimatsu, H | 1 |
| Duffy, HS | 1 |
| Hontecillas, R | 1 |
| Horne, WT | 1 |
| Climent, M | 1 |
| Guri, AJ | 1 |
| Evans, C | 1 |
| Sobral, BW | 1 |
| Bassaganya-Riera, J | 1 |
| Yoshihara, D | 1 |
| Kurahashi, H | 1 |
| Morita, M | 1 |
| Kugita, M | 1 |
| Hiki, Y | 1 |
| Aukema, HM | 1 |
| Yamaguchi, T | 3 |
| Calvet, JP | 1 |
| Wallace, DP | 1 |
| Nagao, S | 3 |
| Ye, P | 1 |
| Wu, SM | 1 |
| Liu, YX | 1 |
| Zhang, HL | 1 |
| Wei, C | 1 |
| Qin, AP | 1 |
| Liu, CF | 1 |
| Hong, LZ | 1 |
| Zhao, XY | 1 |
| Liu, J | 2 |
| Qin, ZH | 1 |
| Hiuge-Shimizu, A | 1 |
| Hirata, A | 1 |
| Nakamura, K | 1 |
| Okuno, A | 1 |
| Kihara, S | 1 |
| Funahashi, T | 1 |
| Stopponi, S | 1 |
| Somaini, L | 1 |
| Cippitelli, A | 1 |
| Cannella, N | 1 |
| Braconi, S | 1 |
| Kallupi, M | 1 |
| Ruggeri, B | 1 |
| Heilig, M | 1 |
| Demopulos, G | 1 |
| Gaitanaris, G | 1 |
| Massi, M | 1 |
| Ciccocioppo, R | 1 |
| Semple, BD | 1 |
| Noble-Haeusslein, LJ | 1 |
| Medhi, B | 1 |
| Aggarwal, R | 1 |
| Chakrabarti, A | 1 |
| Smith, RR | 1 |
| Xie, J | 1 |
| Oki, N | 1 |
| Nonaka, S | 1 |
| Ozaki, S | 1 |
| Blankenship, D | 1 |
| Niemi, J | 1 |
| Thal, SC | 1 |
| Heinemann, M | 1 |
| Luh, C | 1 |
| Pieter, D | 1 |
| Werner, C | 1 |
| Engelhard, K | 1 |
| Zaitone, S | 1 |
| Hassan, N | 1 |
| El-Orabi, N | 1 |
| El-Awady, el-S | 1 |
| Luo, D | 1 |
| Hou, X | 1 |
| Hou, L | 1 |
| Xu, S | 1 |
| Dong, C | 1 |
| Borbath, I | 1 |
| Stärkel, P | 2 |
| Ulusoy, GK | 1 |
| Celik, T | 1 |
| Kayir, H | 1 |
| Gürsoy, M | 1 |
| Isik, AT | 1 |
| Uzbay, TI | 1 |
| Raab, S | 1 |
| Zheng, W | 1 |
| Liu, N | 1 |
| Zhu, T | 1 |
| Xue, L | 1 |
| Song, Z | 1 |
| Mao, J | 1 |
| Li, K | 1 |
| Han, C | 1 |
| Wang, H | 1 |
| Shang, S | 1 |
| Li, C | 1 |
| Sebokova, E | 1 |
| Huang, PL | 1 |
| Sain, H | 1 |
| Mendizábal, Y | 1 |
| Llorens, S | 1 |
| Nava, E | 1 |
| Xu, D | 1 |
| Murakoshi, N | 1 |
| Igarashi, M | 1 |
| Hirayama, A | 1 |
| Seo, Y | 1 |
| Tada, H | 1 |
| Aonuma, K | 1 |
| Samson, SL | 1 |
| Sathyanarayana, P | 1 |
| Jogi, M | 1 |
| Gonzalez, EV | 1 |
| Gutierrez, A | 1 |
| Krishnamurthy, R | 1 |
| Muthupillai, R | 1 |
| Chan, L | 1 |
| Bajaj, M | 1 |
| Nakatsuka, A | 1 |
| Wada, J | 1 |
| Hida, K | 1 |
| Hida, A | 1 |
| Eguchi, J | 1 |
| Teshigawara, S | 1 |
| Murakami, K | 1 |
| Kanzaki, M | 1 |
| Inoue, K | 1 |
| Terami, T | 1 |
| Katayama, A | 1 |
| Ogawa, D | 1 |
| Kagechika, H | 1 |
| Makino, H | 2 |
| Tsujimura, Y | 1 |
| Sasajima, K | 1 |
| Vucic, E | 1 |
| Dickson, SD | 1 |
| Calcagno, C | 1 |
| Rudd, JH | 1 |
| Moshier, E | 1 |
| Hayashi, K | 2 |
| Mounessa, JS | 1 |
| Roytman, M | 1 |
| Moon, MJ | 1 |
| Lin, J | 1 |
| Tsimikas, S | 1 |
| Fisher, EA | 1 |
| Nicolay, K | 1 |
| Fuster, V | 1 |
| Fayad, ZA | 1 |
| Ponce-Lopez, T | 1 |
| Liy-Salmeron, G | 1 |
| Hong, E | 1 |
| Meneses, A | 1 |
| Hempe, J | 1 |
| Elvert, R | 1 |
| Schmidts, HL | 1 |
| Kramer, W | 1 |
| Morrow, JP | 1 |
| Katchman, A | 1 |
| Son, NH | 1 |
| Trent, CM | 1 |
| Khan, R | 1 |
| Shiomi, T | 2 |
| Amin, V | 1 |
| Lader, JM | 1 |
| Vasquez, C | 1 |
| Morley, GE | 1 |
| D'Armiento, J | 1 |
| Homma, S | 1 |
| Goldberg, IJ | 1 |
| Marx, SO | 1 |
| Sakamoto, A | 2 |
| Hongo, M | 2 |
| Furuta, K | 1 |
| Saito, K | 2 |
| Nagai, R | 5 |
| Ishizaka, N | 2 |
| Ghorbani, H | 1 |
| Zaeri, M | 1 |
| Hassanpour, S | 1 |
| Laloux, C | 1 |
| Petrault, M | 1 |
| Lecointe, C | 1 |
| Devos, D | 1 |
| Bordet, R | 1 |
| Xiang, GQ | 1 |
| Tang, SS | 1 |
| Jiang, LY | 1 |
| Hong, H | 1 |
| Li, Q | 1 |
| Wang, C | 1 |
| Wang, XY | 1 |
| Zhang, TT | 1 |
| Yin, L | 1 |
| Fujimoto, M | 1 |
| Tsuneyama, K | 1 |
| Fujimoto, T | 1 |
| Selmi, C | 1 |
| Gershwin, ME | 1 |
| Shimada, Y | 1 |
| Hucke, S | 1 |
| Floßdorf, J | 1 |
| Grützke, B | 1 |
| Dunay, IR | 1 |
| Frenzel, K | 1 |
| Jungverdorben, J | 1 |
| Linnartz, B | 1 |
| Mack, M | 1 |
| Peitz, M | 1 |
| Brüstle, O | 1 |
| Kurts, C | 1 |
| Klockgether, T | 2 |
| Neumann, H | 1 |
| Prinz, M | 1 |
| Wiendl, H | 1 |
| Knolle, P | 1 |
| Searcy, JL | 1 |
| Phelps, JT | 1 |
| Pancani, T | 1 |
| Kadish, I | 1 |
| Popovic, J | 1 |
| Anderson, KL | 1 |
| Beckett, TL | 1 |
| Murphy, MP | 1 |
| Chen, KC | 1 |
| Blalock, EM | 1 |
| Landfield, PW | 1 |
| Porter, NM | 1 |
| Thibault, O | 1 |
| Gupta, R | 1 |
| Gupta, LK | 1 |
| Xi, X | 1 |
| Shi, Z | 1 |
| Wang, G | 1 |
| Huang, X | 1 |
| Nagashima, A | 1 |
| Watanabe, R | 1 |
| Ogawa, M | 1 |
| Suzuki, J | 1 |
| Masumura, M | 1 |
| Hishikari, K | 1 |
| Shimizu, T | 1 |
| Takayama, K | 1 |
| Hirata, Y | 2 |
| Isobe, M | 1 |
| Elrashidy, RA | 1 |
| Asker, ME | 1 |
| Mohamed, HE | 1 |
| Yoo, JY | 1 |
| Yang, SH | 1 |
| Lee, JE | 1 |
| Cho, DG | 1 |
| Kim, HK | 1 |
| Kim, IS | 1 |
| Hong, JT | 1 |
| Sung, JH | 1 |
| Son, BC | 1 |
| Lee, SW | 1 |
| Flores, MBS | 1 |
| Rocha, GZ | 1 |
| Damas-Souza, DM | 1 |
| Osório-Costa, F | 1 |
| Dias, MM | 1 |
| Ropelle, ER | 1 |
| Camargo, JA | 1 |
| de Carvalho, RB | 1 |
| Carvalho, HF | 1 |
| Saad, MJA | 1 |
| Carvalheira, JBC | 1 |
| Wan, H | 1 |
| Yuan, Y | 1 |
| Chen, G | 1 |
| Mandrekar-Colucci, S | 1 |
| Karlo, JC | 1 |
| Mera, Y | 1 |
| Tomimoto, D | 1 |
| Sato, E | 1 |
| Matsushita, M | 1 |
| Fukunaga, N | 1 |
| Suge, R | 1 |
| Shimazu, T | 1 |
| Hasegawa, H | 3 |
| Inoue, I | 1 |
| Hayashibe, H | 1 |
| Nagasaka, H | 1 |
| Araki, N | 1 |
| Katayama, S | 1 |
| Nomura, M | 1 |
| Watanabe, S | 1 |
| Nguyen-Ngoc, M | 1 |
| Glatz, T | 1 |
| Pacana, T | 1 |
| Sanyal, AJ | 1 |
| Teraoka, N | 1 |
| Takasu, S | 1 |
| Takahashi, M | 1 |
| Fujii, G | 1 |
| Komiya, M | 1 |
| Yanaka, A | 1 |
| Wakabayashi, K | 1 |
| Mutoh, M | 1 |
| Yamanaka, M | 1 |
| Ishikawa, T | 1 |
| Griep, A | 1 |
| Axt, D | 1 |
| Masciopinto, F | 1 |
| Di Pietro, N | 1 |
| Corona, C | 1 |
| Bomba, M | 1 |
| Pipino, C | 1 |
| Curcio, M | 1 |
| Di Castelnuovo, A | 1 |
| Ciavardelli, D | 1 |
| Silvestri, E | 1 |
| Canzoniero, LM | 1 |
| Sekler, I | 1 |
| Pandolfi, A | 1 |
| Sensi, SL | 1 |
| Chu, Y | 1 |
| Lund, DD | 1 |
| Weiss, RM | 1 |
| Brooks, RM | 1 |
| Doshi, H | 1 |
| Hajj, GP | 1 |
| Sigmund, CD | 1 |
| Heistad, DD | 1 |
| Kalanderian, A | 1 |
| Abate, N | 1 |
| Patrikeev, I | 1 |
| Wei, J | 1 |
| Vincent, KL | 1 |
| Motamedi, M | 1 |
| Saade, GR | 1 |
| Bytautiene, E | 1 |
| Javadi, S | 1 |
| Ejtemaeimehr, S | 1 |
| Keyvanfar, HR | 1 |
| Moghaddas, P | 1 |
| Aminian, A | 1 |
| Rajabzadeh, A | 1 |
| Mani, AR | 1 |
| Breidert, T | 1 |
| Callebert, J | 1 |
| Landreth, G | 1 |
| Launay, JM | 1 |
| Hirsch, EC | 1 |
| Kasono, K | 1 |
| Nishida, J | 1 |
| Tamemoto, H | 1 |
| Fudaka, K | 1 |
| Namai, K | 1 |
| Kajio, H | 1 |
| Masatoshi, K | 1 |
| Kanazawa, Y | 1 |
| Kawakami, M | 1 |
| Ishibashi, M | 2 |
| Hiasa, K | 1 |
| Inoue, S | 1 |
| Ni, W | 1 |
| Usui, M | 1 |
| Kitamoto, S | 1 |
| Ichiki, T | 1 |
| Takeshita, A | 2 |
| Hayashidani, S | 1 |
| Suematsu, N | 1 |
| Ikeuchi, M | 1 |
| Wen, J | 1 |
| Saubermann, LJ | 1 |
| Nakajima, A | 2 |
| Wada, K | 2 |
| Zhao, S | 1 |
| Aburatani, H | 1 |
| Matsuhashi, N | 1 |
| Blumberg, RS | 1 |
| Suzuki, M | 2 |
| Odaka, H | 4 |
| Diani, AR | 1 |
| Sawada, G | 1 |
| Wyse, B | 1 |
| Murray, FT | 1 |
| Khan, M | 1 |
| Frantz, S | 1 |
| Hu, K | 1 |
| Widder, J | 1 |
| Bayer, B | 1 |
| Witzel, CC | 1 |
| Schmidt, I | 1 |
| Galuppo, P | 1 |
| Strotmann, J | 1 |
| Ertl, G | 1 |
| Bauersachs, J | 1 |
| Dehmer, T | 1 |
| Sastre, M | 2 |
| Dichgans, J | 1 |
| Schulz, JB | 1 |
| Ito, H | 1 |
| Nakano, A | 1 |
| Kinoshita, M | 1 |
| Matsumori, A | 1 |
| Sonta, T | 1 |
| Inoguchi, T | 1 |
| Tsubouchi, H | 1 |
| Sekiguchi, N | 1 |
| Kobayashi, K | 1 |
| Matsumoto, S | 1 |
| Utsumi, H | 1 |
| Nawata, H | 1 |
| Matsuda, M | 1 |
| Inoue, H | 1 |
| Kiaei, M | 1 |
| Kipiani, K | 1 |
| Notoya, K | 1 |
| Naito, T | 1 |
| Unno, S | 1 |
| Nakamura, A | 1 |
| Martel-Pelletier, J | 2 |
| Pelletier, JP | 2 |
| Takano, H | 2 |
| Zou, Y | 1 |
| Qin, Y | 1 |
| Hizukuri, K | 1 |
| Odaka, K | 1 |
| Toyozaki, T | 1 |
| Komuro, I | 2 |
| Hwang, PH | 1 |
| Yi, HK | 1 |
| Song, CH | 1 |
| Chai, OH | 1 |
| Kim, JS | 2 |
| Lee, MK | 1 |
| Dumitrescu-Ozimek, L | 1 |
| Hanke, A | 1 |
| Dewachter, I | 1 |
| Kuiperi, C | 1 |
| O'Banion, K | 1 |
| Van Leuven, F | 1 |
| Hennuyer, N | 1 |
| Tailleux, A | 1 |
| Torpier, G | 1 |
| Mezdour, H | 1 |
| Fruchart, JC | 1 |
| Fiévet, C | 1 |
| Park, HS | 1 |
| Jin, SM | 1 |
| Bodary, PF | 1 |
| Vargas, FB | 1 |
| King, SA | 1 |
| Jongeward, KL | 1 |
| Wickenheiser, KJ | 1 |
| Eitzman, DT | 1 |
| Ledingham, JM | 1 |
| Laverty, R | 1 |
| Misugi, T | 1 |
| Ozaki, K | 1 |
| El Beltagy, K | 1 |
| Tokuyama, O | 1 |
| Honda, K | 1 |
| Ishiko, O | 1 |
| Li, PP | 1 |
| Shan, S | 1 |
| Chen, YT | 1 |
| Ning, ZQ | 1 |
| Sun, SJ | 1 |
| Liu, Q | 1 |
| Lu, XP | 1 |
| Xie, MZ | 1 |
| Shen, ZF | 1 |
| Feinstein, DL | 2 |
| Lacombe, P | 1 |
| Game, BA | 2 |
| He, L | 2 |
| Jarido, V | 1 |
| Nareika, A | 2 |
| Jaffa, AA | 1 |
| Lopes-Virella, MF | 1 |
| Miyamoto, Y | 1 |
| Sawai, K | 1 |
| Mori, K | 1 |
| Mukoyama, M | 1 |
| Nakao, K | 1 |
| Yoshimasa, Y | 1 |
| Suga, S | 1 |
| Annicotte, JS | 1 |
| Iankova, I | 1 |
| Miard, S | 1 |
| Fritz, V | 1 |
| Sarruf, D | 1 |
| Abella, A | 1 |
| Berthe, ML | 1 |
| Noël, D | 1 |
| Pillon, A | 1 |
| Iborra, F | 1 |
| Dubus, P | 1 |
| Maudelonde, T | 1 |
| Culine, S | 1 |
| Fajas, L | 1 |
| Fukazawa, Y | 1 |
| Yamamoto, A | 1 |
| Leclercq, IA | 1 |
| Lebrun, VA | 1 |
| Horsmans, YJ | 1 |
| Lally, S | 1 |
| Owens, D | 1 |
| Tomkin, GH | 1 |
| Garvey, WT | 1 |
| Ota, T | 2 |
| Takamura, T | 2 |
| Kurita, S | 1 |
| Matsuzawa, N | 1 |
| Kita, Y | 1 |
| Uno, M | 1 |
| Akahori, H | 1 |
| Misu, H | 1 |
| Sakurai, M | 1 |
| Zen, Y | 1 |
| Nakanuma, Y | 1 |
| Kaneko, S | 2 |
| Oliveira, AC | 1 |
| Bertollo, CM | 1 |
| Rocha, LT | 1 |
| Nascimento, EB | 1 |
| Costa, KA | 1 |
| Coelho, MM | 1 |
| Gaikwad, AB | 1 |
| Viswanad, B | 1 |
| Tureyen, K | 1 |
| Kapadia, R | 1 |
| Bowen, KK | 1 |
| Satriotomo, I | 1 |
| Liang, J | 1 |
| Vemuganti, R | 1 |
| Fujita, K | 1 |
| Yoneda, M | 1 |
| Mawatari, H | 1 |
| Kirikoshi, H | 1 |
| Inamori, M | 1 |
| Nozaki, Y | 1 |
| Maeyama, S | 1 |
| Saito, S | 1 |
| Iwasaki, T | 1 |
| Lee, EY | 1 |
| Lee, BJ | 1 |
| Won, CS | 1 |
| Koh, JH | 1 |
| Shin, JY | 1 |
| Shin, YG | 1 |
| Cho, BP | 1 |
| Chung, CH | 1 |
| Peiris, M | 1 |
| Monteith, GR | 1 |
| Roberts-Thomson, SJ | 1 |
| Cabot, PJ | 1 |
| Choi, SH | 1 |
| Zhao, ZS | 1 |
| Lee, YJ | 1 |
| Kim, SK | 1 |
| Kim, DJ | 1 |
| Ahn, CW | 1 |
| Lim, SK | 1 |
| Boileau, C | 1 |
| Fahmi, H | 1 |
| Mineau, F | 1 |
| Boily, M | 1 |
| Omasu, F | 1 |
| Yoshizawa, N | 1 |
| Yamakami, K | 1 |
| Huang, PH | 1 |
| Sata, M | 1 |
| Nishimatsu, H | 1 |
| Sumi, M | 1 |
| Nakamura, T | 1 |
| Yamamoto, E | 1 |
| Kataoka, K | 1 |
| Yamashita, T | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Matsuba, S | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Ohtomo, S | 1 |
| Izuhara, Y | 1 |
| Takizawa, S | 1 |
| Yamada, N | 1 |
| Kakuta, T | 1 |
| Saiki, R | 1 |
| Okazaki, M | 1 |
| Iwai, S | 1 |
| Kumai, T | 1 |
| Kobayashi, S | 1 |
| Oguchi, K | 1 |
| Kasai, T | 1 |
| Miyauchi, K | 1 |
| Yokoyama, T | 1 |
| Kajimoto, K | 1 |
| Sumiyoshi, K | 1 |
| Ikeda, E | 1 |
| Daida, H | 1 |
| Yamagishi, S | 1 |
| Ogasawara, S | 1 |
| Mizukami, H | 1 |
| Yajima, N | 1 |
| Wada, R | 1 |
| Sugawara, A | 1 |
| Yagihashi, S | 1 |
| Sasaki, H | 1 |
| Ogawa, K | 1 |
| Shimizu, M | 1 |
| Mori, C | 1 |
| Takatsuka, H | 1 |
| Okazaki, F | 1 |
| Kawai, M | 1 |
| Taniguchi, I | 1 |
| Mochizuki, S | 1 |
| Narala, VR | 1 |
| Ranga, R | 1 |
| Smith, MR | 1 |
| Berlin, AA | 1 |
| Standiford, TJ | 1 |
| Lukacs, NW | 1 |
| Reddy, RC | 1 |
| Choi, IK | 1 |
| Kim, YH | 1 |
| Seo, JH | 1 |
| Pérez, YY | 1 |
| Jiménez-Ferrer, E | 1 |
| Zamilpa, A | 1 |
| Hernández-Valencia, M | 1 |
| Tortoriello, J | 1 |
| Román-Ramos, R | 1 |
| Takatori, S | 1 |
| Zamami, Y | 1 |
| Yabumae, N | 1 |
| Hanafusa, N | 1 |
| Mio, M | 1 |
| Egawa, T | 1 |
| Kawasaki, H | 1 |
| Reiter, MJ | 1 |
| Xu, Y | 1 |
| Chicco, A | 1 |
| Greyson, CR | 1 |
| Schwartz, GG | 1 |
| Yoshioka, K | 1 |
| Wakino, S | 1 |
| Homma, K | 1 |
| Kanda, T | 1 |
| Tatematsu, S | 1 |
| Hasegawa, K | 1 |
| Sugano, N | 1 |
| Ito, O | 1 |
| Omata, K | 1 |
| Saruta, T | 1 |
| Kawaguchi-Niida, M | 1 |
| Toi, S | 1 |
| Hirano, A | 1 |
| Shimano, M | 1 |
| Tsuji, Y | 1 |
| Inden, Y | 1 |
| Kitamura, K | 1 |
| Uchikawa, T | 1 |
| Harata, S | 1 |
| Nattel, S | 1 |
| Murohara, T | 1 |
| Wilson, LD | 1 |
| Tsai, CT | 1 |
| Korantzopoulos, P | 1 |
| Goudevenos, JA | 1 |
| Li, G | 1 |
| Schmerbach, K | 1 |
| Schefe, JH | 1 |
| Krikov, M | 1 |
| Müller, S | 1 |
| Villringer, A | 1 |
| Kintscher, U | 1 |
| Unger, T | 1 |
| Thoene-Reineke, C | 1 |
| Lang, MJ | 1 |
| Mao, XB | 1 |
| Tian, L | 1 |
| Feng, YB | 1 |
| Matsunaga, H | 1 |
| Hokari, R | 1 |
| Kurihara, C | 1 |
| Okada, Y | 1 |
| Takebayashi, K | 1 |
| Okudaira, K | 1 |
| Watanabe, C | 1 |
| Komoto, S | 1 |
| Nakamura, M | 1 |
| Tsuzuki, Y | 1 |
| Kawaguchi, A | 1 |
| Itoh, K | 1 |
| Castle, CK | 1 |
| Colca, JR | 1 |
| Melchior, GW | 1 |
| Kazumi, T | 1 |
| Hirano, T | 1 |
| Ebara, T | 1 |
| Amano, N | 1 |
| Hozumi, T | 1 |
| Ishida, Y | 1 |
| Yoshino, G | 1 |
| Nomura, C | 1 |
| Ikeda, H | 2 |
| Sugiyama, Y | 1 |
| Sohda, T | 1 |
| Asakawa, M | 1 |
| Nagai, T | 1 |
| Uozumi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter, Randomized, Double Blind, Placebo-controlled, Phase II Clinical Trial to Evaluate the Safety and Efficacy of YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus[NCT01836172] | Phase 2 | 136 participants (Anticipated) | Interventional | 2013-04-30 | Active, not recruiting | ||
| Effect of Gymnema Sylvestre Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion[NCT02370121] | Phase 2 | 24 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Efficacy and Safety of Pioglitazone Therapy for Chronic Granulomatous Disease Patients With Severe Infection.[NCT03080480] | Phase 1/Phase 2 | 3 participants (Actual) | Interventional | 2017-09-01 | Terminated (stopped due to The results are negtive.) | ||
| Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus[NCT01432405] | Phase 4 | 24 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Effect of a Systematic Physical Exercise Program and Spirulina Maxima Supplementation on the Body Composition, Physical Function and Blood Lipid Profile in Sedentary Older Adults With Excess Weight[NCT04658875] | 52 participants (Anticipated) | Interventional | 2022-01-17 | Not yet recruiting | |||
| Effect of Pioglitazone Treatment in Patient's Calcific Aortic Valve Disease With Mild Aortic Valve Stenosis[NCT05875675] | Phase 2 | 100 participants (Anticipated) | Interventional | 2023-07-01 | Not yet recruiting | ||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Efficacy, Safety and Tolerability Study of 45 mg Pioglitazone in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole)[NCT00690118] | Phase 2 | 219 participants (Actual) | Interventional | 2008-05-31 | Terminated (stopped due to The interim analysis showed no tendency in favour of the verum group. Therefore it was decided to stop the study prematurely.) | ||
| Pioglitazone in Alzheimer Disease Progression[NCT00982202] | Phase 2 | 25 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| The Effects of the PPARy Agonist Rosiglitazone on Airway Hyperreactivity[NCT00614874] | Phase 2 | 16 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The blood sample for determining of 2-h PG, was taken two hours after the ingestion of the drink with 75 g dextrose and was evaluated by spectrophotometry method. The value was expressed on mmol/L. (NCT02370121)
Timeframe: week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 6.83 |
| Gymnema Sylvestre | 7.22 |
The estimation for AUCG was calculated from parameters obtained during the 2 hours oral glucose tolerant test (OGTT) with 75 g dextrose by trapezoidal integration. The value was expressed mmol/L/min. (NCT02370121)
Timeframe: week 12
| Intervention | mmol/L/min (Mean) |
|---|---|
| Placebo | 965 |
| Gymnema Sylvestre | 914 |
The estimation for AUCI was calculated from parameters obtained during the 2 hours oral glucose tolerant test (OGTT) with 75 g dextrose by trapezoidal integration. The value was expressed on pmol/L/min. (NCT02370121)
Timeframe: week 12
| Intervention | pmol/L/min (Mean) |
|---|---|
| Placebo | 90816 |
| Gymnema Sylvestre | 60468 |
The BMI was calculated by the square of the body height, and is universally expressed in units of kg/m2, resulting from mass in kilograms and height in metres. (NCT02370121)
Timeframe: week 12
| Intervention | kg/m^2 (Mean) |
|---|---|
| Placebo | 30.70 |
| Gymnema Sylvestre | 30.43 |
The BW was evaluated after an overnight fast, through a bioimpedance digital scale results are reported in kilograms with a decimal. (NCT02370121)
Timeframe: week 12
| Intervention | kg (Mean) |
|---|---|
| Placebo | 80.3 |
| Gymnema Sylvestre | 77.9 |
The DBP was evaluated with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of DBP. The value was expressed on mmHg. (NCT02370121)
Timeframe: week 12
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | 83 |
| Gymnema Sylvestre | 78 |
The blood sample for determining of FPG, was taken after an overnight fast and was evaluated by spectrophotometry method. The value was expressed on mmol/L. (NCT02370121)
Timeframe: week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 5.00 |
| Gymnema Sylvestre | 4.83 |
The first phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'). (NCT02370121)
Timeframe: week 12
| Intervention | unitless (Mean) |
|---|---|
| Placebo | 1805 |
| Gymnema Sylvestre | 1366 |
The blood sample for determining of HDL-C, was taken after an overnight fast and was evaluated by colorimetric method. The value was expressed on mmol/L. (NCT02370121)
Timeframe: Week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 1.03 |
| Gymnema Sylvestre | 1.08 |
The insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. (NCT02370121)
Timeframe: week 12
| Intervention | unitless (Mean) |
|---|---|
| Placebo | 2.5 |
| Gymnema Sylvestre | 4.1 |
The blood sample for determining of LDL-C, was taken after an overnight fast and was calculated by Friedewald formula. The value was expressed on mmol/L. (NCT02370121)
Timeframe: Week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 2.77 |
| Gymnema Sylvestre | 2.69 |
The SBP was evaluated with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of SBP. The value was expressed on mmHg. (NCT02370121)
Timeframe: week 12
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | 122 |
| Gymnema Sylvestre | 121 |
The blood sample for determining of TC, was taken after an overnight fast and was evaluated by spectrophotometry method. The value was expressed on mmol/L. (NCT02370121)
Timeframe: week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 5.04 |
| Gymnema Sylvestre | 4.55 |
The total insulin secretion was calculated by the insulinogenic index (ΔABC insulin / ΔABC glucose). (NCT02370121)
Timeframe: Week 12
| Intervention | unitless (Mean) |
|---|---|
| Placebo | 0.95 |
| Gymnema Sylvestre | 0.59 |
The blood sample for determining of TGs, was taken after an overnight fast and was evaluated by spectrophotometry method. The value was expressed on mmol/L. (NCT02370121)
Timeframe: week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 2.79 |
| Gymnema Sylvestre | 1.70 |
The blood sample for determining the VLDL, was taken after an overnight fast and was calculated as triglycerides/5. The value was expressed on mmol/L. (NCT02370121)
Timeframe: week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 0.56 |
| Gymnema Sylvestre | 0.35 |
The WC was evaluated after an overnight fast with a flexible tape in the midpoint between the lowest rib and the iliac crest and is expressed in centimeters. (NCT02370121)
Timeframe: Week 12
| Intervention | cm (Mean) |
|---|---|
| Placebo | 101 |
| Gymnema Sylvestre | 96 |
The effect of exenatide and pioglitazone on liver fat content after one year of treatment in patients with type 2 diabetes. (NCT01432405)
Timeframe: one year
| Intervention | percent of liver fat (Mean) |
|---|---|
| Pioglitazone and Exenatide | 4.7 |
| Pioglitazone | 6.5 |
the effect of the intervention on plasma adiponectin levels. (NCT01432405)
Timeframe: one year
| Intervention | microgram per ml (Mean) |
|---|---|
| Pioglitazone and Exenatide | 23.2 |
| Pioglitazone | 15.8 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
Fraction Exhaled Nitric oxide was measured on each visit prior to bronchoprovocation by chemiluminescence using an analyzer. (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
| Intervention | parts per billion (Mean) | |
|---|---|---|
| Baseline | 12 weeks | |
| Rosiglitazone | 48 | 41 |
FEV1 in liters (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
| Intervention | Liters (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Rosiglitazone | 2.95 | 3.04 |
Spirometry was performed on each visit according to American Thoracic Society guidelines. FEV1 percent predicted was measured. (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
| Intervention | percent predicted (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Rosiglitazone | 82 | 85 |
PC20 is the concentration of methacholine at which patients had a decrease in Forced Expiratory Volume in one second (FEV1) of 20% (NCT00614874)
Timeframe: patients were assessed at baseline and at 12 weeks
| Intervention | mg/mL (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Rosiglitazone | 3.27 | 8.71 |
13 reviews available for pioglitazone and Disease Models, Animal
| Article | Year |
|---|---|
Neuroprotective and Anti-inflammatory Effects of Pioglitazone on Traumatic Brain Injury.
Topics: Animals; Anti-Inflammatory Agents; Brain Injuries, Traumatic; Disease Models, Animal; Humans; Microg | 2022 |
A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer's Disease in transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cognition; | 2019 |
Modulatory effects of peroxisome proliferator-activated receptor-γ on CXCR3 chemokines.
Topics: Animals; Autoimmune Diseases; Chemokines; Disease Models, Animal; Europe; Humans; Immunity, Cellular | 2014 |
Effects of aging on renal function and regenerative capacity.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Aging; Animals; Cellular Senescence; Disease Models, A | 2014 |
Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit.
Topics: Animals; Cardiovascular System; Diabetes Mellitus, Type 2; Disease Models, Animal; Endpoint Determin | 2015 |
Cellular and Animal Studies: Insights into Pathophysiology and Therapy of PCOS.
Topics: Androgens; Animals; Death Domain Receptor Signaling Adaptor Proteins; Decanoic Acids; Disease Models | 2016 |
Pathophysiology-based treatment of urolithiasis.
Topics: Animals; Cardiovascular Diseases; Cholesterol, Dietary; Diabetes Mellitus, Type 2; Disease Models, A | 2017 |
PPAR-γ agonists in polycystic kidney disease with frequent development of cardiovascular disorders.
Topics: Animals; Cardiovascular Diseases; Cell Proliferation; Disease Models, Animal; Fibrosis; Hypoglycemic | 2012 |
Novel strategy to prevent atrial fibrosis and fibrillation.
Topics: Animals; Antioxidants; Atrial Fibrillation; Chemokine CCL2; Disease Models, Animal; Endothelial Cell | 2012 |
Vitamin E and nonalcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Antioxidants; Diabetes Mellitus; Disease Models, Animal; Dose-Respons | 2012 |
[Hypertension and insulin resistance in obese type 2 diabetic Wistar fatty rat].
Topics: Animals; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, Anima | 2003 |
[Preclinical studies of pioglitazone (AD-4833)].
Topics: Animals; Diabetes Mellitus; Disease Models, Animal; Glycogen; Glycolysis; Hypoglycemic Agents; Insul | 1997 |
[Hypoglycemic agents to improve insulin resistance].
Topics: Adipocytes; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; Disease Models, Anim | 2000 |
4 trials available for pioglitazone and Disease Models, Animal
| Article | Year |
|---|---|
Apolipoprotein J is a hepatokine regulating muscle glucose metabolism and insulin sensitivity.
Topics: Adult; Animals; Cell Line; Clusterin; Disease Models, Animal; Female; Glucose; Glucose Clamp Techniq | 2020 |
Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue.
Topics: 3T3-L1 Cells; Adipocytes; Adult; Animals; Disease Models, Animal; Dyslipidemias; Fenofibrate; Humans | 2014 |
Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
Topics: Adult; Aged; Animals; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, | 2011 |
Treatment of rats with pioglitazone in the reperfusion phase of focal cerebral ischemia: a preclinical stroke trial.
Topics: Analysis of Variance; Animals; Brain Infarction; Brain Ischemia; Caspase 9; Cerebral Cortex; Cycloox | 2012 |
330 other studies available for pioglitazone and Disease Models, Animal
| Article | Year |
|---|---|
[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hemoglobins; Hypoglycemic Agents; Mice; | 1994 |
Thiazolidine-2,4-diones derivatives as PPAR-γ agonists: synthesis, molecular docking, in vitro and in vivo antidiabetic activity with hepatotoxicity risk evaluation and effect on PPAR-γ gene expression.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Gene Expression Reg | 2014 |
Discovery of the bifunctional modulator of angiotensin II type 1 receptor (AT1R) and PPARγ derived from the AT1R antagonist, Fimasartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Area Under Curve; Bipheny | 2018 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Disease Models, Animal; Female; Immunity, | 2021 |
A Role for Peroxisome Proliferator-Activated Receptor Gamma Agonists in Counteracting the Degeneration of Cardiovascular Grafts.
Topics: Animals; Aortic Valve; Aortic Valve Insufficiency; Bioprosthesis; Calcinosis; Chondrogenesis; Cryopr | 2021 |
Identification of MDM2, YTHDF2 and DDX21 as potential biomarkers and targets for treatment of type 2 diabetes.
Topics: Animals; Databases, Factual; Datasets as Topic; DEAD-box RNA Helicases; Diabetes Mellitus, Type 2; D | 2021 |
Pioglitazone restores phosphorylation of downregulated caveolin-1 in right ventricle of monocrotaline-induced pulmonary hypertension.
Topics: Animals; Caveolin 1; Disease Models, Animal; Heart Ventricles; Hypertension, Pulmonary; Male; Monocr | 2022 |
The PPARγ agonist pioglitazone produces a female-predominant inhibition of hyperalgesia associated with surgical incision, peripheral nerve injury, and painful diabetic neuropathy.
Topics: Analgesics; Animals; Diabetic Neuropathies; Disease Models, Animal; Female; Hyperalgesia; Male; Mice | 2022 |
Regulation of Neuroinflammatory Signaling by PPARγ Agonist in Mouse Model of Diabetes.
Topics: Animals; Caveolin 1; Diabetes Mellitus, Experimental; Disease Models, Animal; Interleukin-6; Mice; N | 2022 |
Peroxisome proliferator-activated receptor-γ doesn't modify altered electrophysiological properties of the CA1 pyramidal neurons in a rat model of hepatic cirrhosis.
Topics: Animals; Bile Ducts; Disease Models, Animal; Ligation; Liver Cirrhosis; Male; Pioglitazone; PPAR gam | 2022 |
The effects of the voglibose on non-alcoholic fatty liver disease in mice model.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Fructose; Glucose; Glycoside Hydrolase Inhibitors; | 2022 |
Validation of a diet-induced Macaca fascicularis model of non-alcoholic steatohepatitis with dietary and pioglitazone interventions.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Liver; Liver Cirrhosis; Macaca fascicularis; Non-al | 2023 |
Long-Term Pioglitazone Treatment Has No Significant Impact on Microglial Activation and Tau Pathology in P301S Mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Mice; Mice, Transgenic; M | 2023 |
Amelioration of perivascular adipose inflammation reverses vascular dysfunction in a model of nonobese prediabetic metabolic challenge: potential role of antidiabetic drugs.
Topics: Adipose Tissue; Animals; Disease Models, Animal; Feeding Behavior; Hypoglycemic Agents; Inflammation | 2019 |
Pioglitazone treatment prior to transplantation improves the efficacy of human mesenchymal stem cells after traumatic brain injury in rats.
Topics: Administration, Intranasal; Animals; Anti-Inflammatory Agents; Brain Injuries, Traumatic; Brain-Deri | 2019 |
Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease.
Topics: Animals; Bupleurum; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Fructose; Humans; | 2019 |
MicroRNA miR-222 mediates pioglitazone beneficial effects on skeletal muscle of diet-induced obese mice.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; | 2020 |
Pioglitazone protects blood vessels through inhibition of the apelin signaling pathway by promoting KLF4 expression in rat models of T2DM.
Topics: Animals; Apelin; Blood Vessels; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression R | 2019 |
Bioenergetic restoration and neuroprotection after therapeutic targeting of mitoNEET: New mechanism of pioglitazone following traumatic brain injury.
Topics: Animals; Brain Injuries, Traumatic; Disease Models, Animal; Energy Metabolism; Iron-Binding Proteins | 2020 |
A possible alternative therapy for type 2 diabetes using Myristica fragrans Houtt in combination with glimepiride: in vivo evaluation and in silico support.
Topics: Alloxan; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Fema | 2020 |
Retinoprotection by BGP-15, a Hydroximic Acid Derivative, in a Type II Diabetic Rat Model Compared to Glibenclamide, Metformin, and Pioglitazone.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Models, Animal; Ele | 2020 |
The impact of single and combined PPAR-α and PPAR-γ activation on the neurological outcomes following cerebral ischemia reperfusion.
Topics: Animals; Apoptosis; Brain; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Drug Therapy | 2020 |
PPARγ-mediated microglial activation phenotype is involved in depressive-like behaviors and neuroinflammation in stressed C57BL/6J and ob/ob mice.
Topics: Animals; Behavior, Animal; Cognitive Dysfunction; Cytokines; Depression; Disease Models, Animal; Hip | 2020 |
Combination of Peroxisome Proliferator-Activated Receptor (PPAR) Alpha and Gamma Agonists Prevents Corneal Inflammation and Neovascularization in a Rat Alkali Burn Model.
Topics: Animals; Burns, Chemical; Corneal Injuries; Corneal Neovascularization; Cytokines; Disease Models, A | 2020 |
Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft.
Topics: Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone | 2021 |
Ischemia reperfusion-induced metastasis is resistant to PPARγ agonist pioglitazone in a murine model of colon cancer.
Topics: Animals; Colonic Neoplasms; Cytokines; Disease Models, Animal; Disease Progression; Inflammation; Li | 2020 |
Enhanced Anti-Amyloid Effect of Combined Leptin and Pioglitazone in APP/PS1 Transgenic Mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Hippocampus; Humans; Hypo | 2020 |
Suppression of Myocardial Hypoxia-Inducible Factor-1α Compromises Metabolic Adaptation and Impairs Cardiac Function in Patients With Cyanotic Congenital Heart Disease During Puberty.
Topics: Animals; Disease Models, Animal; Fatty Acids; Glucose; Glycolysis; Heart Defects, Congenital; Humans | 2021 |
PPARγ activation improves the microenvironment of perivascular adipose tissue and attenuates aortic stiffening in obesity.
Topics: 3T3 Cells; Adipose Tissue; Animals; Disease Models, Animal; Hypoglycemic Agents; Male; Mice; Mice, I | 2021 |
Carvacrol and PPARγ agonist, pioglitazone, affects inhaled paraquat-induced lung injury in rats.
Topics: Animals; Case-Control Studies; Cymenes; Dexamethasone; Disease Models, Animal; Drug Synergism; Gene | 2021 |
Neuroprotective and antioxidative effects of pioglitazone in brain tissue adjacent to the ischemic core are mediated by PI3K/Akt and Nrf2/ARE pathways.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Brain Ischemia; Cerebrovascular Circulation; Disease M | 2021 |
Effects of KY-903, a Novel Tetrazole-Based Peroxisome Proliferator-Activated Receptor γ Modulator, in Male Diabetic Mice and Female Ovariectomized Rats.
Topics: 3T3-L1 Cells; Adipogenesis; Adiponectin; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, Hi | 2021 |
Pioglitazone Enhances β-Arrestin2 Signaling and Ameliorates Insulin Resistance in Classical Insulin Target Tissues.
Topics: Adipose Tissue; Animals; beta-Arrestin 2; Diet, High-Fat; Disease Models, Animal; Fructose; Hypoglyc | 2021 |
Pioglitazone and/or irbesartan ameliorate COPD-induced endothelial dysfunction in side stream cigarette smoke-exposed mice model.
Topics: Animals; Antihypertensive Agents; Cigarette Smoking; Disease Models, Animal; Endothelium; Hypoglycem | 2021 |
Discovery of new dual PPARγ-GPR40 agonists with robust antidiabetic activity: Design, synthesis and in combo drug evaluation.
Topics: 3T3 Cells; Animals; Blood Glucose; Calcium; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mel | 2017 |
Pioglitazone treatment following spinal cord injury maintains acute mitochondrial integrity and increases chronic tissue sparing and functional recovery.
Topics: Analysis of Variance; Animals; Calcium-Binding Proteins; Disease Models, Animal; Glial Fibrillary Ac | 2017 |
Curcumin reverses the depressive-like behavior and insulin resistance induced by chronic mild stress.
Topics: Animals; Behavior, Animal; Blood Glucose; Corticosterone; Curcumin; Depression; Disease Models, Anim | 2017 |
Mitochondrial Dysfunction in Diabetic Cardiomyopathy: Effect of Mesenchymal Stem Cell with PPAR-γ Agonist or Exendin-4.
Topics: Animals; Cardiolipins; Diabetic Cardiomyopathies; Disease Models, Animal; Exenatide; Hypoglycemic Ag | 2018 |
Pioglitazone improves the ability of learning and memory via activating ERK1/2 signaling pathway in the hippocampus of T2DM rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Hippoca | 2017 |
Pioglitazone Attenuates Injury-Induced Neointima Formation in Mouse Femoral Artery Partially through the Activation of AMP-Activated Protein Kinase.
Topics: Administration, Oral; AMP-Activated Protein Kinases; Animals; Cell Proliferation; Disease Models, An | 2017 |
PPARγ Agonists Attenuate Trigeminal Neuropathic Pain.
Topics: Analgesics, Non-Narcotic; Anilides; Animals; Disease Models, Animal; Facial Pain; Hyperalgesia; Male | 2017 |
Combination Drug Therapy of Pioglitazone and D-cycloserine Attenuates Chronic Orofacial Neuropathic Pain and Anxiety by Improving Mitochondrial Function Following Trigeminal Nerve Injury.
Topics: Analgesics; Animals; Anti-Anxiety Agents; Anxiety; Brain; Chronic Pain; Cognition; Cycloserine; Dise | 2018 |
Synergistic protection against acute flurothyl-induced seizures by adjuvant treatment of the ketogenic diet with the type 2 diabetes drug pioglitazone.
Topics: 3-Hydroxybutyric Acid; Animals; Blood Glucose; Body Weight; Convulsants; Diet, Ketogenic; Disease Mo | 2017 |
Protective effects of asiatic acid in a spontaneous type 2 diabetic mouse model.
Topics: Animals; Biomarkers; Diabetes Mellitus, Type 2; Disease Models, Animal; Glycogen Synthase Kinase 3 b | 2017 |
Pioglitazone-induced bone loss in diabetic rats and its amelioration by berberine: A portrait of molecular crosstalk.
Topics: Animals; Berberine; Biomarkers; Blood Glucose; Bone and Bones; Bone Density; Diabetes Mellitus, Expe | 2017 |
Pioglitazone Enhances Cytosolic Lipolysis, β-oxidation and Autophagy to Ameliorate Hepatic Steatosis.
Topics: Animals; Autophagy; Cell Line; Diet, High-Fat; Disease Models, Animal; Humans; Insulin; Leupeptins; | 2017 |
Targeting cholesterol homeostasis in lung diseases.
Topics: Animals; Cell Differentiation; Cholesterol; Disease Models, Animal; Granulocyte-Macrophage Colony-St | 2017 |
Editor's Highlight: An Impaired Immune Tolerance Animal Model Distinguishes the Potential of Troglitazone/Pioglitazone and Tolcapone/Entacapone to Cause IDILI.
Topics: Animals; Antibodies, Monoclonal; Catechols; Cell Line; Chemical and Drug Induced Liver Injury; CTLA- | 2018 |
Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson's disease in rats.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Male; Mortality; Ne | 2018 |
Inflammatory Response Modulation through a PPARγ Agonist during Surgically Induced Visceral Ischemia in an Animal Model.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Constriction; Cytoprotection; Disease Models, Animal; Infl | 2018 |
Pioglitazone attenuates aging-related disorders in aged apolipoprotein E deficient mice.
Topics: Age Factors; Aging; Animals; Anti-Inflammatory Agents; Antioxidants; Aortic Diseases; Atherosclerosi | 2018 |
Molecular determinants of PPARγ partial agonism and related in silico/in vivo studies of natural saponins as potential type 2 diabetes modulators.
Topics: Animals; Antioxidants; Biomarkers; Blood Glucose; Catalase; Computer Simulation; Diabetes Mellitus, | 2018 |
Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cells, Cultured; Diabetes Complications; Diabetes Melli | 2017 |
Diabetic macular edema-like ocular lesions in male spontaneously diabetic torii fatty rats.
Topics: Animals; Capillary Permeability; Diabetic Retinopathy; Disease Models, Animal; Hyperglycemia; Hypogl | 2018 |
Pioglitazone is effective for multiple phenotyepes of the Zucker fa/fa rat with polycystc ovary morphology and insulin resistance.
Topics: Animals; Animals, Genetically Modified; Body Weight; Disease Models, Animal; Female; Hypoglycemic Ag | 2018 |
Investigation of pharmacological responses to anti-diabetic drugs in female Spontaneously Diabetic Torii (SDT) fatty rats, a new nonalcoholic steatohepatitis (NASH) model.
Topics: Animals; Cholesterol; Diet; Disease Models, Animal; Eating; Female; Hypoglycemic Agents; Metformin; | 2018 |
Effect of pioglitazone and simvastatin in lipopolysaccharide-induced amyloidogenesis and cognitive impairment in mice: possible role of glutamatergic pathway and oxidative stress.
Topics: Amyloid beta-Peptides; Animals; Cerebral Cortex; Cognitive Dysfunction; Disease Models, Animal; Dose | 2019 |
Role of Wnt4/β-catenin, Ang II/TGFβ, ACE2, NF-κB, and IL-18 in attenuating renal ischemia/reperfusion-induced injury in rats treated with Vit D and pioglitazone.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; beta Catenin; Cytoprotection; Disease Mode | 2018 |
Protective effect of pioglitazone on ovarian ischemia reperfusion injury of female rats via modulation of peroxisome proliferator activated receptor gamma and heme-oxygenase 1.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Heme Oxygenase (Decyclizi | 2018 |
Metabolomic and lipidomic analysis of the effect of pioglitazone on hepatic steatosis in a rat model of obese Type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Liver; Hypoglycemic Agents; Lipid | 2018 |
MitoNEET in Perivascular Adipose Tissue Prevents Arterial Stiffness in Aging Mice.
Topics: Adipose Tissue, Brown; Adiposity; Age Factors; Aging; Animals; Cardiovascular Diseases; Diet, High-F | 2018 |
Peroxisome proliferator-activated receptor-gamma targeting nanomedicine promotes cardiac healing after acute myocardial infarction by skewing monocyte/macrophage polarization in preclinical animal models.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Drug Carriers; Injections, Intravenous; M | 2019 |
PPARγ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer's disease: in vitro and in vivo studies.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Blood-Brain Barrier; Cells, Cultured; Di | 2018 |
Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis.
Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Choline; Diet, High- | 2019 |
A metabolome-wide characterization of the diabetic phenotype in ZDF rats and its reversal by pioglitazone.
Topics: Amino Acids; Animals; Bile Acids and Salts; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models | 2018 |
Pioglitazone, a PPARγ agonist, reduces cisplatin-evoked neuropathic pain by protecting against oxidative stress.
Topics: Animals; Antineoplastic Agents; Cells, Cultured; Cisplatin; Disease Models, Animal; Female; Ganglia, | 2019 |
Treatment with the synthetic PPARG ligand pioglitazone ameliorates early ovarian alterations induced by dehydroepiandrosterone in prepubertal rats.
Topics: Animals; Co-Repressor Proteins; Dehydroepiandrosterone; Disease Models, Animal; Estradiol; Female; H | 2019 |
Pioglitazone improves visceral sensation and colonic permeability in a rat model of irritable bowel syndrome.
Topics: Animals; Colon; Disease Models, Animal; Hyperalgesia; Hypoglycemic Agents; Irritable Bowel Syndrome; | 2019 |
The prevention of tracheal graft occlusion using pioglitazone: A mouse tracheal transplant model study.
Topics: Animals; Cell Movement; Disease Models, Animal; Forkhead Transcription Factors; Humans; Immunosuppre | 2019 |
Nanoparticle-mediated local delivery of pioglitazone attenuates bleomycin-induced skin fibrosis.
Topics: Animals; Bleomycin; Cell Differentiation; Delayed-Action Preparations; Disease Models, Animal; Drug | 2019 |
Pioglitazone increases VEGFR3 expression and promotes activation of M2 macrophages via the peroxisome proliferator‑activated receptor γ.
Topics: Animals; Cell Line; Cell Proliferation; Disease Models, Animal; Fibrosis; Gene Expression Regulation | 2019 |
Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; Cholesterol; Diet, High-F | 2019 |
Low-dose pioglitazone can ameliorate learning and memory impairment in a mouse model of dementia by increasing LRP1 expression in the hippocampus.
Topics: Amyloid beta-Peptides; Animals; Dementia; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; | 2019 |
Pioglitazone prevents sevoflurane‑induced neuroinflammation and cognitive decline in a rat model of chronic intermittent hypoxia by upregulating hippocampal PPAR‑γ.
Topics: Animals; Chronic Disease; Cognitive Dysfunction; Disease Models, Animal; Hippocampus; Hypoglycemic A | 2019 |
Pioglitazone strengthen therapeutic effect of adipose-derived regenerative cells against ischemic cardiomyopathy through enhanced expression of adiponectin and modulation of macrophage phenotype.
Topics: Adiponectin; Adipose Tissue; Animals; Cadherins; Cardiomyopathies; Cell Transplantation; Cells, Cult | 2019 |
Reverting Metabolic Dysfunction in Cortex and Cerebellum of APP/PS1 Mice, a Model for Alzheimer's Disease by Pioglitazone, a Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Agonist.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Catalase; Cerebellum; Cerebral Cortex; C | 2019 |
Pharmacological activation of peroxisome proliferator-activated receptor γ (PPAR-γ) protects against hypoxia-associated fetal growth restriction.
Topics: Altitude Sickness; AMP-Activated Protein Kinases; Animals; Disease Models, Animal; Female; Fetal Gro | 2019 |
Pioglitazone decreased renal calcium oxalate crystal formation by suppressing M1 macrophage polarization via the PPAR-γ-miR-23 axis.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Binding Sites; Calcium Oxalate; Crystallization; Disea | 2019 |
PPAR-γ agonist pioglitazone reduces microglial proliferation and NF-κB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Male; Microglia; Motor Activity; Neuroprotective Agents; NF-kappa B | 2019 |
Adiponectin is required for pioglitazone-induced improvements in hepatic steatosis in mice fed a high-fat diet.
Topics: Adiponectin; Animals; Diet, High-Fat; Disease Models, Animal; Fibroblast Growth Factors; Gene Knocko | 2019 |
Peroxisome Proliferator-Activated Receptor-gamma agonists exhibit anti-inflammatory and antiviral effects in an EcoHIV mouse model.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Brain; Cells, Cultured; Disease Models, Animal; | 2019 |
Pioglitazone as an adjuvant of amphotericin B for the treatment of cryptococcosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Antioxidants; Cryptococcosis; Cryptococcus gattii; Disea | 2019 |
A selective peroxisome proliferator-activated receptor-γ agonist benefited propionic acid induced autism-like behavioral phenotypes in rats by attenuation of neuroinflammation and oxidative stress.
Topics: Animals; Anxiety; Autism Spectrum Disorder; Behavior, Animal; Brain; Disease Models, Animal; Explora | 2019 |
Ponatinib treatment promotes arterial thrombosis and hyperactive platelets.
Topics: Animals; Antineoplastic Agents; Arteries; Biomarkers; Blood Platelets; Disease Models, Animal; Drug | 2019 |
Protective effect of pioglitazone on retinal ischemia/reperfusion injury in rats.
Topics: Animals; bcl-2-Associated X Protein; Blotting, Western; Cell Count; Cell Survival; Disease Models, A | 2013 |
Enhanced anti-ulcer effect of pioglitazone on gastric ulcers in cirrhotic rats: the role of nitric oxide and IL-1β.
Topics: Animals; Anti-Ulcer Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Interleukin-1b | 2013 |
An ethanolic extract of Lindera obtusiloba stems, YJP-14, improves endothelial dysfunction, metabolic parameters and physical performance in diabetic db/db mice.
Topics: Albuminuria; Angiotensin II; Animals; Aorta; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; | 2013 |
Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy.
Topics: Adrenoleukodystrophy; Animals; ATP Binding Cassette Transporter, Subfamily D, Member 1; ATP-Binding | 2013 |
Pioglitazone alleviates the mitochondrial apoptotic pathway and mito-oxidative damage in the d-galactose-induced mouse model.
Topics: Acetylcholinesterase; Aging; Animals; Antioxidants; Apoptosis; Behavior, Animal; Brain; Caspase 3; C | 2013 |
A peroxisome proliferator-activated receptor gamma agonist attenuates neurological deficits following spinal cord ischemia in rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Disease Models, Animal; Infarction; Inflammation; M | 2014 |
Effect of a deacyl gymnemic acid on glucose homeostasis & metabolic parameters in a rat model of metabolic syndrome.
Topics: Animals; Blood Glucose; Body Weight; Disease Models, Animal; Female; Fructose; Glucose; Glucose Tole | 2013 |
Pioglitazone does not improve insulin signaling in mice with GH over-expression.
Topics: Animals; Blood Glucose; Disease Models, Animal; Growth Hormone; Hyperinsulinism; Hypoglycemic Agents | 2013 |
Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)--α and γ agonist against a rat model of oral dyskinesia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Disease Models, Animal; Fenofibrate; H | 2013 |
Peroxisome proliferator-activated receptor-γ agonist pioglitazone suppresses experimental autoimmune uveitis.
Topics: Animals; Autoimmune Diseases; Disease Models, Animal; Female; Flow Cytometry; Humans; Hypoglycemic A | 2013 |
PPARγ activation inhibits cerebral arteriogenesis in the hypoperfused rat brain.
Topics: Angiogenesis Inducing Agents; Animals; Blotting, Western; Brain; Brain Ischemia; Disease Models, Ani | 2014 |
An ophthalmic solution of a peroxisome proliferator-activated receptor gamma agonist prevents corneal inflammation in a rat alkali burn model.
Topics: Alkalies; Animals; Burns, Chemical; Chemokines; Collagen Type III; Cornea; Corneal Neovascularizatio | 2013 |
Role of nuclear receptor on regulation of BDNF and neuroinflammation in hippocampus of β-amyloid animal model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain-Derived Neurotrophic Factor; Cognition Diso | 2014 |
Assessment of pharmacokinetic interaction of spirulina with glitazone in a type 2 diabetes rat model.
Topics: Animals; Dexamethasone; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, | 2013 |
The increased gastroprotective effect of pioglitazone in cholestatic rats: role of nitric oxide and tumour necrosis factor alpha.
Topics: Animals; Cholestasis; Disease Models, Animal; Dose-Response Relationship, Drug; Ethanol; Interleukin | 2014 |
Antinociceptive and antidiarrheal effects of pioglitazone in a rat model of diarrhoea-predominant irritable bowel syndrome: role of nitric oxide.
Topics: Analgesics; Animals; Antidiarrheals; Diarrhea; Disease Models, Animal; Irritable Bowel Syndrome; Mal | 2014 |
Suppression of neuroinflammation in forebrain-specific Cdk5 conditional knockout mice by PPARγ agonist improves neuronal loss and early lethality.
Topics: Animals; Apoptosis; Cyclin-Dependent Kinase 5; Cytokines; Disease Models, Animal; Encephalitis; Gene | 2014 |
Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats.
Topics: Animals; Cell Movement; Disease Models, Animal; Hemodynamics; Human Umbilical Vein Endothelial Cells | 2014 |
Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-γ by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Disease Models, Animal; | 2014 |
Decreased PPAR-γ expression in the conjunctiva and increased expression of TNF-α and IL-1β in the conjunctiva and tear fluid of dry eye mice.
Topics: Animals; Cell Count; Conjunctiva; Disease Models, Animal; Dry Eye Syndromes; Female; Gene Expression | 2014 |
Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Eating; Huma | 2014 |
Pioglitazone attenuates lung injury by modulating adipose inflammation.
Topics: Acute Lung Injury; Adipose Tissue; Animals; Apoptosis; Disease Models, Animal; Endotoxins; Hypoglyce | 2014 |
Beneficial effects of pioglitazone and metformin in murine model of polycystic ovaries via improvement of chemerin gene up-regulation.
Topics: Adipokines; Animals; Chemokines; Disease Models, Animal; Drug Combinations; Drug Resistance; Female; | 2014 |
Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice.
Topics: Alzheimer Disease; Animals; Body Weight; Brain; Disease Models, Animal; Exploratory Behavior; Female | 2015 |
Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine.
Topics: Animals; Avoidance Learning; Caspase 3; Disease Models, Animal; Dopamine; Drug Administration Schedu | 2014 |
Pioglitazone suppresses neuronal and muscular degeneration caused by polyglutamine-expanded androgen receptors.
Topics: Animals; Disease Models, Animal; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Muscle, S | 2015 |
PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; DNA-Binding Proteins; Drosophila; Dr | 2015 |
Efficacy of pioglitazone on erectile function recovery in a rat model of cavernous nerve injury.
Topics: Animals; Arterial Pressure; Cyclic GMP; Disease Models, Animal; Dose-Response Relationship, Drug; Er | 2014 |
Involvement of PPAR receptors in the anticonvulsant effects of a cannabinoid agonist, WIN 55,212-2.
Topics: Anilides; Animals; Anticonvulsants; Benzoxazines; Cannabinoid Receptor Antagonists; Disease Models, | 2015 |
Protective effects of pioglitazone and/or liraglutide on pancreatic β-cells in db/db mice: Comparison of their effects between in an early and advanced stage of diabetes.
Topics: Animals; Apoptosis; Blood Glucose; Caspases; Cell Proliferation; Diabetes Mellitus, Type 2; Disease | 2015 |
Pioglitazone restores phagocyte mitochondrial oxidants and bactericidal capacity in chronic granulomatous disease.
Topics: Animals; Disease Models, Animal; Granulomatous Disease, Chronic; Humans; Male; Membrane Glycoprotein | 2015 |
A single dose of PPARγ agonist pioglitazone reduces cortical oxidative damage and microglial reaction following lateral fluid percussion brain injury in rats.
Topics: Animals; Brain Edema; Brain Injuries; Cyclooxygenase 2; Cytokines; Disease Models, Animal; Dose-Resp | 2015 |
Peroxisome proliferator-activated receptor-γ agonist pioglitazone ameliorates white matter lesion and cognitive impairment in hypertensive rats.
Topics: Animals; Blood Pressure; Brain; Cognition Disorders; Disease Models, Animal; Male; Maze Learning; Ne | 2015 |
Pioglitazone lowers serum retinol binding protein 4 by suppressing its expression in adipose tissue of obese rats.
Topics: Adipose Tissue; Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Hypoglycemic Agents; I | 2015 |
Pioglitazone blocks ethanol induction of microglial activation and immune responses in the hippocampus, cerebellum, and cerebral cortex in a mouse model of fetal alcohol spectrum disorders.
Topics: Animals; Cerebellum; Cerebral Cortex; Disease Models, Animal; Ethanol; Female; Fetal Alcohol Spectru | 2015 |
Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure.
Topics: Alanine Transaminase; Aldehydes; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Body We | 2015 |
The possible protective effect of simvastatin and pioglitazone separately and in combination on bleomycin-induced changes in mice thin skin.
Topics: Animals; Bleomycin; Disease Models, Animal; Hypoglycemic Agents; Mice; Pioglitazone; PPAR gamma; Sim | 2015 |
Influence of drug transporters and stereoselectivity on the brain penetration of pioglitazone as a potential medicine against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; ATP Binding Casse | 2015 |
Protective effect of pioglitazone on sepsis-induced intestinal injury in a rodent model.
Topics: Amine Oxidase (Copper-Containing); Animals; Bacterial Translocation; Disease Models, Animal; Interle | 2015 |
Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cells, Cultured; Cyclin-Dependent Kinase 5; Disea | 2015 |
LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD).
Topics: Animals; Cyclooxygenase 2; Diet, High-Fat; Disease Models, Animal; Epidermal Growth Factor; I-kappa | 2015 |
Peroxisome proliferator-activated receptor-γ agonist inhibits the mammalian target of rapamycin signaling pathway and has a protective effect in a rat model of status epilepticus.
Topics: Animals; CA3 Region, Hippocampal; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Immunoh | 2015 |
Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Axl Receptor Tyrosine Kinase; Benzoates; Benzylamines; Bexarotene; c-Mer | 2015 |
Mitoflash altered by metabolic stress in insulin-resistant skeletal muscle.
Topics: Animals; Bacterial Proteins; Disease Models, Animal; Hypoglycemic Agents; Insulin Resistance; Lumine | 2015 |
The Metabolic Syndrome and Microvascular Complications in a Murine Model of Type 2 Diabetes.
Topics: Animals; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Disease Models, Animal; Hypo | 2015 |
Activation of central PPAR-γ attenuates angiotensin II-induced hypertension.
Topics: Angiotensin II; Anilides; Animals; Blood Pressure; Brain; Disease Models, Animal; Hypertension; Infu | 2015 |
Pioglitazone Identifies a New Target for Aneurysm Treatment: Role of Egr1 in an Experimental Murine Model of Aortic Aneurysm.
Topics: Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Base Sequence; Binding Sites; Calcium Chloride; | 2015 |
Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Apolipoproteins E; Behavior, Animal; Ben | 2015 |
Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.
Topics: Angiotensin Receptor Antagonists; Animals; Aortic Diseases; Apolipoproteins E; Apoptosis; Atheroscle | 2015 |
Peroxisome Proliferator-Activated Receptor Gamma Promotes Mesenchymal Stem Cells to Express Connexin43 via the Inhibition of TGF-β1/Smads Signaling in a Rat Model of Myocardial Infarction.
Topics: Animals; Cell- and Tissue-Based Therapy; Connexin 43; Disease Models, Animal; Enzyme Activation; Mal | 2015 |
Effect of pioglitazone, quercetin, and hydroxy citric acid on vascular endothelial growth factor messenger RNA (VEGF mRNA) expression in experimentally induced nonalcoholic steatohepatitis (NASH).
Topics: Analysis of Variance; Animals; Antioxidants; Calcium Chelating Agents; Citric Acid; Disease Models, | 2015 |
Establishment of a rabbit model to study the influence of advanced glycation end products accumulation on osteoarthritis and the protective effect of pioglitazone.
Topics: Animals; Cartilage, Articular; Disease Models, Animal; Glycation End Products, Advanced; Hypoglycemi | 2016 |
Hyperglycemia and PPARγ Antagonistically Influence Macrophage Polarization and Infarct Healing After Ischemic Stroke.
Topics: Animals; Anticoagulants; Cell Polarity; Cerebral Hemorrhage; Diabetes Mellitus, Experimental; Diseas | 2015 |
Role of high-fat diet on the effect of pioglitazone and melatonin in a rat model of breast cancer.
Topics: Animals; Antioxidants; Carcinogens; Diet, High-Fat; Disease Models, Animal; Drug Therapy, Combinatio | 2016 |
Impaired efferocytosis in human chronic granulomatous disease is reversed by pioglitazone treatment.
Topics: Adolescent; Adult; Animals; Cells, Cultured; Child; Disease Models, Animal; Female; Granulomatous Di | 2015 |
The Effects of Sub-Chronic Treatment with Pioglitazone on the Septic Mice Mortality in the Model of Cecal Ligation and Puncture: Involvement of Nitric Oxide Pathway.
Topics: Animals; Cecum; Cytokines; Disease Models, Animal; Guanidines; Ligation; Male; Mice; Nitric Oxide; N | 2015 |
In Vivo Detection of Mitochondrial Dysfunction Induced by Clinical Drugs and Disease-Associated Genes Using a Novel Dye ZMJ214 in Zebrafish.
Topics: Animals; Anti-Bacterial Agents; Anticonvulsants; Benzophenones; Carbocyanines; Chromans; Disease Mod | 2016 |
Calcium Channel Blockade and Peroxisome Proliferator Activated Receptor γ Agonism Diminish Cognitive Loss and Preserve Endothelial Function During Diabetes Mellitus.
Topics: Animals; Attention; Blood-Brain Barrier; Brain; Calcium Channel Blockers; Calcium Channels; Capillar | 2016 |
Alterations in the intrinsic electrophysiological properties of Purkinje neurons in a rat model of hepatic encephalopathy: Relative preventing effect of PPARγ agonist.
Topics: Action Potentials; Animals; Biophysics; Disease Models, Animal; Electric Stimulation; Hepatic Enceph | 2016 |
Ameliorative potential of pioglitazone and ceftriaxone alone and in combination in rat model of neuropathic pain: Targeting PPARγ and GLT-1 pathways.
Topics: Animals; Ceftriaxone; Disease Models, Animal; Drug Delivery Systems; Drug Therapy, Combination; Exci | 2016 |
Neuroinflammation impairs adaptive structural plasticity of dendritic spines in a preclinical model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Anti-Inflammatory Agents; Aspartic | 2016 |
Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
Topics: Animals; Arterial Pressure; Cardiovascular Agents; Disease Models, Animal; Fibrosis; Heart Ventricle | 2016 |
Pioglitazone-Incorporated Nanoparticles Prevent Plaque Destabilization and Rupture by Regulating Monocyte/Macrophage Differentiation in ApoE-/- Mice.
Topics: Administration, Intravenous; Angiotensin II; Animals; Apolipoproteins E; Atherosclerosis; Brachiocep | 2016 |
Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Inflammation; Mese | 2016 |
Activation of Peroxisome Proliferator-activated Receptor γ Prevents Development of Heart Failure With Preserved Ejection Fraction; Inhibition of Wnt-β-catenin Signaling as a Possible Mechanism.
Topics: Animals; beta Catenin; Collagen Type I; Disease Models, Animal; Disease Progression; Fibrosis; Heart | 2016 |
Identification and modification of amyloid-independent phenotypes of APOE4 mice.
Topics: Age Factors; Alzheimer Disease; Amyloid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apolipopr | 2016 |
Pioglitazone increases PGC1-α signaling within chronically ischemic myocardium.
Topics: Animals; Chromatography, Liquid; Disease Models, Animal; Female; Heart; Hypoglycemic Agents; Myocard | 2016 |
Pioglitazone, a Peroxisome Proliferator-Activated Receptor x03B3; Agonist, Ameliorates Chronic Kidney Disease by Enhancing Antioxidative Capacity and Attenuating Angiogenesis in the Kidney of a 5/6 Nephrectomized Rat Model.
Topics: Animals; Antioxidants; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Down-Regulation; Hyp | 2016 |
Effect of ruthenium red, a ryanodine receptor antagonist in experimental diabetes induced vascular endothelial dysfunction and associated dementia in rats.
Topics: Animals; Aorta; Blood Glucose; Body Weight; Brain; Calcium Channel Blockers; Dementia; Diabetes Mell | 2016 |
Proteomic differences in brain vessels of Alzheimer's disease mice: Normalization by PPARγ agonist pioglitazone.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Biomarkers; Blood | 2017 |
Regulation of brain PPARgamma2 contributes to ketogenic diet anti-seizure efficacy.
Topics: 3-Hydroxybutyric Acid; Age Factors; Anilides; Animals; Animals, Newborn; Anticonvulsants; Blood Gluc | 2017 |
Parkinson Disease and Pioglitazone: Could Traumatic Brain Injury Catch a Lift?
Topics: Disease Models, Animal; Humans; Hypoglycemic Agents; Parkinson Disease; Pioglitazone; Thiazolidinedi | 2016 |
Pioglitazone Ameliorates Smooth Muscle Cell Proliferation in Cuff-Induced Neointimal Formation by Both Adiponectin-Dependent and -Independent Pathways.
Topics: Adiponectin; Animals; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Humans; Mice; Mic | 2016 |
The antidepressant-like effects of pioglitazone in a chronic mild stress mouse model are associated with PPARγ-mediated alteration of microglial activation phenotypes.
Topics: Animals; Antidepressive Agents; Body Weight; Cell Line, Transformed; Chronic Disease; Cytokines; Dis | 2016 |
Resveratrol Ameliorates the Depressive-Like Behaviors and Metabolic Abnormalities Induced by Chronic Corticosterone Injection.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Blood Glucose; Body Weight; Corticosterone; Depres | 2016 |
Therapeutic effects of adipose-derived stem cells pretreated with pioglitazone in an emphysema mouse model.
Topics: Adipose Tissue; Animals; Cell Line; Disease Models, Animal; Female; Lung; Mice, Inbred C57BL; Pancre | 2016 |
Simultaneous Administration of Statins and Pioglitazone Limits Tumor Growth in a Rat Model of Malignant Glioma.
Topics: Animals; Brain Neoplasms; Disease Models, Animal; Glioma; Hydroxymethylglutaryl-CoA Reductase Inhibi | 2016 |
Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents.
Topics: Animals; Biomarkers, Tumor; Bronchi; Carcinoma, Squamous Cell; Chemokines, CXC; Chemoprevention; Dis | 2017 |
PPARγ activation ameliorates postoperative cognitive decline probably through suppressing hippocampal neuroinflammation in aged mice.
Topics: Aging; Anilides; Animals; Brain-Derived Neurotrophic Factor; Cells, Cultured; Cognitive Dysfunction; | 2017 |
Peroxisome proliferator-activated receptor-γ agonist pioglitazone reduces the development of necrotizing enterocolitis in a neonatal preterm rat model.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Enterocoliti | 2017 |
Genomic binding of PAX8-PPARG fusion protein regulates cancer-related pathways and alters the immune landscape of thyroid cancer.
Topics: Adenocarcinoma, Follicular; Animals; Binding Sites; Chromatin Immunoprecipitation; Disease Models, A | 2017 |
The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cardiomyopathy, Hypertrophic; Diabetes Mellitus, Type | 2017 |
Appropriate Insulin Level in Selecting Fortified Diet-Fed, Streptozotocin-Treated Rat Model of Type 2 Diabetes for Anti-Diabetic Studies.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dis | 2017 |
Thiazolidinediones abrogate cervical cancer growth.
Topics: Animals; Cell Differentiation; Cell Proliferation; Complement Factor D; Disease Models, Animal; Fema | 2017 |
Establishment of a novel mouse model for pioglitazone-induced skeletal muscle injury.
Topics: Adenosine Triphosphate; Animals; Aspartate Aminotransferases; Buthionine Sulfoximine; Creatine Kinas | 2017 |
Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist.
Topics: Acetylcholine; Acetylcysteine; Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein | 2008 |
Oral glyburide, but not glimepiride, blocks the infarct-size limiting effects of pioglitazone.
Topics: Administration, Oral; Animals; Body Weight; Coronary Vessels; Data Interpretation, Statistical; Deca | 2008 |
Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Cardiovascular Agents; Cyclooxygenase 2; Cytochrome P-450 Enz | 2008 |
Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia.
Topics: Animals; Anti-Inflammatory Agents; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Ence | 2008 |
Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease.
Topics: Administration, Oral; Animals; Avoidance Learning; Cognition; Discrimination Learning; Disease Model | 2009 |
Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury.
Topics: Adipocytes; Analgesics; Anilides; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; | 2008 |
BLX-1002, a novel thiazolidinedione with no PPAR affinity, stimulates AMP-activated protein kinase activity, raises cytosolic Ca2+, and enhances glucose-stimulated insulin secretion in a PI3K-dependent manner.
Topics: AMP-Activated Protein Kinases; Animals; Calcium; Cells, Cultured; Cytosol; Diabetes Mellitus; Diseas | 2009 |
Mulberry leaf ameliorates the expression profile of adipocytokines by inhibiting oxidative stress in white adipose tissue in db/db mice.
Topics: Adipokines; Adiponectin; Adipose Tissue, White; Adiposity; Animals; Antioxidants; Blood Glucose; Bod | 2009 |
Acute neuroprotection by pioglitazone after mild brain ischemia without effect on long-term outcome.
Topics: Adenosine Triphosphate; Animals; Animals, Newborn; Bromodeoxyuridine; Calcium-Binding Proteins; Cell | 2009 |
Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
Topics: Abdominal Fat; Adiposity; Animals; Body Weight; Dietary Fats; Disease Models, Animal; Fenofibrate; H | 2009 |
Translation of basic science into clinical medicine: novel targets for diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomedical Research; Clinical Medicine; Diabetic N | 2009 |
Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction.
Topics: Androstadienes; Anilides; Animals; Blood Glucose; Blotting, Western; Decanoic Acids; Disease Models, | 2009 |
Protective effects of pioglitazone against global cerebral ischemic-reperfusion injury in gerbils.
Topics: Animals; Brain Ischemia; Disease Models, Animal; DNA Fragmentation; Gerbillinae; Hippocampus; Hyperk | 2009 |
Thiazolidinediones: antidiabetic agents with effects on bone.
Topics: Aged; Animals; Bone and Bones; Bone Density; Bone Resorption; Diabetes Mellitus, Type 2; Disease Mod | 2009 |
Activation of PPARgamma by rosiglitazone attenuates intestinal Cl- secretion.
Topics: Administration, Oral; Animals; Calcium; Carbachol; Chlorides; Cholera Toxin; Colforsin; Colon; Cycli | 2009 |
PPARgamma and RXRgamma ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models.
Topics: Analysis of Variance; Animals; Annexin A5; Antineoplastic Agents; bcl-2-Associated X Protein; Brain | 2009 |
Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice.
Topics: Abdominal Fat; Adipocytes; Animals; Blood Glucose; Cell Count; Diabetes Mellitus, Type 2; Disease Mo | 2009 |
The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus.
Topics: Animals; Cardiomyopathies; Disease Models, Animal; Endothelium, Vascular; Female; Inflammation Media | 2009 |
Peroxisome proliferator-activated receptor gamma agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation.
Topics: Animals; Asthma; Disease Models, Animal; Down-Regulation; Female; Inflammation Mediators; Interleuki | 2009 |
Exploring mechanism of pioglitazone-induced memory restorative effect in experimental dementia.
Topics: Acetylcholinesterase; Animals; Blood Glucose; Brain; Dementia; Disease Models, Animal; Glutathione; | 2009 |
Effect of pioglitazone on survival and renal function in a mouse model of polycystic kidney disease.
Topics: Animals; Blood Pressure; Disease Models, Animal; Hypertension, Renal; Hypoglycemic Agents; Kaplan-Me | 2009 |
Improving insulin sensitivity via activation of PPAR-gamma increases telomerase activity in the heart of OLETF rats.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Fibrosis; Hypoglycemic A | 2009 |
Molecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARgamma agonist.
Topics: Animals; Apoptosis; Cell Differentiation; Cell Proliferation; Diabetes Mellitus, Type 2; Disease Mod | 2010 |
Activation of STAT3 and inhibitory effects of pioglitazone on STAT3 activity in a mouse model of SOD1-mutated amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Enzyme Activation; Humans; Immunoblo | 2010 |
Long-term pioglitazone treatment augments insulin sensitivity and PKC-epsilon and PKC-theta activation in skeletal muscles in sucrose fed rats.
Topics: Animals; Animals, Congenic; Blood Glucose; CD36 Antigens; Dietary Sucrose; Disease Models, Animal; G | 2010 |
PPARgamma agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis.
Topics: Angiotensin Receptor Antagonists; Animals; Antigens, Differentiation; Disease Models, Animal; Fibros | 2010 |
Activation of PPARgamma by pioglitazone does not attenuate left ventricular hypertrophy following aortic banding in rats.
Topics: Animals; Aorta, Thoracic; Atrial Natriuretic Factor; Disease Models, Animal; Echocardiography; Hyper | 2010 |
Peroxisome proliferator-activated receptor-(gamma) receptor ligand partially prevents the development of endometrial explants in baboons: a prospective, randomized, placebo-controlled study.
Topics: Animals; Disease Models, Animal; Disease Progression; Endometriosis; Endometrium; Female; Papio anub | 2010 |
Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury.
Topics: Anilides; Animals; Apoptosis; bcl-2-Associated X Protein; Blotting, Northern; Blotting, Western; Cas | 2010 |
Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation.
Topics: Administration, Oral; Animals; Cholesterol, Dietary; Dietary Carbohydrates; Disease Models, Animal; | 2010 |
The nephroprotective effects of pioglitazone and glibenclamide against gentamicin-induced nephrotoxicity in rats: a comparative study.
Topics: Animals; Antioxidants; Creatinine; Disease Models, Animal; Gentamicins; Glyburide; Kidney Diseases; | 2010 |
Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-Upsilon (PPARUpsilon) in Huntington's disease.
Topics: Animals; Antioxidants; Benzhydryl Compounds; Body Weight; Corpus Striatum; Disease Models, Animal; E | 2010 |
Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biomarkers; Biphenyl | 2010 |
Study of the effect of inhibiting galanin in Alzheimer's disease induced in rats.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Avoidance Learning; Brain; | 2010 |
Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion.
Topics: Animals; Behavior, Animal; Blood Pressure; Brain; Brain Ischemia; Cell Adhesion Molecules; Disease M | 2010 |
Repeated administration of pioglitazone attenuates development of hyperalgesia in a rat model of neuropathic pain.
Topics: Animals; Brain; Cytokines; Disease Models, Animal; Hyperalgesia; Interleukin-1beta; Male; Neuralgia; | 2010 |
Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia.
Topics: Animals; Apoptosis; Castration; Cell Proliferation; Dietary Fats; Disease Models, Animal; Glucose To | 2010 |
Development and prevention of postsurgical adhesions in a chimeric mouse model of experimental endometriosis.
Topics: Animals; Disease Models, Animal; Endometriosis; Endometrium; Female; Humans; Mice; Mice, Nude; Piogl | 2011 |
Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury.
Topics: Analysis of Variance; Animals; Brain Injuries; CD11b Antigen; Cerebral Cortex; Cognition Disorders; | 2011 |
Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection.
Topics: Animals; Chemokines; Disease Models, Animal; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Hum | 2010 |
Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats.
Topics: Administration, Oral; Animals; Atrial Fibrillation; Blotting, Western; Disease Models, Animal; Echoc | 2011 |
Inflammatory responses in the atria: should they stay or should they go?
Topics: Animals; Atrial Fibrillation; Disease Models, Animal; Fibrosis; Heart Atria; Inflammation; Inflammat | 2011 |
Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease.
Topics: Animals; Anti-Inflammatory Agents; Cells, Cultured; Colitis; Colon; Computational Biology; Dextran S | 2011 |
PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
Topics: Animals; Blood Urea Nitrogen; Cell Proliferation; Disease Models, Animal; Disease Progression; Femal | 2011 |
[Pioglitazone inhibits cardiac hypertrophy of rats in vitro and in vivo].
Topics: Animals; Atrial Natriuretic Factor; Cardiomegaly; Cell Line; Cytokines; Disease Models, Animal; Inte | 2005 |
Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor-κB signaling pathway.
Topics: Animals; Blotting, Western; Brain; Disease Models, Animal; Immunohistochemistry; Infarction, Middle | 2011 |
Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Adipose Tissue, White; Animals; Apolipoproteins E; Atheroscle | 2011 |
Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking.
Topics: Adrenergic alpha-2 Receptor Antagonists; Alcohol Drinking; Alcohols; Analysis of Variance; Anilides; | 2011 |
Broad-spectrum neuroprotection against traumatic brain injury by agonism of peroxisome proliferator-activated receptors.
Topics: Animals; Brain Injuries; Cerebral Cortex; Cognition Disorders; Disease Models, Animal; Encephalitis; | 2011 |
Neuroprotective effect of pioglitazone on acute phase changes induced by partial global cerebral ischemia in mice.
Topics: Acute-Phase Reaction; Animals; Antioxidants; Brain Edema; Brain Ischemia; Carotid Artery, Common; Ce | 2010 |
Protection of neurons and microglia against ethanol in a mouse model of fetal alcohol spectrum disorders by peroxisome proliferator-activated receptor-γ agonists.
Topics: Analysis of Variance; Animals; Brain; Cell Count; Cell Survival; Cells, Cultured; Disease Models, An | 2011 |
The effects of an arabinogalactan-protein from the white-skinned sweet potato (Ipomoea batatas L.) on blood glucose in spontaneous diabetic mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Disease Models, Animal; Female; Glucose Tolerance Test; H | 2011 |
Oral pioglitazone reduces infarction volume and improves neurologic function following MCAO in rats.
Topics: Administration, Oral; Animals; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Hypoglyc | 2011 |
Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR-γ-independent mechanisms.
Topics: Animals; Brain Damage, Chronic; Brain Injuries; Disease Models, Animal; Hypoglycemic Agents; Male; M | 2011 |
Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Biomarkers; Body Weight; C | 2011 |
Effect of pioglitazone on altered expression of Aβ metabolism-associated molecules in the brain of fructose-drinking rats, a rodent model of insulin resistance.
Topics: Amyloid beta-Peptides; Animals; Brain; Disease Models, Animal; Down-Regulation; Drinking; Fructose; | 2011 |
Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Models, Animal; Farnesol; Humans; | 2011 |
Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease.
Topics: Animals; Antineoplastic Agents; Antioxidants; Disease Models, Animal; Hypoglycemic Agents; Male; Mot | 2011 |
Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone.
Topics: Animals; Blood Vessels; Disease Models, Animal; Disease Progression; Dyslipidemias; Hyperinsulinism; | 2011 |
Pharmacological investigations on potential of peroxisome proliferator-activated receptor-gamma agonists in hyperhomocysteinemia-induced vascular dementia in rats.
Topics: Animals; Dementia, Vascular; Disease Models, Animal; Hyperhomocysteinemia; Hypoglycemic Agents; Male | 2011 |
Effects of pioglitazone and rosiglitazone on vascular function of mesenteric resistance arteries in rat genetic hypertension.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Animals; Blood Pr | 2011 |
PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model.
Topics: Aging; Animals; Antioxidants; Apoptosis; Atrial Fibrillation; Cardiotonic Agents; Disease Models, An | 2012 |
RXR antagonism induces G0 /G1 cell cycle arrest and ameliorates obesity by up-regulating the p53-p21(Cip1) pathway in adipocytes.
Topics: Adipocytes; Animals; Anti-Obesity Agents; Benzoates; Biphenyl Compounds; Cell Proliferation; Cell Si | 2012 |
Effects of pioglitazone on survival and omental adipocyte function in mice with sepsis induced by cecal ligation and puncture.
Topics: Adipocytes; Adiponectin; Animals; Cecum; Chemokine CCL2; Disease Models, Animal; Gene Expression; Hy | 2011 |
Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortography; Atherosclerosis; Biomarkers; Contrast Media; | 2011 |
Lithium, phenserine, memantine and pioglitazone reverse memory deficit and restore phospho-GSK3β decreased in hippocampus in intracerebroventricular streptozotocin induced memory deficit model.
Topics: Animals; Conditioning, Classical; Disease Models, Animal; Enzyme Inhibitors; Glycogen Synthase Kinas | 2011 |
Appropriateness of the Zucker Diabetic Fatty rat as a model for diabetic microvascular late complications.
Topics: Animals; Blood Chemical Analysis; Caloric Restriction; Diabetes Mellitus, Type 2; Diabetic Nephropat | 2012 |
Mice with cardiac overexpression of peroxisome proliferator-activated receptor γ have impaired repolarization and spontaneous fatal ventricular arrhythmias.
Topics: Action Potentials; Animals; Calcium; Connexin 43; Death, Sudden, Cardiac; Disease Models, Animal; El | 2011 |
Pioglitazone ameliorates systolic and diastolic cardiac dysfunction in rat model of angiotensin II-induced hypertension.
Topics: Angiotensin II; Animals; Blood Pressure; Diastole; Disease Models, Animal; Heart Diseases; Hypertens | 2013 |
Sub-chronic treatment with pioglitazone exerts anti-convulsant effects in pentylenetetrazole-induced seizures of mice: The role of nitric oxide.
Topics: Analysis of Variance; Animals; Anticonvulsants; Disease Models, Animal; Drug Administration Routes; | 2012 |
Reduction of renal lipid content and proteinuria by a PPAR-γ agonist in a rat model of angiotensin II-induced hypertension.
Topics: Angiotensin II; Animals; Disease Models, Animal; Ferritins; Gene Expression Regulation; Heme Oxygena | 2012 |
Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Male; Mice; Mice, Inbred C57BL; Motor Activit | 2012 |
PPARγ agonist pioglitazone improves scopolamine-induced memory impairment in mice.
Topics: Administration, Oral; Alzheimer Disease; Animals; Avoidance Learning; Cerebral Cortex; Disease Model | 2012 |
Spirulina improves non-alcoholic steatohepatitis, visceral fat macrophage aggregation, and serum leptin in a mouse model of metabolic syndrome.
Topics: Animals; Cell Aggregation; Cholesterol; Disease Models, Animal; Fatty Acids, Nonesterified; Fatty Li | 2012 |
Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor γ.
Topics: Analysis of Variance; Animals; Animals, Newborn; Antigens, CD; Autoimmunity; CD4-Positive T-Lymphocy | 2012 |
Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Biomarkers; Brain Chemistry; Disease Models, Animal; Drug Administration | 2012 |
Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Blood Glucose; Body Weight; Disease Models, Animal; Male; Maze Learning; | 2012 |
Protective effects of pioglitazone on renal ischemia-reperfusion injury in mice.
Topics: Acute Kidney Injury; Animals; Apoptosis; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Hy | 2012 |
Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Antihypertensive Agents; Ben | 2012 |
Beneficial effects of pioglitazone against cardiovascular injury are enhanced by combination with aliskiren in a rat model of diabetic nephropathy.
Topics: Amides; Animals; Antihypertensive Agents; Cardiomyopathies; Diabetic Nephropathies; Disease Models, | 2012 |
E-cadherin as a predictive marker of brain metastasis in non-small-cell lung cancer, and its regulation by pioglitazone in a preclinical model.
Topics: Aged; Animals; Brain; Brain Neoplasms; Cadherins; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Li | 2012 |
RETRACTED: Obesity-induced increase in tumor necrosis factor-α leads to development of colon cancer in mice.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Azoxymethane; Blotting, Western; | 2012 |
Pioglitazone, a PPAR-γ activator, attenuates the severity of cerulein-induced acute pancreatitis by modulating early growth response-1 transcription factor.
Topics: Acinar Cells; Acute Disease; Anilides; Animals; Cell Line, Tumor; Ceruletide; Chemokine CCL2; Chemok | 2012 |
Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apolipoproteins E; Astrocytes; Brain; Cells, Cult | 2012 |
Diabetic peripheral neuropathy in Spontaneously Diabetic Torii-Lepr(fa) (SDT fatty) rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Disease Model | 2012 |
Cerebral antioxidant enzyme increase associated with learning deficit in type 2 diabetes rats.
Topics: Adiponectin; Animals; Antioxidants; Brain; Cerebral Cortex; Conditioning, Operant; Corpus Striatum; | 2012 |
Suppressive effect of pioglitazone, a PPAR gamma ligand, on azoxymethane-induced colon aberrant crypt foci in KK-Ay mice.
Topics: Aberrant Crypt Foci; Adipokines; Animals; Azoxymethane; Biomarkers; Carcinogens; Colorectal Neoplasm | 2012 |
PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Behavior, Animal; Brain; Cognition; Dise | 2012 |
Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice.
Topics: Alzheimer Disease; Animals; Cognition; Disease Models, Animal; Female; Glucose; Humans; Male; Mice; | 2012 |
Pioglitazone attenuates valvular calcification induced by hypercholesterolemia.
Topics: Adiponectin; Animals; Aorta; Aortic Valve; Aortic Valve Stenosis; Apolipoprotein B-100; Apoptosis; B | 2013 |
Pioglitazone therapy in mouse offspring exposed to maternal obesity.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Female; Hypoglycemic Agents; Male; Metabolic Syndro | 2013 |
Pioglitazone potentiates development of morphine-dependence in mice: possible role of NO/cGMP pathway.
Topics: Animals; Cell Line, Tumor; Cyclic AMP; Cyclic GMP; Disease Models, Animal; Enzyme Inhibitors; Gliobl | 2013 |
Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; | 2002 |
Thiazolidinediones increase the number of platelets in immune thrombocytopenic purpura mice via inhibition of phagocytic activity of the reticulo-endothelial system.
Topics: Animals; Antibody-Dependent Cell Cytotoxicity; Autoantibodies; Blood Platelets; COS Cells; Disease M | 2002 |
Antiinflammatory and antiarteriosclerotic effects of pioglitazone.
Topics: Animals; Anti-Inflammatory Agents; Arteriosclerosis; Blood Glucose; Blood Pressure; Chemokine CCL2; | 2002 |
Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction.
Topics: Administration, Oral; Animals; Aspartate Aminotransferases; Blood Glucose; Cytokines; Disease Models | 2002 |
Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis.
Topics: Acute Disease; Animals; Antibody Formation; Antioxidants; Chromans; Colitis; Cytokines; Disease Mode | 2002 |
Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Glycemic Index; H | 2004 |
Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure.
Topics: Animals; Disease Models, Animal; Heart Failure; Humans; Ligands; Mice; Myocardial Infarction; Piogli | 2004 |
Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction.
Topics: Animals; Aorta; Blood Glucose; Body Weight; Chronic Disease; Collagen; Coronary Vessels; Cytokines; | 2004 |
Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation.
Topics: Animals; Brain; Disease Models, Animal; Enzyme Activation; Enzyme Inhibitors; I-kappa B Proteins; Ma | 2004 |
Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model.
Topics: Animals; Chemokine CCL2; Disease Models, Animal; Hypoglycemic Agents; Intercellular Adhesion Molecul | 2003 |
Evidence for contribution of vascular NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity.
Topics: Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Electron Spin Resonance Spectrosco | 2004 |
Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure.
Topics: Animals; Chemokine CCL2; Diabetes Mellitus, Type 2; Disease Models, Animal; Heart Diseases; Humans; | 2004 |
Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice.
Topics: Adiponectin; Animals; Blood Glucose; Body Weight; Cell Count; Diabetes Mellitus, Type 2; Disease Mod | 2005 |
Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis.
Topics: Administration, Oral; Amyotrophic Lateral Sclerosis; Animals; Cell Count; Disease Models, Animal; Di | 2005 |
Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs.
Topics: Administration, Oral; Animals; Cartilage, Articular; Collagenases; Disease Models, Animal; Disease P | 2005 |
Pioglitazone, a peroxisome proliferator-activated receptor gamma activator, ameliorates experimental autoimmune myocarditis by modulating Th1/Th2 balance.
Topics: Animals; Autoimmune Diseases; Body Weight; Cytokines; Disease Models, Animal; Female; Hemodynamics; | 2005 |
PPAR-gamma modulates allergic inflammation through up-regulation of PTEN.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Eosinophils; Female; Gene Exp | 2005 |
Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Amyloidosis; Animals | 2005 |
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Topics: Animals; Apolipoprotein E2; Apolipoproteins E; Atherosclerosis; Blood Glucose; Disease Models, Anima | 2005 |
The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain.
Topics: Animals; Brain; Brain Edema; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Encephalit | 2005 |
Involvement of IL-10 in peroxisome proliferator-activated receptor gamma-mediated anti-inflammatory response in asthma.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Eos | 2005 |
Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance.
Topics: Animals; Carotid Arteries; Disease Models, Animal; Drug Evaluation, Preclinical; Glipizide; Insulin | 2005 |
Effects of glitazones on blood pressure and vascular structure in mesenteric resistance arteries and basilar artery from genetically hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Basilar Artery; Blood Pressure; Disease Models, An | 2005 |
Insulin-lowering agents inhibit synthesis of testosterone in ovaries of DHEA-induced PCOS rats.
Topics: 17-Hydroxysteroid Dehydrogenases; Adjuvants, Immunologic; Animals; Chromans; Dehydroepiandrosterone; | 2006 |
The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Carbazoles; Disease Models, Animal; Dyslipidemias; Gene Expr | 2006 |
Pioglitazone does not increase cerebral glucose utilisation in a murine model of Alzheimer's disease and decreases it in wild-type mice.
Topics: Alzheimer Disease; Analysis of Variance; Animals; Brain; Carbon Radioisotopes; Deoxyglucose; Disease | 2006 |
Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice.
Topics: Animals; Aorta; Atherosclerosis; Cells, Cultured; Connective Tissue Growth Factor; Diet, Atherogenic | 2007 |
Altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Diabetes Mellitus, Type 2; Diabetic Nephropat | 2006 |
Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer.
Topics: Animals; Cadherins; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Disease Progressio | 2006 |
Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice.
Topics: Amphetamine-Related Disorders; Anilides; Animals; Behavior, Animal; Brain; Brain Chemistry; Cell Nuc | 2007 |
Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone.
Topics: Animals; Blood Glucose; Disease Models, Animal; Fatty Liver; Female; Hepatitis, Chronic; Hypoglycemi | 2007 |
The different effect of pioglitazone as compared to insulin on expression of hepatic and intestinal genes regulating post-prandial lipoproteins in diabetes.
Topics: Animals; Cholesterol, VLDL; Chylomicrons; Diabetes Mellitus; Disease Models, Animal; Gene Expression | 2007 |
Administration of pioglitazone in low-density lipoprotein receptor-deficient mice inhibits lesion progression and matrix metalloproteinase expression in advanced atherosclerotic plaques.
Topics: Animals; Atherosclerosis; Disease Models, Animal; Disease Progression; Gene Expression; Matrix Metal | 2006 |
Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Topics: Animal Feed; Animals; Choline; Collagen Type I; Collagen Type I, alpha 1 Chain; Diabetes Mellitus, T | 2007 |
Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Carrageenan; Disease Models, Animal; Dose-Response Re | 2007 |
Pioglitazone in nonalcoholic steatohepatitis.
Topics: Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Liver; H | 2007 |
PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance.
Topics: Angiotensin II; Animals; Aorta, Thoracic; Blood Pressure; Dietary Fats; Disease Models, Animal; Dose | 2007 |
Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents.
Topics: Anilides; Animals; Cerebral Infarction; Chemotaxis, Leukocyte; Cytokines; Diabetes Mellitus, Type 2; | 2007 |
Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats.
Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; B | 2007 |
Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Hypoglycemic Age | 2007 |
A model of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice for the characterisation of intervention therapies.
Topics: Adjuvants, Immunologic; Animals; Central Nervous System; Chemotaxis, Leukocyte; Disability Evaluatio | 2007 |
The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Metformin; Pioglita | 2007 |
The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: in vivo protective effects mediated through the inhibition of key signaling and cataboli
Topics: Animals; Cartilage; Disease Models, Animal; Dogs; Femur; Hypoglycemic Agents; Osteoarthritis; Piogli | 2007 |
Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Disease Models | 2007 |
Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Endothelium, Vascular; Hypoglycemic Agen | 2008 |
Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure.
Topics: Animals; Blood Glucose; Blood Pressure; Cerebral Arteries; Cytokines; Diabetes Complications; Diseas | 2007 |
Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glycation End Pr | 2007 |
Effects of pioglitazone on increases in visceral fat accumulation and oxidative stress in spontaneously hypertensive hyperlipidemic rats fed a high-fat diet and sucrose solution.
Topics: Animals; Catalase; Dietary Fats; Disease Models, Animal; Fatty Acids, Nonesterified; Female; Glutath | 2007 |
Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting.
Topics: Animals; Chemokine CCL2; Coronary Restenosis; Coronary Vessels; Disease Models, Animal; Humans; Hypo | 2008 |
Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-gamma-ligand, in insulin-deficient diabetic rats.
Topics: Analysis of Variance; Animals; Carbohydrate Metabolism; Cell Movement; Diabetes Mellitus, Experiment | 2008 |
The insulin sensitizer pioglitazone improves the deterioration of ischemic preconditioning in type 2 diabetes mellitus rats.
Topics: Animals; Arrhythmias, Cardiac; Coronary Circulation; Diabetes Mellitus, Type 2; Disease Models, Anim | 2007 |
Pioglitazone is as effective as dexamethasone in a cockroach allergen-induced murine model of asthma.
Topics: Allergens; Animals; Antigens, Plant; Asthma; Dexamethasone; Disease Models, Animal; Female; Mice; Mi | 2007 |
PPAR-gamma ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo.
Topics: Animals; beta Catenin; Cell Proliferation; Colonic Neoplasms; Disease Models, Animal; Dose-Response | 2008 |
Effect of a polyphenol-rich extract from Aloe vera gel on experimentally induced insulin resistance in mice.
Topics: Aloe; Animals; Blood Glucose; Body Weight; Disease Models, Animal; Eating; Flavonoids; Hypoglycemic | 2007 |
Pioglitazone opposes neurogenic vascular dysfunction associated with chronic hyperinsulinaemia.
Topics: Administration, Oral; Angiotensin II; Animals; Blood Glucose; Blood Pressure; Chronic Disease; Disea | 2008 |
Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs.
Topics: Animals; Blood Pressure; Disease Models, Animal; Heart; KATP Channels; Pioglitazone; Rosiglitazone; | 2008 |
Renal cytochrome P450 as a determinant of impaired natriuresis by PPAR-gamma ligands in ovariectomized obese rats.
Topics: Animals; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Dinoprostone; Disease Models, Anima | 2008 |
Effects of the PPARgamma activator pioglitazone on p38 MAP kinase and IkappaBalpha in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Anti-Inflammatory Agents; Blotting, Western; Calcium-Binding | 2008 |
Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Benzimi | 2008 |
Heart failure-related atrial fibrillation: a new model for a new prevention strategy?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Benzimidazoles; Biphenyl Comp | 2008 |
Role of pioglitazone treatment on atrial remodeling and atrial fibrillation (AF)promotion in an experimental model of congestive heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Disease Models, Animal; Heart | 2008 |
Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Astrocytes; Benzimidazoles; Biph | 2008 |
Antiapoptosis and mitochondrial effect of pioglitazone preconditioning in the ischemic/reperfused heart of rat.
Topics: Animals; Animals, Newborn; Apoptosis; bcl-2-Associated X Protein; Cardiovascular Agents; Caspase 3; | 2008 |
Omega-3 fatty acids exacerbate DSS-induced colitis through decreased adiponectin in colonic subepithelial myofibroblasts.
Topics: Adiponectin; Animals; Anti-Inflammatory Agents; Cells, Cultured; Colitis; Dextran Sulfate; Dietary F | 2008 |
Lipoprotein profile characterization of the KKA(y) mouse, a rodent model of type II diabetes, before and after treatment with the insulin-sensitizing agent pioglitazone.
Topics: Animals; Apolipoprotein A-I; Apolipoproteins B; Carrier Proteins; Cholesterol Ester Transfer Protein | 1993 |
VLDL triglyceride kinetics in Wistar fatty rats, an animal model of NIDDM: effects of dietary fructose alone or in combination with pioglitazone.
Topics: Animals; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Disease Models, | 1996 |
Effect of an insulin sensitizer, pioglitazone, on hypertension in fructose-drinking rats.
Topics: Animals; Blood Glucose; Blood Pressure; Disease Models, Animal; Drinking; Fructose; Hypertension; Hy | 1997 |
Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.
Topics: Actins; Angiotensin II; Animals; Atrial Natriuretic Factor; Body Weight; Cardiomegaly; Cell Size; Ce | 2002 |